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Ultraviolet radiation (UVR) is present in the sunlight that reaches the Earth, and can
also be artificially produced. Artificial sources of UVR can be used therapeutically,
for the treatment of skin disease such as psoriasis. UVR is a source of DNA damage,
and the major causative agent for the development of skin cancers. UV-induced DNA
damage can be repaired by a number of DNA repair pathways, principally the
nucleotide excision repair (NER) pathway and the base excision repair pathway
(BER), preventing DNA lesions from becoming incorporated into the genome.
Defects in the genes involved with NER lead to three, rare, recessive syndromes,
Xeroderma pigmentosum (XP), Cockayne's Syndrome (CS) and Trichothiodystrophy
(TTD). Individuals affected with any of these syndromes have varying degrees of
photosensitivity, with XP patients also having a greater than 1000 fold increased risk
of skin cancer. As UVR is one of the most frequently exposed to sources of DNA
damage, and also used as a therapeutic reagent, it would be useful to have a genetic
marker which might predict an individual's response to UVR.
Polymorphisms in the genes involved with the NER, BER and other repair pathways
will be examined in this thesis, to determine if any are associated with sensitivity to
UVR. Sensitivity to UVR will be determined as the level of erythema induced by an
incremental range ofUV doses in two independent study groups, of 74 and 31
individuals. Erythema will be measured using reflectance spectrophotometry, which is
an analytical measure, rather than the widely used minimal erythemal dose (MED).
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The sunlight that reaches the Earth is part of a continuous spectrum of electromagnetic
radiation. Of great biological and medical interest is one component of this
electromagnetic spectrum, ultraviolet radiation (UVR), which ranges from 100-400
nanometres (nm). Other components of the electromagnetic spectrum are radiowaves,
microwaves, infrared, visible light (400-700nm), X-rays and gamma radiation. The
properties of any particular component of the spectrum are characterised by the
wavelength of the radiation.
Ultraviolet radiation is subdivided into three regions, UVA, UVB and UVC. UVA has the
longest wavelengths, from 315 to 400nm, UVB 280-315nm and UVC 100-280nm. These
regions are usually further defined by dermatological photobiologists as UVA 320-
400nm, UVB 320-290nm, and UVC as 290-200nm. Little UVC radiation reaches the
surface of the earth, due to it being blocked by the stratospheric ozone layer, exposure to
UVC is therefore mainly through man-made sources, such as germicidal lamps. UVA and
UVB both reach the Earth's surface, and can be absorbed by the skin. In summer, in the
UK, UVB (when defined as 280-315 nm) comprises approximately 3.5% of the UVR that
reaches the Earth's surface, while UVA comprises the remaining 96.5%.
Beneficial Effects of UVR
Phototherapy
UVR is commonly used as a treatment for psoriasis in Dermatology clinics. Psoriasis is a
chronic, relapsing skin disease with variable clinical features. The most common type is
psoriasis vulgaris. Circular plaques are predominant on the elbows, knees and lower
back, whereas erupting guttate lesions are often confined to the trunk and proximal
extremities. Psoriasis is a disease universal in its occurrence. The worldwide incidence
varies, in the USA affecting approximately 2% of the population, in the UK around 1.6%,
0.97% in South America, and 2.8% in the Faeroe Islands. The higher incidence of
psoriasis in the Faeroe Islands could be partly due to a Founder effect, leading to
relatively little genetic variation, but also due to its latitude at 61° north. Sunlight is
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beneficial in the treatment of most cases of psoriasis. Psoriasis is due to excessive, but
controlled, cellular proliferation and inflammation, occurring within 0.2mm of the
surface of the skin. UVA and UVB are both used in different treatment regimes to "clear"
psoriatic plaques. UVA is commonly used during photochemotherapy (PUVA). Patients
orally ingest a potent photosensitiser, such as 8-methoxypsoralen (8-MOP) and are then
exposed to variable doses of UVA. Psoralens such as 8-MOP intercalate with DNA, and
with the energy from UVA, co-valently cross link nucleic acids with opposing strands of
duplex regions of DNA. The formation of these cross-linking photoadducts leads to the
irreversible photo-inhibition of DNA synthesis and mitosis (Pohl et al, 1979). This
reaction is thought to be important in the hyperproliferative psoriatic epidermis. A typical
course to clear psoriasis is 19-25 treatments. The long-term effects of PUVA include
photoageing, but also photocarcinogenesis. Patients who have received PUVA treatment
have a dose-related increased frequency of squamous cell carcinoma (SCC) (Stern et al,
1984). Patients who have had over 250 PUVA treatments are especially at risk of
malignant melanoma (Stern et al, 1997).
UVB is also used in the treatment of psoriasis. It is thought to be efficient at clearing
plaques through its immune suppression activities, depleting Langerhans cells, decreasing
leukocyte adhesion to the microvasculature, leading to the depletion of intraepidermal T
cells, and the induction of IL-10 production from macrophages, which acts as an anti¬
inflammatory mediator (Cai et al, 1996; Krueger et al, 1995; Meunier et al, 1995 and
Kang et al, 1994).
Photosynthesis of Vitamin D
Vitamin D is essential for health, promoting the absorption of calcium and phosphate
from food. It is essential in the formation of bones and teeth. Deficiencies of vitamin D
leads to a failure of the bones to grow, and causes rickets in children and osteomalacia in
adults. UVR photosynthesises 7-dehydrocholesterol into vitamin D3. 7-
dehydrocholesterol is present in the epidermis of the skin, and absorbs UVR less than
320nm. Upon absorbance of UVR, this converts into the vitamin D precursor, previtamin
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D3. Previtamin D3 then isomerises to become vitamin D, binding to binding proteins
present in the capillaries. Although in most industrial countries the level of vitamin D
present in food is enough to satisfy requirements for everyday health, it has been
suggested that recent sun awareness campaigns have resulted in vitamin D deficiencies in
some individuals, particularly the elderly, in whom levels of 7-dehydrocholesterol in the
skin decrease with age. In its role in the photosynthesis of vitamin D, UVR has a
beneficial effect on our health. Some studies have also suggested vitamin D may play a
role in the regulation of the cell cycle, and might have an effect in reducing cancer of the
prostate (Konety et al, 1999; Getzenberg et al, 1997) and of the breast (Lowe et al, 2003;
O'Kelly and Koeffler, 2003).
Erythema
The main acute clinical effects of UVR on normal skin are UV-induced erythema,
sometimes referred to as sunburn inflammation, and tanning. Chronic exposure of the
skin to UVR leads to photoageing, and carcinogenesis. In general, the intensity of
erythema is determined by the amount of radiation the skin receives. Low doses over a
longer period of time will lead to the same level of erythema as a higher dose over a
shorter period of time. A method of determining skin sensitivity to UVR is by
determining the amount of UVR required to induce visible erythema after 24 hours, the
minimal erythemal dose (MED). This can be just perceptible erythema (MEDjp) or
clearly defined erythema with distinct margins. Erythema is the most conspicuous acute
response to UVR, and can vary greatly between individuals, and between body sites
within individuals. The MED is routinely used as an end-point for the assessment of
erythema in both clinical practise and research studies. However, it is a subjective
measure, and is therefore open to errors ofjudgement. The MED is based on an
assessment of a binary outcome, whether a particular degree of erythema occurs
following exposure to a graded series of doses ofUV (Farr and Diffey, 1984, 1986). The
particular degree of erythema chosen as the endpoint varies between researchers, as
mentioned above this can include just perceptible erythema or erythema with distinct
margins. Error can be introduced when determining the MED as it is dependent upon the
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human eye and definition of erythema that is just perceptible or that with defined margins
can vary between individuals. As the MED is a threshold measurement, the exact value of
the MED is dependent on the dose increment chosen for the series of irradiation (Diffey
and Farr, 1989; Lock-Andersen and Wulf, 1996).
An action spectrum demonstrates the relative photobiological efficiency at different
wavelengths, and can be used to identity chromophores or to calculate the relative
importance of difference wavelengths under actual environmental conditions. The action
spectrum for erythema can be seen in the figure below.
Wavelength (nm)
Figure 1, erythemal action spectrum
In animals, UVB-induced erythema peaks between 6 and 24 hours, depending upon
UVR dose (Macher et al, 1969). UVA also induces erythema, often causing an immediate
erythemal response, which is followed by a second erythema as with UVB. Both UVA
and UVB-induced erythema can be prolonged in fair-skinned individuals. Some
individuals with the UV-sensitive disorder Xeroderma pigmentosum (described later)
also show prolonged UV-induced erythemal responses, lasting for several weeks.
Chromophores within the epidermis absorb UVR, changing the skin biology.
Chromophores within the epidermis are DNA, proteins, urocanic acid and melanin
precursors. Nuclear DNA is the most well characterised chromophore for UVB. Young et
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al (1998) determined action spectra for thymine dimers, a type of cyclobutane dimer, and
UV-induced erythema. The epidermal dimer action spectra was analysed and compared
with erythema action spectra from the same UVR sources and group of volunteers.
Comparisons between the two suggest the DNA is the major chromophore for erythema
at 280-340nm.
Skin Cancer
The link between UVR and skin cancer was first described over 100 years ago, when, in
1894, Unna described that sun exposed skin sites in sailors were likely to develop skin
cancer. Dubrevilh (1896) noted an increased frequency of keratoses and skin cancer cases
in vineyard workers compared with their mainly indoor-working city dwelling
neighbours in the Bordeaux region of France. The development of artificial sources of
UVR led to early mouse experiments which demonstrated that mice irradiated daily with
UVR from a mercury arc developed skin cancers unlike mice of the same strain who
were not exposed to UVR (Findlay, 1928). It is now well established that repeated
exposure to sun light, or artificial sources of UVR, such as tanning lamps, over a period
of years can lead to chronic degenerative changes in human skin - skin ageing,
premalignant and malignant skin lesions. Skin cancer in humans can be classified into
one of two categories, non-melanoma skin cancer (NMSC) and malignant melanoma.
NMSC are predominantly basal cell carcinoma (BCC) and squamous cell carcinoma
(SCC). Together, BCC and SCC are the most common cancer in humans (Glass and
Floover, 1989), but fortunately are also one of the most easily and successfully treated
cancers in man. In contrast, malignant melanomas are less common than NMSC,
although their incidence in increasing, but are potentially much more dangerous. Skin
cancer is a growing problem in the UK. Data from the UK cancer registries shows that
70,038 cases of skin cancer were registered in 2001 (Cancer Research UK, 2004). Of
these, the vast majority, over 62,700, were cases ofNMSC. It is known that not all cases
of NMSC are registered; therefore there the true number of NMSC cases will be higher.
More than 7,300 cases of malignant melanoma were diagnosed in 2001. In 2003, 2280
people died from skin cancer in the UK, of which 1770 were due to malignant melanoma,
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demonstrating the seriousness of this cancer. Within the last ten years, the problem of
malignant melanoma has dramatically increased; with the increase in incidence the
largest of all incidence rates compared with other major cancers (Cancer Research UK,
2002).
Tanenbaum et al (1976) found that individuals with a prolonged erythemal response or a
more intense erythemal response to UVR were at an increased risk of developing skin
cancer. Mutations in the tumour suppressor gene p53 are one of the most common in a
great variety of human cancers. Studies by Daya-Grosjean et al (1995) and Ziegler et al
(1993) suggested that UVR-induced mutations of p53 play a key role in the initiation of
NMSCs. Tandem dipyrimidine mutations in p53 are rare in internal cancers, with a
frequency of less than 1%, but occur in 14% of NMSC in the general population, and in
53% of NMSCs in Xeroderma pigmentosum patients. 61% of p53 base substitutions
occur opposite dipyrimidine sequences in internal tumours, compared with an increased
frequency of over 90% in NMSC (Daya-Grosjean et al, 1995).
UVR and DNA
UV-induced photoproducts
UVA and UVB are both able to mutate DNA. DNA is efficient at absorbing UVR, with
maximal absorption in the UVC region at around 260nm. There is also significant
absorption in the solar UVB region, as well as some absorption in the UVA region
(Sutherland and Griffin, 1981). UVB is therefore much more efficient at causing
biological damage than UVA, contributing around 80% towards UV-induced DNA
damage, while UVA contributes towards only 20% of UVR-induced DNA damage.
While UVB-induced DNA damage is direct, UVA-mediated damage occurs indirectly,
through absorption of UVR through exogenous sensitisers, which generate reactive
oxygen species (ROS). These oxygen radicals can in turn lead to breaks in the DNA,
which will ultimately cause the accumulation of mutations if not repaired. Cadet and
colleagues (2000) found that the oxygen radicals formed by UVA radiation target the
guanine base of DNA, giving rise to the mutagenic species, 8-hydroxyguanine. Of the
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UVR that reaches the earth, UVB is the most damaging component to animals, including
humans. UVB can penetrate the skin's epidermis, leading to erythema and burning at the
cutaneous level, but also inducing DNA damage at a cellular level, such as cyclobutane
pyrimidine dimers (CPD), and 6-pyrimidine-4-pyrimidone photoproducts (6-4PPs).
Figure 2, Pyrimidine dimer induced by UVR. This figure uses thymine as an example. Cytosine
may form a similar dimer.
CPDs are the major class of lesion produced by UVB radiation; 6-4PPs are the second
most common, with CPDs occurring 5-10 times more often (Eveno et al, 1995). CPDs
and 6-4PPs are most common where there are strings of pyrimidine bases in the DNA. 6-
4PPs are formed between the 5' six position and the 3' four position of two adjacent
pyrimidines, most often between TC and CC residues. UVB-induced DNA lesions are
extremely common - Ichihasi and colleagues (1998) found that exposure to sunlight for






the development of approximately 100,000 CPDs per cell. Left unrepaired this DNA
damage will result in the accumulation of DNA mutations, ultimately leading to
carcinogenesis. Ruven et al (1993) investigated the rate of repair of CPDs in the mouse,
and found that 60% of CPD repair activity in actively transcribed genes occurred within
the first four hours after exposure to UVR, with no repair in non transcribed strands, the
same group showed preferential repair of mutations in the p53 gene in the transcribed
strand of DNA in mouse skin, with 80% of lesions repaired after 24 hours, with no such
repair being observed in non-transcribed strands of the same gene (Ruven et al, 1994).
Mutations induced by both CPDs and 6-4PPs include C->T or CC->TT transitions, the
latter being a hallmark of UV damage. The mechanism that repairs these UVR-induced
lesions is known as Nucleotide Excision Repair (NER). As well as CPDs and (6-4)PPs,
UVR also induces other types of lesions, such as single-strand breaks in DNA. As
mentioned above, UVA, and visible light, induce DNA damage indirectly through the
generation of reactive oxygen species, short-lived, highly reactive molecules, which
produce single-stranded breaks in the DNA, DNA-protein crosslinks, and altered DNA
bases. Altered bases, in particular 8-hydroxyguanine, are a more frequent product of
reactive oxygen species than single-strand breaks or DNA-protein crosslinks (Tchou et
al, 1991).
Reactive oxygen species
Reactive oxygen species (ROS) are a family of oxygen-based free radicals that contain,
or are capable of producing, an unpaired electron. The major intracellular source of
oxygen radicals is probably leakage associated with the reduction of oxygen to water
during mitochondrial respiration. These products are singlet oxygen, peroxide radicals
(•02), hydrogen peroxide (H202) and hydroxyl peroxide (-OH). Extracellular sources of
reactive oxygen species include ionizing radiation, and UVR, particularly at 320 to
380nm (Tyrell, 1991).
At low levels, the superoxide ion, hydroxyl radicals, hydrogen peroxide and molecular
oxygen are involved with many cellular processes, such as cell proliferation, apoptosis
and cellular differentiation. However, overproduction, or the inefficient removal, of ROS
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generates oxidative stress, which has a negative impact on cellular integrity. The -OH
radical is the most directly damaging to DNA of these components. The -OH radical can
damage DNA directly by attacking the double bond of thymine at C-5 or C-6, and, to a
lesser extent, can abstract hydrogen from the methyl group (Jovanovic and Simic, 1986;
Simic, 1994). This intermediate can react with O2 to yield thymine glycol (Demple and
Linn, 1982) which appears to block DNA replication (Ide et al, 1985; Clark and
Beardsley, 1987; Clark et al, 1987). The -OH radical can also generate 8-
hydroxyguanine, due to the addition of the -OH group to C-8 of guanine (Jovanovic and
Smith, 1989; Kasai and Nishimura, 1991). 8-hydroxyguanine is a mispairing lesion
during DNA replication, which if not repaired will result in DNA damage (Kuchino et al,
1987; Shubutani et al, 1991; Cheng et al, 1992). Antioxidants help to delay or prevent
ROS-induced damage on cells, by reducing local oxygen concentrations, impairing chain
initiation reactions. Antioxidants include P-carotene, ascorbate, uric acid and glutathione
(GSH). GSH is an important water-phase antioxidant, which is conjugated by the
Glutathione S-transferase (GST) enzymes. GSH is involved in the recycling of oxidised
antioxidants and serves as a scavenger of O2 and OH (Rice-Evans and Burdon, 1994).
The effect of anthralin on DNA
Anthralin is a substance commonly used in the treatment of psoriasis (see Kemeny et al,
1990, for a review of its mode of action). The extract of the legume tree Andira araroba
(Goa powder) was first seen to be beneficial in the treatment of psoriasis by the English
dermatologist Squire. Liebermann and Seidler determined in 1878 that the active
component in Goa powder was the anthrone-derivative chrysarobin, l,8-dihdroxy-3-
methyl-9-anthrone. Based on this, the first synthetic psoriasis treatment, chrysarobin, 1,8-
dihydroxy-3-methyl-9-anthrone, was developed in Germany, and later named anthralin
(also known as dithranol). Anthralin acts via several mechanisms, which are not fully
understood, but include the inhibition of cell proliferation (Kemeny et al, 1990) and the
suppression of the immune system (Anderson et al, 1987). The antiproliferative effect is
thought to be due in some part to an effect on DNA duplication and repair (Lowe and
Breeding, 1981). Anthralin is highly reactive and is readily oxidised by light and oxygen
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(Hsieh and Acosta, 1991). Its oxidised metabolites lead to the formation of reactive
oxygen species (ROS) that are suggested to play an important role in the mode of action
of anthralin (Finnen et al, 1984). Anthralin has been shown to generate ROS in several
studies (Bruce et al, 1987, Muller et al, 1990, Halmekoski et al, 1982). Miiller et al
(1987) demonstrated that anthralin generates superoxide anion particles by the
measurement of the auto-oxidation of anthralin by the reduction of the superoxide
scavenger Nitro blue tetrazolium. The consequences of oxidative stress are repaired by
the DNA repair pathways base excision repair (BER) and nucleotide excision repair
(NER) (see later for details of these pathways). It is possible that polymorphisms in genes
involved in these pathways will affect the ability of the repair system to deal with the
oxidative stress generated, resulting in increased sensitivity to anthralin.
DNA Repair Pathways
Mammalian cells can make use of a variety of repair pathways, many of which overlap
and share components. DNA repair pathways show remarkable evolutionary
conservation, demonstrating their great importance. Lindahl (1993) estimates that several
thousand DNA alterations occur per cell per day. If efficient DNA repair pathways did
not exist, our DNA would be destroyed over our lifetime. NER, along with other repair
pathways, will be considered in some detail in this introduction.
Direct Reversal of Damage - Photoreactivation of DNA
Photoreactivation is a process that reverses the most common DNA lesions that are
induced by UVR, the CPD, in many prokaryotes and eukaryotes. It is not, however,
found above the evolutionary level of marsupials in mammals (Li et al, 1993; Yasui et al,
1994). The enzymes that catalyse this reaction are termed photolyases, and are most
widely studied in E.coli. In E.coli, under normal conditions, there are only 10-20
molecules of DNA photolyase. The photolyase has two chromophore co-factors, which
absorb light. Upon absorption of a single photon by one chromophore, its excitation
energy is transferred to the second chromophore. Excitation of the second chromophore
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leads to electron transfer to the CPD. This electron transfer causes the cyclobutane dimer
to revert to a monomeric state.
Double Strand Break Repair
Double stand breaks (DSBs) in DNA can occur for a number of reasons, and can be
environmental or spontaneous. Environmental causes of DSBs include ionising radiation,
free radicals and mechanical stress. DSBs can also occur due to endonuclease activity in
the DNA repair process and due to recombinational events, such as meiosis or V(D)J
recombination, which are normal cellular processes. Leaving DSBs unrepaired can lead
to DNA mutations or rearrangement of chromosomes, which prevents the correct
segregation of the genome to daughter cells.
In mammals, the main pathway for the repair of DSBs is Non-Homologous End Joining
(NHEJ). In lower eukaryotes, such as yeast, homologous recombination (HR) carries out
DSB repair.
During NHEJ, an extended region of homology between the DNA strands at the repair
site is not needed. This enables NHEJ to take place when there is as little as a single
complementary base pair between the overhanging ends of DNA. Roth and Wilson
(1986) determined that NHEJ is required to rejoin specific DSBs produced during V(D)J
recombination. Mammalian cells deficient in NHEJ are immunodeficient, due to their
inability to complete V(D)J recombination, and are hypersensitive to ionising radiation
which induced DSBs (Baumann et al, 1998).
NHEJ in eukaryotes has been analysed through in vitro studies, and the proteins required
have been shown to be DNA Ku, DNA-PK(cs), XRCC4 and DNA ligase IV, which either
bind the ends of linear DNA directly, or through associations with other proteins. In
yeast, Rad50, Mrel 1/Xrs2 and the Sir proteins 2, 3 and 4 are also required. DNA-PK(cs)
is the catalytic subunit of DNA protein kinase, which regulates kinase activity through its
association with the DNA. DNA-PK(cs) is recruited to the site of the DSB by the DNA
Ku protein, a heterodimer of Ku70 and Ku80, which when all together comprise the
whole DNA protein kinase complex. XRCC4 and DNA ligase IV form a complex, which
ligates one strand of the DNA with minimal base pairing to the anti-parallel strand. If the
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repair process needs to remove any overhanging DNA at the site of the DSB, or
resynthesise a missing gap, nuclease or polymerase is required. Overhanging DNA
sequences can occur as the DNA is being aligned according to regions of
microhomology. The polarity of the DNA strand determines which type of nuclease is
required, Wu et al (1999) and Lieber (1999) proposed that the 5' nucleases FEN1 and
EXOl, and the 3' nuclease MEW11 might be likely candidates. An alignment protein,
which was proposed by King et al (1994) to be DNA polymerase, is thought to be
required to hold the strands in place while any modifications are being carried out before
the ligation of both strands by DNA ligase IV. Murine knockouts of DNA ligase IV and
XRCC4 are embryonic lethals, due to their inability to carry out NE1EJ (Lieber, 1999).
Small deletions in the DNA that extend in both directions from the DSB site and end
within the region of microhomology is a common result of NHEJ, and typically results in
regions of short repeats around the DSB.
Homologous Recombination
Homologous Recombination (HR) gives faithful restoration of a sequence at the point of
the DSB. The process requires a non-damaged template for the restoration of the
damaged or missing sequence; the homologous chromosome to the damaged DNA. The
5' strand ends of the DSB are digested by a nuclease, believed to be encoded from the
Mrel 1/RAD50/Nbsl (MRN) protein, to yield 3' single stranded overhanging tails
(D'Amours and Jackson, 2002; Tauhi et al, 2002). The RAD52 group of genes then
encode a protein that binds to the 3' single strand DNA ends in S.cerevisiae (Van Dyck et
al, 1999; Stasiak et al, 2000). This complex targets the template for repair, the
homologous intact duplex DNA on the undamaged chromosome. Single strand exchanges
occur, leading to the formation of Holliday junctions, joint molecules between the
damaged strand and the template strand. Synthesis of the missing DNA is initiated, and
the Holliday junctions are then resolved (Szostak et al, 1983).
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Base Excision Repair
Base Excision Repair (BER) removes damaged or inappropriate DNA bases, which can
be small DNA adducts, fragmented bases, oxidised and reduced bases and
apurinic/apyrimidinic (AP) sites. This DNA damage can come from a number of sources,
free radicals resulting from normal metabolic processes or ionising radiation can give rise
to reduced or fragmented bases, spontaneous hydrolysis or oxidative damage can give
rise to AP sites. There are two subpathways of BER, which contain some common
proteins; short-patch BER, which repairs single bases, and long-patch BER, which repairs
strands of bases from 2-10nt long.
Short-patch BER
In the short patch BER pathway, recognition of a damaged base and initiation of BER is
carried out by a DNA glycolyase specific to that base, for instance, the base uracil, which
is inappropriate for DNA, is recognised by uracil-DNA glycosylase, while methylated
adenine is recognised by 3-methyladenine DNA glycosylase. Human glycosylases have
structural and functional homology to bacterial glycosylases, for example, the human
glycosylase NTH1, which has specificity for a variety of oxidised pyrimidines, has been
shown to be the homologue of the bacterial endonuclease III (Aspinwall et al, 1997). The
N-glycosylic bond between the base and the deoxyribose-phosphate backbone is then
hydrolysed, releasing the base (Dianov and Lindahl, 1994; Frosina et al, 1996; Lindahl,
1995). Paradoxically, this then forms an AP site, which in itself is a type of DNA
damage. REF1, an AP endonuclease, makes an incision 5' to the AP site by hydrolysis of
the bond in the phosphodiester backbone (Demple and Harrison, 1994; Sancar and
Sancar, 1998; Wallace, 1998). The AP endonuclease leaves a strand break with a 5'
terminal deoxyribose-phosphate moiety (dRP), which must be removed before repair
synthesis can occur. In short-patch BER, the deoxyribose 5' phosphatase activity of the
DNA polymerase p removes the dRP, and DNA polymerase P can then synthesise new
DNA. DNA ligase III and XRCC1 are responsible for the ligation of the newly
synthesised DNA to the damaged strand. DNA polymerase P is thought to be regulated
by the tumour suppressor p53, thus p53 can affect BER. Zhou et al (2001) determined
that cells that lacked p53 were deficient in BER.
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Long-patch BER
During long-patch BER, the dRP moiety, along with several downstream nucleotides, is
removed by flap endonuclease I (FEN1). The damaged bases being repaired are
displaced, creating a 5' terminal overhang. FEN1 binds to and moves along the
overhanging region from the 5' end, until it reaches the cleavage site. Here it makes an
incision that releases the overhanging region. PCNA interacts with FEN1, enhancing its
ability to bind and cleave. FEN 1 is displaced from PCNA by p21, and released from the
replication fork for the removal of the dRP. DNA polymerases 8 and/or s are utilised in
the place of polymerase p in long-patch BER, and ligation is performed by DNA ligase I
(Fortini et al, 2003; Klungland and Lindahl, 1997).
Defects in key proteins of the BER process, such as AP endonuclease or DNA
polymerase P, lead to embryonic lethal phenotypes in the mouse, indicating the repair of
endogenous DNA lesions is essential during development (Wood and Thompson, 1997).
Mismatch Repair
Mismatched bases can be introduced into DNA during DNA synthesis or recombination
events. Bases can be incorporated during synthesis if they occur opposite bases that have
been damaged by oxidation or UVR. Bases can be introduced during recombination if
there are differences between the sequences of the DNA strands that form the
heteroduplex. Mismatched bases can also occur when imperfect palindromes in the DNA
sequence form hairpin structures, or when deamination of a methylated cytosine (5-
methylcytosine) in a G:C pair leads to the incorporation of a T opposite the G. In
mismatch repair, the mismatched bases do not have to be biochemically altered or
damaged; they can simply be in the wrong location. Genes involved in mismatch repair
(MMR) are highly conserved between prokaryotes and eukaryotes (for a general review
of mismatch repair, see Friedberg et al, 1995).
When a mismatched base occurs during DNA synthesis or recombination, it must be
recognised as such, and dealt with, so that it does not become a permanent fixture. The
correct strand of DNA must be used as a template to resynthesise the base. In
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prokaryotes, the distinction between the two DNA strands occurs following replication by
determining the methylation state of the newly synthesised strand. As there is a delay
between the synthesis and methylation of DNA, mismatches in the daughter strand can be
identified after replication as being on the daughter strand, as this strand is
undermethylated compared with the parental strand. This ensures the correct strand is
repaired, and is referred to as methyl-directed MMR. A number of genes involved with
methyl-directed MMR are conserved between prokaryotes and eukaryotes. In E.coli,
MutS, MutL and MutH are crucial to the MMR process (Rydberg, 1978). Mismatches are
initially recognised by the protein MutS (Su et al, 1998). MutL is thought to be a
secondary recognition factor in MMR due to its ability to bind MutS bound heteroduplex
mismatches. MutH distinguishes the two strands on the basis of their methylation state,
and has some endonuclease activity that allows it to cut 5' to the mismatch on the
daughter strand (Langle-Ronault et al, 1987; Lahue et al, 1989). The DNA around the
mismatch is then unwound by DNA helicase II. The mismatch is excised, and DNA
polymerase III synthesises new DNA. It is likely that DNA ligase is required to seal the
strands, as the co-substrate for DNA ligase, NAD+ has been shown to be required for
MMR. In man, at least six different proteins are involved with MMR. The MSH2 protein
forms a heterodimer with either MSH6 or MSH3, for mismatch recognition (Marsischky
et al, 1996; Kolodner and Marsischky, 1998). MSH6 is required for the correction of
single-base mispairs, while both MSH6 and MSH3 may be involved in the correction of
insertion-deletion loops. The interaction between the mismatch recognition complex and
other proteins necessary for MMR is coordinated by a heterodimer of the proteins MLH1
and PMS2. Other required proteins are thought to include exonuclease I, PCNA, and the
DNA polymerases 8 and s (Bertrand et al, 1998).
Inherited errors in the MMR system are involved with the hereditary nonpolyposis colon
cancer syndrome. Hereditary nonpolyposis colon cancer (HNPCC) is one of the most
common cancer syndromes in humans. Germline mutations in one of four major
HNPCC-associated MMR genes, MLH1, MSH2, MSH6 and PMS2 are detected in up to
80% of HNPCC families. Defective MMR capacity is associated with other cancers
outside the HNPCC syndrome, such as cancer of the prostate (Yen et al, 2001), of the
bladder (Thykjaer et al, 2001) and oesophagus (Uchida et al, 2001).
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Nucleotide Excision Repair
Nucleotide excision repair (NER) can repair a wide spectrum of DNA damage, including
lesions induced by UVR, cross-linking agents, free radicals and interstrand crosslinks
(Wood, 1996; Sancar 1996, Lindahl et al, 1997). NER is the sole mechanism for the
removal of bulky chemical adducts such as CPDs and 6-4PPs induced by UVR.
During NER, a single stranded fragment of around 30 nucleotides (Friedberg, 2003),
which contains the lesion, is excised from the double helix. The remaining strand is used
as a template to synthesise a new, lesion-free strand. There are 5 stages ofNER, a) the
recognition of the DNA lesion which is distorting the double helix; b) unwinding of the
helix; c) incision upstream and downstream of the lesion (the so-called Dual Incision); d)
synthesis of the new DNA strand, and e) ligation of the strand breaks.
Two sub pathways of NER exist, global genome repair (GGR) and transcription-coupled
repair (TCR) (Bohr et al, 1985; Mellon et al, 1987; Mellon and Hanawalt, 1989). GGR
acts over the entire genome at a slower rate than TCR, which is more rapid, preferentially
repairing expressed genes on the transcribed strand. The main difference between the
processes is the way in which the DNA damage is recognised. A complex of the 125-kDa
XPC protein and 58-kDa HHR23B recognises DNA damage during GGR, while the
stalled RNA polymerase II complex recognises the damage in TCR. Upon recognition of
a DNA lesion in GGR the XPC/HHR23B complex binds to the lesion site, distorting the
helical structure and leading to partial opening of the helix. The DNA surrounding the
lesion is opened further by 3 protein complexes, TFIIH, XPA and replication protein A
(RPA). TFIIH is a 9-subunit complex involved in the initiation of RNA polymerase II
transcription (Conaway and Conaway, 1989; de Laat et al, 1999), NER (Feaver et al,
1993, Schaeffer et al, 1993; Drapkin et al, 1994; van Vuuren et al, 1994; Vermeulen et
al, 1994; Wang et al, 1994) and possibly in the regulation of the cell cycle (Feaver et al,
1994; Serizana et al, 1995). TFIIH is recruited to the damage through its affinity to bind
with the C-terminus of XPA. TFIIH contains 2 DNA helicase subunits, XPB and XPD
(van Vuuren et al, 1994), which are ATP-dependent. XPB and XPD unwind the DNA in
opposite directions; XPB is a 3' to 5' helicase while XPD is a 5' to 3' helicase. XPA
verifies the damage, and is crucial for the assembly of the rest of the repair machinery.
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RPA binds to the undamaged single strand DNA, preventing both the formation of
secondary structures and the undamaged single stranded region from being cut, which is
important, as it is the template for repair replication. The exonucleases required for the
dual incision are the ERCC1/XPF complex at the 5' end, and XPG at the 3' end. Free
ERCC1 (33kDa) and XPF (120kDa) are rapidly degraded in the cell (Sijbers et al, 1996).
They are tightly bound in complex, which is achieved by the interaction of the C terminal
amino acids 224 to 227 of ERCC1 and the C terminal amino acids 814 to 905 of XPF.
XPG is recruited by the N-terminal domain of XPC, and incises the DNA 6-9 nucleotides
(nt) 3' of the lesion (O'Donovan et al, 1994; Huang et al, 1992). The ERCC1/XPF
complex then makes the second incision 15-24 nt 5' to the incision. RPA is responsible
for the correct orientation of the endonucleases. When it is bound to the undamaged
single strand of DNA, the 3' orientated side of RPA binds the ERCC1/XPF complex, and
the 5' orientated side binds XPG (de Laat et al, 1998).
The 22-32nt excised fragment leaves a single strand gap, which is still bound by RPA
(Mu et al, 1996). The single strand gap is fdled by DNA polymerase 5 or 8 and
replicating factor C (RPC). Petit and Sancar (1999) showed both polymerases to be
proliferating cell nuclear antigen (PCNA)-dependent. PCNA is recruited to the template
strand by XPA. RF-C facilitates binding of PCNA onto the template, followed by the
DNA polymerase. The DNA polymerase adds nucleotides to the affected strand in a 5' to
3' direction. The last two nucleotides cannot join together, and the repair process is
completed with the ligation of the newly synthesised DNA to the original sequence, a
reaction which DNA ligase I can catalyse.
Global genome repair and transcription-coupled repair follow the same mechanisms,
apart from the initial damage recognition. The XPC/HHR23B complex is not needed in
TCR (Venema et al, 1990, 1991; van Hoffen et al, 1995), as the RNA polll complex that
is transcribing the DNA is stalled by the presence of a lesion (de Boer and Hoeijmakers,
2000). Here, the stalled RNA pol II acts as the signal to attract the NER proteins. The rate
of repair by GGR varies depending upon the lesion type. For example, 6-4PPs are
removed much more quickly than CPDs from the genome, most likely because of
differences in the affinity of XPC-HHR23B. The location of a lesion and how accessible
it is also affects the lesion removal rate.
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Araujo et al (2000) demonstrated that the overall genome repair reaction could be
reconstituted in vitro with recombinant human proteins. Repair can be achieved in vitro
by the concomitant presence of 10 components, RPA, XPA, XPC/HHR23B, XPG,
ERCC1/XPF, TFIIH, DNA pol 8 and/or e, RPC, PCNA and DNA ligase I. However, this
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In contrast to defects in BER, which are embryonic lethal, defects in NER in man can
lead to a variety of phenotypes. Defects in NER are associated with three rare recessive
syndromes, Xeroderma pigmentosum (XP) (see OMIM entry 278700 and entries therein),
Cockayne's Syndrome (CS) (OMIM %216400 and entries therein) and
Trichothiodystrophy (TTD) (#601675 and entries therein).
Xeroderma pigmentosum
Xeroderma pigmentosum (Xeroderma meaning parchment skin, and pigmentosum
reflecting freckling, both of which are seen in this disease) is a rare, autosomal recessive
disorder, where affected individuals are extremely photosensitive. Mutations in several of
the genes involved in XP give rise to similar phenotypes (Boulikas, 1996). Its incidence
varies according to geographical location, with a frequency of around 1 in 1 million in
Europe and the United States, and 1 in 100,000 in Japan (Takebe et al, 1987). As a result
of the extreme photosensitivity, sufferers have a more than 1000-fold increased risk of
skin cancers, both non-melanoma and melanoma on sun-exposed sites, with a mean age
of onset of around 8 years of age, 50 years earlier than in the US white population
(Kraemer et al, 1994). This is one of the largest reductions of age of onset of cancer of
any genetic disorder. Stringent measures of avoiding UVR results in a lack of the
cutaneous damage usually seen in XP (Davis et al, 1994). It is unclear whether the
heterozygous genotype, with one wild-type repair gene and one mutated repair gene, has
any phenotypic effect, such as increased sensitivity to UVR and a higher skin cancer risk,
although increased freckling has been claimed to be such a manifestation. Normal skin
fibroblasts can repair UVR-induced DNA damage, however, Cleaver (1968), in a seminal
paper, found that fibroblast cells from XP patients have a greatly reduced ability to repair
UV-induced DNA damage. Cell fusion experiments identified 7 complementation groups
in XP (XP-A to -G), and a variant form, XPV. In XPE and XPV, NER is either normal or
only slightly reduced. Defects in XP cell lines from different complementation groups
vary in the ability to repair the two main classes of UV-induced mutations, CPDs and 6-
4PPs, indicating that different subpathways of NER repair the two types of lesions.
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The photosensitivity is due to defective NER, which results in the accumulation of
photoproducts that are converted to mutagenic mutations during semi-conservative DNA
synthesis. Thompson (1998) determined that the extent of DNA repair deficiency, as
measured by cell survival curves and incision activity, correlates with the age at which
symptoms develop, and the rate of tumour growth. There is also an increased risk of
tumour development on other sites that are exposed to UVR, such as the tip of the tongue
and the eyes (Kraemer et al, 1987, 1994), as well as an increased incidence of internal
tumour development. Patients develop progressive neurological abnormalities in 20% of
XP cases, this being more common in XP-A patients than XP-D and XP-G patients. Loss
of neurons, particularly in the cerebellum and cerebral cortex (Thompson, 1998) leads to
these neurological abnormalities, which can include hyporeflexia, sensorineural deafness
mental retardation and microcephaly. There can also be, in some cases, slowed growth
and delayed onset of secondary sexual characteristics. The degree of severity of
neurological dysfunction also seems to be associated with the level of NER deficiency.
Andrews et al (1978) demonstrated a correlation between the degree of sensitivity of
cultured fibroblasts to UVR (as measured by their ability to form colonies) and the
severity of neurological abnormalities. They concluded that DNA repair is required for
maintenance of the functional integrity of the nervous system, by preventing the
premature death of neurons. Neurological damage is thought to occur due to an inability
to repair oxidative DNA damage in the brain.
Swift and Chase (1979) examined the families of 31 XP patients, and observed that
significantly more blood relatives had had NMSC than spouse controls. This supports the
hypothesis that individuals heterozygous for XP genes may be predisposed to skin
cancers, perhaps in association with a substantial amount of exposure to UVR, which
could overwhelm their DNA repair genes.
Cockayne's Syndrome
Individuals with CS are also photosensitive, although much less so than those with XP, or
those with combined XP/CS, and are not predisposed to skin cancer. Patients with CS
suffer a range of symptoms, which include dwarfism, due to arrested growth and
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development (despite normal growth hormone levels), progressive neurological
degeneration and a shortened lifespan (median life span 12 years). The neurological
abnormalities seen in CS are due to demyelination in nerve tissue. Other classical features
of the CS phenotype are cataracts, deafness, dental caries, intracranial calcifications, and
abnormally large facial features and limbs in proportion to body size.
Cell fusion experiments have identified 5 complementation groups associated with CS,
although only those not also associated with XP are formally recognised as CS (CS-A
and CS-B). The genes mutated in CS-A and CS-B have been cloned. Orrent et al (1996)
transfected the normal CSB gene into hamster cells with the CSB phenotype, and found
that the TCR-deficiency and UV-sensitivity found in these cells was restored to that seen
in normal cells, indicating that the defect in TCR in CSB cells is due to mutations in the
CSB gene. Depending on the mutations involved, the CS that is associated with XP is
referred to as XP-B/CS, XP-D/CS or XP-G/CS.
XP/CS patients show the same level of photosensitivity as in XP, and will, in some cases,
go on to develop skin cancers. They do not, however, develop primary neuronal
degeneration, or ichthyosis or brittle hair. There is higher neurodysmyelination than in
CS alone, or TTD, but mental retardation and failure to grow is similar to CS and TTD.
Cells from patients with XP/CS are more sensitive to UV killing than even XP-A cells,
although the repair deficiency is similar to that found in XP-D cells, which are less
sensitive to UVR. (Lehman, 2001). Cells from CS patients have UV hypersensitivity due
to a defect in NER. UV-induced CPDs (but not other photoproducts) are unable to be
repaired from the template strand in actively transcribed DNA as the cells are defective in
TCR. RNA synthesis is normally depressed following UVR, recovering after repair of
DNA damage. In CS cells, this defect in TCR means that the damage in actively
transcribing cells is not repaired and the RNA levels cannot return to normal after DNA
damage. A clinical method of diagnosing CS is to measure the recovery rate of RNA
synthesis following UV-induced DNA damage. The defect in TCR in CS is not only
found after exposure to UVR, but also after exposure to forms of oxidative stress (Cooper




TTD is a term first introduced by Price et al in 1980 for sulphur-deficient brittle hair.
TTD is an autosomal recessive disorder, comprising a variety of different sulphur-
deficient brittle hair disorders, including Pollitt (OMIM %275550), Amish brittle hair
brain syndrome (#234050), and Sabinas brittle hair syndrome (OMIM %211390)
(Bergmann and Egly, 2001). Approximately half of all TTD patients are photosensitive,
which is linked to deficient excision repair as seen in XP cell lines. These TTD patients
fall within the definition PIBIDS, standing for Photosensitivity, Ichthyosis, sulphur- and
cysteine- deficient Brittle hair, impaired Intelligence (mental retardation, spasticity,
tremor and ataxia), Decreased fertility, and Short stature. The severity of symptoms can
vary, from mild to extremely severe, leading to a failure to thrive and/or death in early
childhood. TTD is not however a cancer prone disease, and patients have no
predisposition to skin cancers, as seen in XP (Itin and Pittelkow, 1990; Stary and Sarasin,
1996). Neuronal abnormalities in TTD are predominantly due to demyelination.
Cellular features of the NER deficiency syndromes
Cell fusion experiments have identified 3 complementation groups in TTD; XP-D, which
accounts for the majority of TTD patients, XP-B and TTD-A, whose protein is part of the
basal transcription factor TFIIH (Thompson, 1998). The most highly photosensitive TTD
lines are found within the XP-D complementation group, with the XPD gene being able
to correct the repair deficiency in these cells. The ability of XPD to correct the repair
defect was explained when it was found to be involved with both NER and transcription.
Only XP is associated with the early onset of skin cancer. All three disorders possess a
degree of defectiveness in NER capacity, reflected in the photosensitivity the patients
display. Most XP groups are deficient in both GGR and TCR, except XP-C, where only
GGR is defective. CS groups are defective in TCR, XP/CS is defective in both. TTD
groups are defective in transcription, while the NER level can be normal, intermediate or
defective. Transcription-coupled repair, rather than global genome repair is implicated in
27
the detection and repair of UV induced erythema and resulting DNA damage. Garssen et
al (2000) examined levels of UVB-induced erythema, as determined as the lowest dose of
UV that was able to induce a significant oedema and erythema (the MED), in mouse
models. Wild type mice, with efficient GGR and TCR sub pathways of NER had an
MED of 1500J/m2. XPA mice, which are deficient in both GGR and TCR, were
significantly more sensitive to UVR, with an MED of <150mJ per cm/m2. A similar
MED was observed in CSB mice, which are efficient at GGR, but deficient in TCR. XPC
mice have deficient GGR, but wild type-levels of TCR. XPC mice showed similar MED
to wild type mice, i.e. 1500J/m2. As mice with deficient GGR only had UVR sensitivity
equivalent to that observed in wild type mice, and mice which have deficiencies in both
GGR and TCR (XPA mice) are no more sensitive to UV than mice with only TCR-
deficiency, these results indicate that erythema reactions induced by UV are primarily
determined by TCR alone. This data obtained from mouse studies is in agreement with
Japanese studies of XP patients. Ichihashi et al (1981) and Kondo et al (1989) found
XPA patients had a low MED, while patients with XPC had MEDs within the range seen
in healthy humans (Kondo et al, 1992).
The wide clinical heterogeneity seen associated with NER defects is likely due to
additional functions of the NER components involved.


























* These XP patients have DeSanctis Cacchione Syndrome, cutaneous XP associated with
microcephaly, progressive mental degeneration, dwarfism and immature sexual
development.
The identification of XP, CS and TTD groups by complementation studies were mainly
based on analysis of repair capacity of the different cell lines. Overlap between XP cell
lines and some phenotypically similar rodent cell lines, which contain 11
complementation groups, lead to studies investigating whether human DNA could rescue
the rodent phenotypes. A series of genes which, when transfected into rodent mutants,
corrected the rodent phenotypes, was cloned, and designated ERCC (standing for
Excision Repair Cross Complementing). These are ERCC1, ERCC2, ERCC3, ERCC4,
ERCC5, ERCC6 and ERCC8, and they partially overlap with XP genes (Wood, 1997).
ERCC2 is equivalent to XP-D, ERCC3 to XP-B, ERCC4 to XP-F, ERCC5 to XP-G,
ERCC6 to CS-B and ERCC8 to CS-A. Mutations in rodent groups 1 and 4 display
extreme hypersensitivity to DNA cross-linking agents, such as mitomycin C and
cisplatin, a feature which is not seem amongst human NER mutants. Mutant groups 1 and
4 are unique in this respect among the NER-deficient phenotypes in mammalian cell
mutations (Thompson, 1998).
DNA Repair Capacity
Variation in DNA repair capacity, as measured by several lymphocyte assays, has been
observed in the general population. Individuals with a repair capacity of 65-80% of the
population mean have been observed more often in cancer cohorts than in control cohorts
in several studies of different cancer types, such as basal cell carcinoma (Wei et al,
1994,1995), lung cancer (Wei et al, 1996) and squamous cell carcinoma of the head and
neck (Cheng et al, 1998), although other studies have not observed a reduced repair
capacity in patients with basal cell carcinoma (Hall et al, 1994) or cutaneous melanoma
(Xu et al, 2000) suggesting further analysis is required. Repair capacity of 65-80% of the
mean has been found, at least by some, to constitute a risk factor for cancer. When this
level of repair capacity is compared with that seen in cells from XP patients, which can
have a NER repair capacity barely above the experimental background level of around
2% of the general population mean, it is feasible that even small amino acid changes (that
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do not lead to XP, TTD or CS) in genes involved with the NER pathway might constitute
a cancer risk in the general population. This may also be true of genes involved in other
DNA repair pathways.
Genes analysed in this study
XPD (ERCC2)
As previously described, the XPD gene encodes a protein essential to the NER pathway,
an 86.9 kDa 5' to 3' DNA helicase which is a component of the TFIIH complex. The
TFIIH complex is involved in the initiation of RNA polymerase II transcription and
Nucleotide Excision Repair; de Laat et al (1999) suggest that it might also be involved
with the regulation of the cell cycle. XPD contains 23 exons, which are highly conserved
in humans, the hamster (90% identity with human), mouse (89.8% identity) and fish,
Xiphophorus maculates (76% identity), (Lamerdin et al, 1996), highlighting the
evolutionary importance of XPD, although the introns are not conserved. Flejter et al
(1992) proved that the ERCC2 gene corrected the UVR-sensitivity and defective
nucleotide excision repair seen in cells from patients with XP complementation group D,
and that ERCC2 and XPD are the same gene. The human XPD maps on the long arm of
chromosome 19, bands 13.2-13.3. This same region contains other repair genes, ERCC1
(crucial to the NER pathway) and XRCC1, a component of the BER pathway. It also
contains apoliprotein (APO) genes, the muscle creatine kinase (CKM) gene locus, the
myotonic dystrophy (DM) gene, and DNA ligase I. Lamerdin et al (1996) determined the
organisation of this region to be:
centromere....3,XRCC15'...APO....3'CKM5'...3,XPD5'...3'ERCC15'....DM...tel
The CKM, XPD and ERCC1 genes are physically linked within an approximately 250kb
segment, therefore if a mutation in the XPD gene gave rise to an increased cancer risk,
CKMM and ERCC1 might seem to show an association too.
The XPD protein is 760 amino acids (aa) in length, and it too shows a high degree of
homology with its hamster, mouse and fish equivalents. The main structures of the XPD
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protein are an ATP binding motif, at aa35-52, a putative nuclear localisation signal
(aa234-237) and seven helicase motifs (amino acids 35-51, 69-88, 225-240, 464-478,
539-360, 587-611 and 654-671). Hoeijmakers (1993) and Ellis (1997) identified a DNA
binding domain within helicase motif V, one of the regions where the majority of
mutations in XP, XP/CS or TTD mutations occur (the others being helicase motifs I, II,
III and VI). The N-terminus interacts with the C-terminal domain of p53 (Leveillard et al,
1996).
Polymorphisms in the XPD gene in the general population were identified by Shen et al
(1998), who proposed that they might have associations with increased risk of
susceptibility to different cancers.
Vodicka et al (2004) studied the frequency of chromosomal aberrations and single strand
breaks in DNA in cells from individuals with different genotypes at the exon 23
polymorphism of XPD. Chromosomal aberrations are positively associated with the onset
of cancer, particularly in smokers (Bonassi et al, 2000). Vodicka et al found that the CC
genotype had less chromosome aberrations than the AA and AC genotypes (p=0.028),
and lower levels of single strand breaks in DNA after gamma irradiation (p=0.033),
which might suggest the CC genotype confers some protective affect against the
development of cancer, and is more efficient at repairing chromosomal aberrations, or is
less prone to them in the first place.
Tomescu et al (2001) found associations between 3 polymorphisms in XPD (which were
an A to C change in exon 6, a C to T change in exon 22, and an A to C change in exon
23) and an increased risk of cutaneous melanoma. Two of these polymorphisms, in exon
6 and exon 22, do not result in an amino acid substitution, while the third, in exon 23
leads to a Lys-> Gin change. In a study of 28 patients with melanoma and 33 matched-
controls the A allele at exon 6 was found to be over- represented in the melanoma cohort,
although this was not formally significant (Odds Ratio (OR) 2.0, 95% Confidence
Interval (CI) 0.9-4.5, P=0.08. The C allele in the exon 22 polymorphism was also
significantly over-represented in the melanoma patients, with an OR 2.6, 95% CI 1.1-6.7
and P value of 0.04. In exon 23, the A allele was more frequent in the melanoma cohort
(OR 2.8, 95% CI 1.2-7.0, P= 0.02). Winsey et al (2000) investigated the exon 6 and exon
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23 polymorphisms in melanoma patients, and found no association between either
polymorphism genotype and melanoma risk.
The XPD exon 6 polymorphism has been observed to be associated with an increased risk
of basal cell carcinoma (OR 1.9; 95% CI 1.0-3.8, Vogel et al, 2001). The association was
higher among individuals with no family history of non-melanoma skin cancer. The exon
6 polymorphism has also been studied for possible associations with other cancers. Mort
et al (2003) examined a cohort of colorectal cancer patients to determine any association
between colon cancer and a variety of repair genes. Mismatch repair has been shown to
be important for the prevention of the development of colorectal cancer, with deficiencies
in MMR seen in 15% of cases. No association was found between exon 6 of XPD and
colorectal cancer, or exon 22 or 23, which are also examined here.
The XPD exon 23 polymorphism has been analysed for association with lung cancer by
several groups. Carcinogens in tobacco smoke induce lesions in DNA, which are part of
the wide range of DNA damage repaired by nucleotide excision repair. As the XPD gene
is crucial for efficient NER of DNA, it is possible that if the XPD exon 23 polymorphism
is functional it could give rise to an increased risk of lung cancer in smokers. The exon 23
polymorphism was studied in a large, hospital-based study in America by Zhou et al
(2002) for any association with lung cancer. 1092 cases and 1240 controls were analysed.
No increased risk of lung cancer was seen in the overall data set; however, an increased
risk of lung cancer was observed in non-smokers (OR 2.0; 95% CI 1.1-3.4). Hou et al
(2002) found a similar association with smoking status in a smaller study in Sweden,
although other investigators have found no suggestion of association or an interaction of
the exon 23 polymorphism with smoking status influencing lung cancer risk (Park et al,
2002; David-Beabes et al, 2001).
The three polymorphisms described in XPD will be analysed to determine any




In complex with XPF, ERCC1 makes the 5' incision to damaged DNA during NER. The
gene is approximately 15kb in size, and is located close to XPD, on human chromosome
19ql3.2. The ERCC1 cDNA gives rise to a transcript of l.lkb, which encodes a 297
amino acid product. The human ERCC1 gene was used as a probe to isolate the mouse
ERCC1 gene. The human and mouse genes are highly conserved, with their proteins
showing an 85% amino acid similarity. Human ERCC1 is also homologous to the
Saccharomyces cerevisiae RADIO gene, which links with RAD1 to form an
endonuclease, and the Saccharomyces pombe swi 10 gene (Rodel et al, 1997),
highlighting its evolutionary importance.
XPF (ERCC4)
A previously described, XPF and ERCC1 form a complex, which is the endonuclease
responsible for making the incision 5' to the damaged DNA during NER. The XPF gene
was identified by Sijbers et al (1996), who isolated a human gene which was homologous
to the yeast gene Radl, and found it to correct the repair defects seen in cells from
patients in the XP group F, as well as the rodent group 4. The XPF gene contains 11
exons, and spans 28.2kb (Brookman et al, 1996). As ERCC4, the gene was mapped to
chromosome 16 (Siciliano et al, 1987), which was refined to 16p 13.2-p 13.1 by Sijbers
and colleagues.
None of the human NER-deficiency disorders, XP, TTD or CS, are associated with
mutation of ERCC 1, leading to suggestions that ERCC 1 -deficiency results in an
embryonic lethal phenotype. Erccl-deficient mice were produced by gene targeting by
McWhir et al (1993). The Erccl-deficient pups were severely runted, weighing 20% less
than their wild-type littermates. The liver cells of these mice were abnormal, resulting in
polyploid liver cells, which are normally only found in older mice. The Erccl-deficient
pups died within three weeks of birth, prior to weaning. The human and mouse proteins
have an 85% homology, therefore it is possible that a complete lack of ERCC 1 function
in humans may indeed give rise to an embryonic lethal phenotype. Mutations which give
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rise to a less severe genotype could give rise to a reduced repair capacity phenotype in
humans, leading to increased cancer risk.
As well as its role in NER, the ERCC1 -XPF complex has also been shown to be involved
in recombination repair processes distinct from NER. Chipchase and Melton (2002)
demonstrated that rodent cells, in which chromosomal aberrations are common after
exposure to UVR, which do not express ERCC1 or XPF have a lower ratio of chromatid
exchanges to breaks than wild type cells which are not deficient in ERCC1 or XPF. Cells
deficient in other genes involved with NER (XPB, XPD and XPG) display similar rations
of exchanges to breaks as wild-type cells, implying that ERCC1 and XPF are involved in
the formation of UV-induced chromosomal aberrations out with their role in NER. The
dual role of ERCC 1 and XPF in the defence of DNA against UV-induced damage
suggests that polymorphisms of these genes would be good candidates for markers of
association with UV-induced erythema, which is itself a marker for UV-induced DNA
damage.
XPG (ERCC5)
ERCC5 was localised on chromosome 13 by Siciliano et al (1987) and Thompson et al
(1987) by the study of somatic cell hybrids between normal cells, and Chinese hamster
cells which had a repair deficiency. ERCC5's location was further refined to 13q32.3-
q33.1 by use of fluorescence in situ hybridisation (Takahashi et al, 1992).
The XPG-complementing protein was generated from a 4kb mRNA, which was present
in normal amounts in XPG cell lines. An antibody directed against a fragment of the XPG
complementing protein inhibited excision repair by normal cell extracts, this activity
could be re-established with an XPG/group 5 complementing fraction. ERCC5 and XPG
were confirmed as being the same by sequence analysis of the cDNAs by Maclnnes et al
(1993).
The polymorphism at exon 15, a G to C change, which leads to an amino acid change
(from Asp to His) has been studied by a number of groups. This change does not result in
an XP or XP/CS phenotype.
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As mentioned above, XPG patients that have a truncated version of the XPG protein also
suffer from CS (Vermeulen et al, 1993; Nouspikel et al, 1997). In addition to the NER
defect, cells from such patients have a reduced ability to remove thymine glycol (Tg), an
oxidised DNA base, from their DNA after exposure to ionising radiation (Cooper et al,
1997). This defect is most striking in a transcription-coupled repair process, but is also
seen in general transcription-independent repair. The main repair pathway for the
removal of Tg lesions from DNA is by BER, which is initiated by Nthl. It now appears
that in vivo this BER process might be improved by XPG, which has traditionally been
thought of as an NER factor. Klungland et al (1999) reconstituted BER of oxidative DNA
damage using purified human factors and DNA substrates containing toxic or mutagenic
oxidised forms of pyrimidines. They found the initial step on the reaction, catalysed by
Nthl, to be rate limiting, but that it is strongly stimulated by purified XPG protein, which
promotes binding ofNthl to its DNA substrate, although XPG does not act as a substrate-
specific nuclease in this process. This is consistent with cellular studies, which have
indicated a function for XPG in the repair of oxidative damage that is distinct from its
NER endonuclease activity (Cooper et al, 1997; Nouspikel et al, 1997).
Vodicka et al (2004) found that the exon 15 polymorphism was marginally associated
with an increased level of chromosomal aberrations in GG homozygotes as compared
with CC homozygotes. Studying the repair of 8-oxyguanines after gamma irradiation in
lymphocytes to determine the DNA repair rate, they found the irradiation specific DNA
repair capacity to be moderately higher in CC homozygotes compared with the GG
homozygotes. This was not significant (p=0.089) but is of interest, as it supports the
chromosome aberration data in suggesting a protective role of the CC homozygotes.
The exon 15 polymorphism has also been associated with increased risk of lung cancer.
Jeon et al (2003) studied the polymorphism in 310 lung cancer patients, and 311 matched
controls, in Korea, and found the GG genotype to be more frequent in controls than cases,
being associated with a decreased risk of lung cancer (OR 0.54, 95% CI 0.37-0.8)
compared with the CG and CC genotypes.
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XRCC1
XRCC1 (X-ray Repair, Complementing Defective in Chinese Hamster, 1) was identified
by its ability to restore DNA repair deficiency in the Chinese hamster ovary cell lines
EM-9 and EM-11. These cell lines are hypersensitive to ionising radiation and alkylating
reagents (Caldecott et al, 1995, Thompson et al, 1990; Zdzienicka et al, 1992). These
cells have increased rates of spontaneous and mutagen-induced sister chromatid
exchanges, and have defects in rejoining single-strand breaks after exposure to X-rays
(Thompson et al, 1982; Zdzienicka et al, 1992). Both EM-9 and EM-11 cells have a
mutated XRCC1 gene, and lack XRCC1 protein. The human XRCC1 gene consists of 17
exons, spanning 3 l,9kb (Lamerdin et al, 1995).
Shen et al (1998) identified three coding polymorphisms in XRCC1 at codons 194 (Arg
to Trp), 280 (Arg to His) and 399 (Arg to Gin), of which the polymorphism at codon 399,
in exon 10, is the most extensively studied. Poly (ADP-ribose) polymerase (PARP)
detects DNA strand breaks induced by ionising radiation, and is believed to participate in
BER. XRCC1 negatively regulates PARP by binding to it via the XRCC1 central domain.
The exon 10 polymorphism is within this PARP binding domain, therefore any functional
effects of the polymorphisms could ultimately affect the repair of DNA damage normally
repaired by BER. Various studies have investigated whether the exon 10 R399Q (a G to
A base change) polymorphism confers an increased risk of different types of cancer.
These studies have suggested associations with risk of cancer in different directions for
different cancer types. Nelson et al (2002) reported the AA genotype lead to a decreased
risk of non-melanoma skin cancer, for basal cell carcinoma OR=0.7, 95% CI 0.4-1.0 and
for squamous cell carcinoma OR=0.6, 95% CI, 0.3-0.9. This genotype was also seen to
confer a decreased risk of oesophageal cancer (Lee et al, 2001) amongst drinkers (OR=
0.4; 95% CI 0.1-0.9) and of bladder cancer (Matullo et al, 2001; Stern et al, 2001). Duell
et al (2001) studied the association of the exon 10 polymorphism, and found it to confer
an increased risk of breast cancer in African Americans (OR 1.7; 95% CI 1.1-2.4).
Studies of the effect of the polymorphism on squamous cell carcinoma of the head and
neck (SCCHN) gave inconsistent results. Sturgis et al (1999) observed an increase in risk
associated with the AA genotype, (OR, 1.6; 95% CI, 1.0-2.8) while Olshan et al (2002)
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observed a decrease in risk (or, 0.1; 95% CI 0.04-0.6). No association was seen between
this polymorphism and melanoma (Winsey et al, 2000).
XRCC3
The human XRCC3 gene is located on chromosome 14, position 14q32.3 (Tebbs et al,
1995). The XRCC3 gene was shown to correct the X-ray cross-linking sensitivities and
spontaneous chromosomal aberrations of the CHO cell line irslSF (Tebbs et al, 1995).
This cell line is hypersensitive to ionising radiation, and cross-sensitive to a range of
DNA-damaging agents, including UVR, ethyl methanesulphonate, mitomycin C and
cisplatin.
XRCC3 is involved with the homologous pathway of repair of double stranded DNA,
preventing the chromosomal fragmentation and the accumulation of translocations and
deletions. XRCC3 is structurally similar to Radl, a component essential for
recombination repair. Cells deficient in XRCC3 fail to form Rad521 foci following
exposure to radiation, and display genetic instability and an increased sensitivity to DNA
mutagens, such as UVR. It is therefore possible that subtle mutations in the XRCC3 gene
could affect sensitivity to UVR in humans.
In a study of the association between polymorphisms in DNA repair genes and the
development of malignant melanoma, a polymorphism in exon 7 of XRCC3 was
investigated (Winsey et al, 2000). The C to T polymorphism at position 18067 was
genotyped in 125 individuals with malignant melanoma. The presence of a T allele was
seen to be significantly associated with melanoma development (p=0.004, OR 2.36). As
UVR is the key causative agent for development of malignant melanoma, it is plausible
that polymorphisms associated with melanoma will also associate with UVR-induced
erythema.
P53
Mutations and deletions of the p53 gene (OMIM +191170) that lead to a loss of tumour
suppressor function and cell cycle control are found in more than 50% of all human
cancers, in more than 50 different types of cells and tissues. Single base pair substitutions
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comprise the most common mutational events, followed by single base frameshifts and
small deletions. In addition to germline mutations, mutations develop due to exogenous
mutagens or endogenous mutagenic processes which damage the genome in characteristic
ways, leaving so-called "mutagen fingerprints" in the DNA (Greenblatt et al, 1994).
Examples ofmutation fingerprints in p53 are the G: C to T:A transversion in codon 249,
which Hsu et al (1991) observed at high frequencies in hepatocellular carcinomas in
regions where there was a high ingestion of the mutagen aflotoxin, and the characteristic
mutations produced by UVR. UVR induces a high fraction of CC to TT tandem
mutations, or C to T transitions at dipyrimidine sites.
Loss of p53 activity is strongly selected for in tumour development. p53 can be
inactivated in several ways, including mutation, the loss of part of chromosome 17p,
which harbours the gene, or the binding of products of certain oncogenic tumour viruses
to the wild-type protein, for instance the large T antigen of SV40, which led to the
original identification of p53. Binding of the human papilloma virus 16 E6 protein to
wild-type p53 results in a loss of function of the p53 protein, and along with other
transforming genes for HPV appears to contribute to the ability of HPV to transform
cells, at least in vitro.
Li-Fraumeni syndrome (OMIM # 151623) highlights the role of p53 as a tumour
suppressor. Li-Fraumeni syndrome is a rare, autosomal dominant syndrome, where
affected individuals carry heterozygous mutations of p53 in the germline. DNA damage
leads to the acquisition of further mutations, and the loss of the wild-type p53 allele.
Consequently, affected individuals develop a variety of mesenchymal and epithelial
tumours at an early age, including breast cancer, soft tissue sarcomas, brain tumours,
osteosarcoma, leukaemia and adrenocortical carcinoma (Li and Fraumeni, 1969, 1982;
Birch et al, 1984, 1990).
The p53 protein is normally present at low levels in the cell, but can be stabilised, by, for
example, DNA damage or hypoxia. The E3 ubiquitin ligase, MDM2, closely regulates
p53 under normal circumstances, mediating both the ubiquiylation and proteasome-
dependent degradation of p53 (Michael and Oren, 2003). p53 and MDM2 function within
an auto regulatory loop. The mdm2 gene is itself a p53 target, and p53 positively
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regulates MDM2 expression, while MDM2 negatively regulates p53 levels and activity
(Wu et al, 1993). DNA damage shown to activate p53 includes that generated by UVR,
ionising radiation and radiomimetic drugs. The biological consequence of p53
upregulation is the initiation of processes that lead to either cell cycle arrest or apoptosis.
After DNA damage has occurred, the p53 protein is accumulated in cells, then
translocates to the nucleus and activates gene transcription. p53 acts as a transcription
factor, binding to specific sites in the regulatory regions of p53-responsive genes.
Different stresses can act through different processes to interrupt the p53-MDM2
regulatory cycle, but all lead to the induction of the p53 protein and its biological
consequences. UVR and DNA strand breaks inhibit the ability of MDM2 to mediate p53
degradation, while hypoxia is thought to act on the regulatory loop by repressing the
expression of mdm2. Hyperproliferation, induced by oncogenes, can induce the
expression of pl4ARF, which binds to MDM2, blocking its ability to mediate
ubiquitylation and degradation of p53. This results in either cell cycle arrest, or
programmed cell death (apoptosis). By initiating cell cycles arrest, there is time for
damaged DNA to be repaired before new DNA synthesis occurs, thus preventing the
accumulation of mutations in the genome. Apoptosis in cells with excessive damage,
where the damaged DNA cannot be repaired has a similar outcome; permanently
removing damaged and mutated cells from the population of dividing cells, ensuring any
mutations cannot be replicated.
Nucleotide excision repair (NER) can eliminate a variety of UV-induced lesions, such as
cyclopyrimidine dimers (CPDs) and 6-4 photoproducts (6-4PPs) from the genome of UV-
exposed cells. NER includes two distinct pathways, global genome repair (GGR), which
removes lesions from the entire pathway, and transcription coupled repair (TCR) which
repairs DNA damage in the transcribed strand of actively transcribing genes. Ford and
Hanawalt (1995, 1997) have shown that p53 is required for the efficient nucleotide
excision repair through the GGR pathway of UV-induced cyclopyrimidine dimers from
genomic DNA. Adimoolam and Ford (2002) then went on to investigate whether p53
regulates the expression of genes required for GGR, and found the NER gene XPC to be
DNA-damage inducible and regulated by p53. It is therefore plausible to ask whether a
polymorphism of the p53 gene could affect sensitivity to UVR.
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The polymorphism at codon 72, in exon 4, of p53 was first determined by Harris et al
(1986). A single base change occurs, with either a G or C nucleotide present in the
middle position of the codon. This leads to a nonconservative amino acid change,
resulting in either an arginine, (CGC), or a proline, (CCC), at codon 72. It had been
shown that a number of human transformed cell lines expressed more than one discrete
p53 protein, as did human primary tumours, although analysis of human genomic DNA
with p53 cDNAs revealed a single p53 gene. The two different p53 protein species
expressed in human transformed cell lines are distinguishable by their different rates of
migration during SDS-polyacrylamide gel electrophoresis.
In investigating how the single p53 gene could code of more than one p53 protein Harris
et al detailed the codon 72 polymorphism. Using a cDNA library derived from the SV-80
cell line, which expresses in vivo two discrete forms of p53 protein, individual cDNA
clones, which encoded one of the two p53 proteins, were isolated. Sequence analysis of
these revealed a single base pair difference between the different cDNAs. Two clones, of
the same size and restriction map, which coded for different proteins showed the single
base change. One clone had a guanine, while the other contained a cytidine, resulting in
arginine being expressed by the first clone, and a proline by the later. The faster
migrating species expressed an arginine, which has a large side chain, and is positively
charged in physiological conditions. In contrast, proline, the equivalent residue expressed
by the slower migrating protein, has a small, nonpolar side chain. Similar studies by
Matlashewski et al (1987), which found both arginine and proline at codon 72 of p53 in
clones from SV80 cell lines, lead to this change becoming a well documented
polymorphism.
Thomas and colleagues (1999) suggested that the polymorphic variants of codon 72
might have distinct biological and chemical properties. The p53 Arg protein was found to
be more susceptible to degradation induced by the HPV E6 protein than p53Pro, which
suggested that individuals homozygous for the Arg allele might have an increased
susceptibility to HPV-induced tumours. Many different molecular epidemiological
studies have investigated the association between the codon 72 polymorphism and the
risk of cancer. These include cancer of the bladder (Soulitzis et al, 2002), cervix (Helland
et al, 1998; Josefsson et al, 1998; Andersson et al, 2001; Zehbe et al, 2001; Saranath et
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al, 2002), head and neck (Sourvinos et al, 2001; Shen et al, 2002), lung (Fan et al, 2000;
Wu et al, 2002), non-melanoma skin (Marin et al, 2000;Bastiaens et al, 2000, Shen et al,
2003) and prostate (Henner et al, 2001). However, much controversy still surrounds
whether any of these studies have conclusively linked any of the p53 codon 72 genotypes
with risk of malignancy.
The allele frequency of the p53 codon 72 polymorphism has been shown to vary in
different populations. Beckman et al (1994) investigated allele frequencies in individuals
from different ethnic groups, and found a statistically significant correlation between the
frequency of the Pro allele and latitude. They suggested that alleles that encode a proline
at position 72 might be advantageous in environments subject to high levels of UVR.
McGregor and colleagues (2002) report an association between the allelic variants at
codon 72 and sunburn and non-melanoma skin cancer, with Pro/Pro homozygotes having
a higher minimal erythemal dose (MED) i.e. less sensitive to UVR. Shen et al (2003)
have also reported an association between these variants and melanoma, with the Pro
homozygotes being less at risk. They analysed 289 melanoma patients, and 308 cancer-
free controls, all ofwho were non-Hispanic whites, finding an Arg allele frequency of
78.2% in cases, and 73.2% in controls, with a p value of 0.045. Genotype frequencies of
Arg/Arg, Arg/Pro and Pro/Pro were 62.6%, 31.1% and 6.2%, respectively, in the cases,
and 53.9%, 38.6%, and 7.5% respectively in the controls (p=0.096). Using logistic
regression analysis they found that the Arg/Arg genotype was associated with an
increased risk of melanoma (odds ratio = 1.43, 95% confidence interval = 1.02-2.02)
compared with other genotypes, particularly in the over 50s (Odds Ratio (OR)=2.32, 95%
CI= 1.39-388). However, these findings are not conclusive in proving a link between the
Arg allele and increased risk of cutaneous melanoma, as the difference in genotype
frequencies between cases and controls not being formally significant. An association
between the allelic variants of the p53 gene and UVR sensitivity is important, as it may
provide insight into the mechanics of the reported association with skin cancer.
Not all studies have however shown an association between the p53 codon 72
polymorphism and cutaneous malignancies. Bastiaens et al (2001) genotyped the codon
72 allele in 86 subjects with squamous cell carcinoma, 168 healthy controls, 121 with
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basal cell carcinoma and 108 subjects with non-familial malignant melanoma. They
found no association between any of the alleles and any of the cutaneous malignancies.
In their investigation of the relationship between p53 codon 72 polymorphisms and
susceptibility to sunburn and skin cancer, McGregor and colleagues determined
susceptibility to sunburn as the minimal dose of solar-stimulated radiation required to
induce just perceptible radiation on previously unexposed buttock skin.
The same p53 variants will be examined in this thesis with relation to UVR sensitivity,
but will be measured not by the MED as in the McGregor study, but by use of reflectance
spectrophotometry. The MED is a threshold measurement, and can be influenced by basal
pigmentation. Reflectance spectrophotometry with examination of a range of UV doses at
two different body sites will give a more reliable indicator of any association between the
allelic variants at codon 72 and sensitivity to UVR.
GSTT1
The GST genes encode enzymes which catalyse the conjugation of glutathione (GSH)
and are involved in the detoxification of a variety of reactive and mutagenic compounds,
including the products of oxidative stress. GSTs are thought to have evolved to protect
cells against reactive oxygen metabolites, and the proteins are found in all prokaryotic
and eukaryotic systems, where they can be seen in the cytoplasm, microsomes and
mitochondria (Laughlin et al, 1998). Oxidative stress can be caused by a variety of
cellular processes, environmental agents and chemicals, including UVR and anthralin.
The crucial role of GST genes in the protection of cells from cytotoxic and mutagenic
effects suggests that polymorphisms associated with a reduced enzyme activity will give
rise to an increased susceptibility to a wide range of diseases.
At least seven separate classes of soluble GSTs have been identified to date; these are
alpha, mu, pi, sigma, theta, kappa and zeta. The enzymes were classified on the basis of
substrate specificity, structure, amino acid sequence and behaviour of the enzyme.
The theta class of GSTs was discovered by Meyer et al (1991), and have different
catalytic activity compared with other GSTs (Jemth et al, 1997). The theta class of GSTs
have a Ser-11 residue, which replaces the tyrosine found in the N-terminal of the alpha,
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mu and pi classes. Board et al (1995), Blocki et al (1993) and Liu et al (1992) determined
that the residue in this position has a key role glutathione deprotonation and activation.
This residue also accounts for the particular enzymatic behaviour of the theta GSTs
(Meyer et al, 1991, 1993). Mutation of Ser-11 inactivates the theta enzyme by raising the
pKa of bound GSH, and lowering the turnover number (Board et al, 1995; Carruri et al,
1997). The serine residue, as opposed to the tyrosine, can form a hydrogen bond with the
glutathionyl sulphur atom; this can be responsible for the differences in affinity towards
GSH in the theta class compared with the other GST classes.
Deletion polymorphisms in GSTT1 are common in the Caucasian population, with a
frequency of around 20%. This null genotype results in a lack of functional enzyme
activity. The rate of enzymatic activity has been shown to be around ten-fold higher in
the theta class compared with the alpha, mu and phi classes, and affinity towards the
glutathione-conjugates is much lower in GST thetas than in other classes, therefore some
conjugate products can inhibit the alpha, mu and phi classes of GSTs much easier than
they can the theta class (Meyer et al, 1993; Ouwerkerk-Mahadev and Mulder, 1998). The
biological importance of the theta class is suggested at due to its remarkable conservation
in all organisms studied. Theta-like GSTs have been shown to be present in mammals
such as man, mouse and rat, but also in shellfish (Hiltonen et al, 1996), a variety of
insects including the Australian sheep blowfly (Carruri et al, 1997; Board et al, 1994),
the insect Orthosia gothica (Egaas et al, 1995), maize (Gronwald et al, 1998) and bacteria
(Laughlin et al, 1998; Pemble and Taylor, 1992).
The human GSTT1 and GSTT2 genes are separated in the genome by approximately
50kb, and are of similar structure, each with five exons with identical introns/exon
boundaries (Coggan et al, 1998). The GSTT1 is 8.1kb long, while the GSTT2 gene is
3.7kb. A phenotype in humans where glutathione-conjugation of halomethanes, which
result in DNA adducts, has been described, with conjugator and non-conjugator
phenotypes (Hallier et al, 1993). This polymorphic phenotype is due to a deletion of part
of the GSTT1 gene, determined by Pemble and colleagues in 1994. This deletion results
in no functional enzyme being synthesised. The GSTT1 null genotype varies in
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distribution worldwide. Chinese and Korean populations have among the highest
frequencies of the null genotype observed, Nelson et al (1995) found the null genotype
frequency to be 64.4% in Chinese and 60.2% in Koreans. The null genotype is found in
around 20% of Caucasians (Brockmoller et al, 1996), with lower prevalence in Mexicans
(9.7%, Nelson et al, 1995) and Finns (13.3%, Saarikoski et al, 1998). The null genotype
has been suggested to lead to increased risk of a variety of cancers, due to its inability to
detoxify endogenous or exogenous carcinogens. As the GSTT1 null genotype results in
no functional protein being produced, an individual with such a genotype has a reduced
ability to conjugate GSH with a variety of DNA damaging agents, for example,
dibromomethane, dichloromethane, ethylene oxide and methyl bromide ( Pemble et al,
1994; Guengerich et al, 1995; Sherratt et al, 1997;). Cells in individuals with the GSTT1
null genotype are as a result subjected to greater levels of DNA damaging agents than in
individuals who produce the functional GSTT1 protein, who are better able to withstand
harmful substances due to their detoxification ability. Reduced ability to deal with DNA
damaging agents means a greater amount of DNA damage will occur, increasing the risk
of accumulation of deleterious mutations and the possibility of cancer development.
Smoking related cancers have been among the most frequent cancer types studied for
association with the GSTT1 null allele. In a study of laryngeal carcinoma patients, Jahnke
et al (1996) found the frequency of the null allele to be slightly increased in patients
compared with controls (p=0.064, OR 0,5, 95% CI 0.24-1.05). Oude Ouphis et al (1998)
examined 185 patients with SCC of the head and neck (SCCHN), 78 patients with benign
head and neck lesions, and 201 healthy controls. They found no difference in the GSTT1
null allele frequency between the SCCHN patients and controls, but found the null allele
to have a higher frequency in patients with benign lesions of the head and neck compared
with the controls (33.3% compared with 20.3%, p=0.03). In a different study of 42
patients with SCCHN and 42 matched controls, Trizna et al (1995) found the absence of
the GSTT1 allele to give rise to an increased risk of this cancer (OR 2.18, CI 0.91-5.23).
From these studies, there is no conclusive evidence to suggest the presence or absence of
the gene gives rise to an increased risk of these cancer types. It is of note that almost all
studies involving the GSTT1 null polymorphism only detect either the presence or
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absence of the gene, and do not differentiate between homozygous and heterozygous
status.
As UVB exposure results in oxidative stress, and many of the products of oxidative stress
are detoxified by GSTT1, the null allele has been suggested to be a risk factor for
sensitivity to UV, and thus susceptibility to cutaneous carcinogenesis. Kerb et al (2002)
investigated the effect of the GSTT1 polymorphism on the response to UVB, as measured
by the MED. 110 healthy Caucasians were genotyped for the GSTT1 polymorphism,
using a PCR reaction that allowed the heterozygous and homozygous genotypes to be
differentiated. They reported that subjects homozygous for the GSTT1 null allele had
lower MED than those who were heterozygous, or homozygous for the functional allele
(p<0.001). Kerb and colleagues suggested that this suggested the absence of the
functional GSTT1 allele gives rise to increased sensitivity to UV. Concurrently to this
paper being published, GSTT1 was considered a candidate gene for sensitivity to UV in
this study. As previously mentioned, the MED is not an ideal measure of sensitivity to
UV, being open to error. The use of reflectance spectrophotometry to determine levels of
erythema via an erythema meter should provide an increased accuracy in order to
investigate this polymorphism further.
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Chapter 2, Methods
Selection of study groups
Two groups of subjects were used for this study. The first group consisted of 74 healthy
volunteers, with no history of skin disease. Group 2 (n=31) were patients undertaking
MED phototesting before phototherapy for the treatment of psoriasis. Patients were under
the care of Prof. JL Rees. All studies had appropriate ethics committee approval. All
volunteers gave informed, signed, consent for the study in which they participated. None
of the volunteers received fees for taking part in any experiment.
Group 1, the larger of the two study groups, was composed from volunteers, who were
recruited via the local media from the local population. Volunteers had no history of skin
disease and were not selected for on the basis of skin type or any other factor which could
influence sensitivity to UVR. There was no evidence to suggest this study group did not
represent a random sample of the local population. Group 2 consisted of patients
attending the Dermatology Outpatients department to receive treatment for psoriasis, by
phototherapy. All members of the second group therefore had active skin disease at the
time of phototesting. As phototherapy is less efficient in individuals with darker skin
types, it is likely that the second group contained a lower proportion of individuals with
darker skin types than by chance. It is possible that the presence of active skin disease in
these patients could have had some unrecognised effect on their cutaneous sensitivity to
UVR. However, as all patients in group 2 had active psoriasis and were being compared
with each other and not directly against the volunteers from group 1, this should not
affect the analysis of variation within each group. In neither group was there any obvious
selection for level of sensitivity to UVR.
Phototesting
Group 1 were irradiated on the lower back using a range of UVB doses (119-300mJ/cm2)
from a lamp unit designed by Prof. Brian Diffey, (Regional Medical Physics, Newcastle,
UK), containing a Philips 9w/12 tube. Volunteers in group 1 were phototested by Dr Lisa
Naysmith and Ms Karen Waterston, Department of Dermatology.
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In Group 2, patients were irradiated on the inner forearm with a similar luminaire with six
doses of UVB from a TLOl Philips tube (0.47-1.5J/cm2).
Erythema was measured at 48 hours in group 1 and at 24 hours in group 2, using a
reflectance instrument (Dia-Stron, Andover, UK), with readings taken in triplicate.
(Erythema measured at 24 hours in group 2 to minimise disruption to patients' routine
care and at 48 hours in Group 1 due to time restrictions). Baseline reflectance
measurements were also taken in triplicate of adjacent unirradiated skin. UVR-induced
erythema was defined as the increase in reflectance from the baseline values.
UVR sources
Group 1 were phototested with a broadband UVB source, described above, and designed
by Prof. Brian Diffey with (3V 2 increments). A TLOl UV unit was used to phototest the
volunteers in group 2. TLOl is a narrowband UVB UV source, used in phototherapy.
TLO1 lamps emit an approximately monochromatic spectrum, at a wavelength of 31 lnm.
Erythema Meter
The reflectance instrument obtained from Dia-Stron is based on the work by Diffey and
Farr (1984), and utilised reflectance spectrophotometry. Haemoglobin present in the
blood vessels in the upper dermis is the main cutaneous chromophore of green light.
Cutaneous erythema can be quantified by illuminating the skin with white light, and
measuring the levels of green and red light re-emitted from the skin according to the
equation:
Erythema index = logio (Intensity of red component of reflected light/ Intensity of green
component of reflected light).
The erythema meter used here contains a tungsten-halogen lamp, which shines white
light into a fibre optic probe. The probe is held against the skin, illuminating it, and then
collects diffuse light scattered from within the skin. The instrument contains narrow band
interference filters, which the reflected light passes through. The filters are at three
wavelengths, of which two, at 546nm (green) and 632nm (orange/red) are used to
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determine erythema. The erythema index determined by Diffey and Farr is multiplied by
1000, and the instrument has an output of +999 to -999 erythema units.
Anthralin Exposure
Doubling doses of anthralin (also known as dithranol) (0.01%, 0.02%, 0.04% and 0.08%
in final volume of 0.15mL) in Lassar's paste (24% zinc oxide, 2% salicylic acid, 24%
starch, in white soft paraffin, 50%) were applied to the mid-back. Lassar's paste alone
was applied as a control. All applications were occluded under 8mm Finn chambers
(Epitest Ltd, Hyryla, Finland) and secured with Mepore tape (Tendra, Molnlycke Health
Centre AB, Goteborg, Sweden). Applications were left in situ for 24 hours. The resulting
erythema at all sites was measured at 48 hours, by Contact laser Doppler flowmetry
(moorLAB satellite, Moor Instruments Ltd., Axeminster, UK). Laser Doppler flowmetry
was used in order to circumvent the potential for confounding by pigmentation. Baseline
values were taken an adjacent skin. Doppler flux is expressed as an arbitrary number in
"flux units" (Farr and Diffey, 1986). The resulting erythema was defined as the increase
in flux units after subtraction of baseline values.
MOLECULAR BIOLOGY
Unless otherwise stated, all common molecular biology reagents were obtained from
Sigma.
Collection of Blood for DNA analysis
Blood samples were obtained from each participant in this study for the purpose of DNA
analysis. 20mls venous blood was collected in Heparin tubes, and 10ml stored at -20°C
for a period of no longer than one month before DNA extraction. lOmls from each
volunteer were kept in the original tube at -70°C for long term storage.
Extraction of DNA from Blood
DNA was extracted from blood using the BACC3 DNA extraction kit from Nucleon. The
principle steps involved in the BACC3 protocol are cell lysis by Reagent A (see below
for details), deproteinisation with sodium perchlorate, followed by DNA extraction with
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chloroform and the Nucleon resin. The Nucleon resin covalently binds proteins and forms
a semi-solid stratum during partitioning. This traps the protein-containing material at the
interface and in the organic phase after centrifugation. The DNA-containing upper phase
can then be easily removed and the DNA washed with ethanol.
The collected blood was mixed with 4 times the volume Reagent A, and mixed for 4
minutes at room temperature. It was then centrifuged at 1300g for 5 minutes. The
supernatant was discarded without disturbing the pellet. The pellet was re-suspended in
2ml Reagent B. 500pl of sodium perchlorate solution was added, and the sample mixed
by inverting at least 7 times. 2ml of chloroform were then added, and mixed as above,
before the addition of 300pl ofNucleon resin. Samples were centrifuged at 1300g for 3
minutes, after which the upper phase was transferred to a clean tube. 4 volumes of cold
absolute ethanol were added, and the tube inverted until the precipitate appeared. DNA
was pelleted by centrifugation at 4000g for 5 minutes, and the supernatant discarded. The
DNA was washed with 2ml cold 70% (v/v) ethanol, and re-centrifuged. The supernatant
was again discarded, and the pellet allowed to air dry for 10 minutes ensuring the
removal of all the ethanol. The DNA was then re-dissolved in an appropriate volume of






Adjust to pH 8.0 using 40% (w/v) NaOH.
Autoclave at 121°C for 15 minutes.
Phenol/Chloroform Extraction of DNA
1 pi of each newly extracted DNA sample was run on an agarose gel to check DNA
quality. Samples which had a carry over of other cell material were treated to purify the
DNA.
400pl of each DNA sample was used; to which 400pl PCA was added. The samples were
placed on a shaker for 15 minutes at room temperature, centrifuged at 13000rpm for 5
minutes and the resulting upper layer transferred to a fresh tube. This process was
repeated. 500pl of CA was then added, the sample placed on a shaker for 15 minutes as
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above, then centrifuged at 13000rpm for 5 minutes and the upper layer transferred to a
fresh tube. 500pl propan-2-ol was added, and the sample inverted until precipitate
formed. The sample was left to stand for 10 minutes, before centrifugation at DOOOrpm
for 3 minutes. The pellet was rinsed in 1ml 70% ethanol, and centrifuged at 13000rpm for
3 minutes. The supernatant was discarded, and the pellet allowed to air dry for
approximately 1 hour, before redissolving it in 50-200pl dFBO (depending on pellet size).




Chloroform, iso-amyl alcohol solution
48ml chloroform
2ml iso-amyl alcohol
Polymerase Chain Reaction (PCR)
PCR was carried out using Promega Taq, with a PCR mix made up as below.
Approximately lOOng template DNA was used, and a negative control without DNA was
run for each reaction. Oligonucleotides were supplied by Sigma-Genosys. Reactions were
run on either a Techne PHC-2 PCR machine, in which case each sample was overlaid
with ~2 drops of mineral oil to stop evaporation, or a Biometra T3 Thermocycler
machine, which has a heated lid to prevent evaporation, eliminating the need for mineral
oil. If evaporation did occur, the concentration of the reagents in the reaction mixture
would be altered, which could lead to no amplification occurring, or a reduction in the
amount of amplification.
PCR master mix








10 x PCR buffer
50mM KC1
1.5mM MgCl2
lOmM Tris-HCl, pH 8.3
0.01% w/v gelatin
0.45% v/v Triton X-100
0.45% v/v Tween 20
PCR products were detected by agarose gel electrophoresis. lOpl of each sample were




































































p53 codon 72 (f) ATCTACCGTCCCCCTTGCCG
(r) GCAACTGACCGTGCAAGTCA

























1498 95°C 1 min,
35 cycles:
94°C 1 min
























Agarose Gel Electrophoresis of DNA
DNA fragments were separated by electrophoresis through an agarose gel. Agarose was
made up at 1-2% w/v in 1 x TBE buffer, and heated to dissolve. Ethidium bromide was
added to cooled agarose to give a final concentration of lOOng/ml. Loading buffer was
added to each DNA sample (1:5). Bioline HyperLadder I, a size marker, was routinely
loaded alongside samples. DNA was visualised using a BIO-RAD Gel Doc 2000.
10 x TBE Buffer
0.9M Tris-HCl
0.9M boric acid
20mM EDTA, pH 8.0





All restriction enzymes were supplied by New England Biolabs. Restriction digests were
carried out as described in the table below.
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Restriction Digest Conditions
Gene/Exon Enzyme Digest Conditions
XPD exon 6 Hinfl PCR product 20pl
1 OX NEB buffer 2 5 pi
20U Hinfl 2pi
H20 23 pi
Digest at 37°C for at least 2 hours.
Run 20pl on 2% regular agar gel.
XPD exon 22 Fokl PCR product 20pl
1 OX NEB buffer 4 5 pi
4U Fokl lpl
H20 24pl
Digest at 37°C for 2 hours
Run 20pl on a 2% low melting
point gel.
XPD exon 23 PstI PCR product 20pl
1 OX NEB buffer 3 5 pi
20U PstI lpl
H20 24pl
Digest at 37°C for at least 2 hours.




BsrDI PCR product 20pl




Digest at 65°C for at least 2 hours.
Run 20pl on a 2% regular gel.
XPG exon 15 Nlalll PCR product 20pl




Digest at 37°C for at least 2 hours.
Run 20pl on a 2% regular gel.
XPF exon 11 AlwNI PCR product
20pl
1 OX NEB buffer 4 5 pi
20U AlwNI 2pl
H20 23pl
Digest at 37°C for at least 2 hours.





10X NEB buffer 2 5 pi
50U Mspl 2.5pl
H20 22.5pl
Digest at 37°C for at least 2 hours.




Nlalll PCR product 20pl





Digest at 37°C for at least 2 hours.
Run 20pl on a 2% regular gel.
CKM 8 TaqI PCR product 20pl
10X NEB buffer U 5pl
100XBSA
Digest at 65°C for at least 2 hours.





rs4150265 Ncol PCR product 20pl
10X NEB buffer 4 5 pi
20U Ncol 2pl
H20 23pi
Digest at 37°C for at least 2 hours.
Run 20pl on a 2% regular gel.
p53 codon 72 BstUI PCR product 20p
1 OX NEB buffer 2 2pl
BstUI 5 pi
H20 23 pi
Digest at 60°C for at least 2 hours.




The ABI PRISM SNaPshot Multiplex Kit from Applied Biosystems was used in
conjunction with the ABI 310 Genetic Analyzer, located within the MRC Human
Genetics Unit, Edinburgh, to genotype polymorphisms for which no restriction site
existed. The multiplex kit is based on the dideoxy single-base extension of an unlabeled
oligonucleotide primer. Each primer binds to a complimentary template in the presence
of fluorescently labelled ddNTPs and AmpliTaq DNA Polymerase, FS. The polymerase
extends the primer by one nucleotide, adding a single ddNTP to its 3' end. GeneScan
Analysis Software from Applied Biosystems was then used to analyse polymorphisms.
Overview of SNaPshot technique
Template Preparation
• genomic DNA amplified by PCR
• removal of dNTPs and primers, by use of SAP and Exol




Reaction Preparation - sample prepared for reaction, combining:
• Template DNA
• Primer, designed so as to stop immediately 5' to target nucleotide
• SNaPshot reaction mix
Thermocyling
• Denature template
• Anneal unlabelled primer


















• Electrophorese samples on ABI 310 machine
• Analyse data with GeneScan software
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The fluorescent dyes assigned to the individual ddNTPs are as follows:





PCR products were the starting point for the SNaPshot analysis, and were obtained as
described above.
Preparation of PCR products.
Primers and unincorporated dNTPs were removed from the template to avoid interference
with the subsequent primer-extension reaction. 15pl of PCR product was added to 5 units
of shrimp alkaline phosphatase (SAP) (USB, 100 unit/ml) and 2 units of Exonuclease I
(Exo I) (USB, 10 units/pl) then mixed thoroughly. The samples were incubated at 37 °C
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for 60 minutes, then at 75 °C for 15 minutes to inactivate the enzymes. The samples were
kept at 4 °C until the primer-extension reaction was set up.
SNaPshot Primer-Extension Reactions.
Control reactions for the primer-extension were included in the reaction kit. The positive
control contained six distinct primers, with length of final products varying from 21nt to
6Int. The control template contained an amplicon from CEPH DNA. All 4 signal colours
were represented. This control enabled approximate run times to be determined. A
negative control reaction was run without control template DNA. In addition, a sample
containing the primers designed specifically for analysis of each SNP was run, without
template DNA, enabling any peaks produced by the primers to be eliminated from the
final GeneScan analysis.
Primer-extension reactions carried out as below. 3 pi of treated PCR products were added
to the following master mix:
SNaPshot Multiplex Ready Reaction Mix 5pl
Pooled SNaPshot primers 1 pi
ddH20 lpl





The reaction mix was kept on ice before putting it in the thermal cycler. The conditions
were as follows:
25 cycles of:
Rapid thermal ramp to 96 °C
96 °C for 10 seconds
Rapid thermal ramp to 50 °C
50 °C for 5 seconds
Rapid thermal ramp to 60 °C
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60 °C for 30 seconds
Samples were kept at 4 °C until post-extension treatment was carried out.
Post-Extension treatment.
Post-extension treatment removed unincorporated ddNTPs. If left untreated, the
unincorporated [F]ddNTPs would co-migrate with the fragment of interest. Removal of
the 5' phoshoryl groups by phosphatase treatment alters the migration of the
unincorporated [FjddNTPs and thus prohibits interference.
To conduct post-extension treatment 1 unit of SAP was added to the reaction mixture,
mixed thoroughly, and incubated at 37° C for 60 minutes. Samples were then incubated at
75 °C for 15 minutes to deactivate the enzyme. The reactions were kept at 4 °C for up to
24 hours before electrophoresis on the 310 system.
Electrophoresis using ABI PRISM 310 Genetic Analyzer.
In order to denature samples, 1 pi of each sample was placed in the well of a 96-well
plate. 9pl deionised formamide was added, mixed briefly and quickly spun down. The
samples were denatured by placing them at 95 °C for 5 minutes before being loaded on
the 310 Genetic Analyzer. The POP-4 polymer was used, in conjunction with the GS
POP-4 (lmL) E5 module. The E5 Run Module encodes the following parameters on the
310 instrument:
Parameter GS POP-4 (lmL) E5
Injection time 5 seconds
Electrophoresis voltage 15kV
Collection time 24 minutes
EP voltage 15 kV
Heat plate temperature 60 °C
Syringe pump time 150 seconds
Preinjection EP 120 seconds
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ABI PRISM GeneScan Analysis Software version 3.1 was used to analyse data obtained
after the samples had undergone electrophoresis.
Statistical Analysis
For each polymorphism the erythemal response to each dose of UVR was plotted against
individual genotypes. Note some values are superimposed on others, a limitation of the
software used. Analysis of variance (One way, unstacked) tests were carried out to
determine if any association existed. Statistical analysis was carried out using the Minitab
programme. The analysis of variance (ANOVA) test is a measure of the total variability
in a set of data, which is given by the sum of squared differences of the observations from
their overall mean, called the total sum of squares. This quantity is sub-divided into
components that are identified with different causes of variation. After the contributions
of all the specified sources of variation have been determined, the ermained, the residual
sum of squares, or error sum of squares, is attributed to random variation. The mean
square corresponding to the error sum of square (error SS) is often used as a measure of
assessing the importance of the specified sources of variation, and the ratio of the error
sum of squares compared to the total sum of squares value.
Lymphocyte preparation
Whole blood (10-20ml fresh blood/heparin) was collected from volunteers and
lymphocytes extracted by Density Gradient Isolation within 2 hours.
Whole blood was diluted 1:1 with PBS, then carefully layered over 3ml Histopaque 1077
in a 50ml Falcon tube and centrifuged for at 400g for 20 minutes. Histopaque-1077 is a
solution of polysucrose and sodium diatrizoate, which is adjusted to a density of 1.077+/-
O.OOlg/ml. During centrifugation, erythrocytes and granulocytes are aggregated by
polysucrose and sediment; whereas, lymphocytes remain at the plasma-Histopaque
interface. The interface cells were removed using sterile disposable pastettes and diluted
1:1 with PBS before centrifugation at 400g for 10 minutes. The resulting pellet was
resuspended in 10 ml PBS, and centrifugation carried out at 400g for 10 minutes. The
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pellet was washed once more in lymphocyte-culture medium, without Concanavalin A,
and centrifuged for a final time. The final pellet was resuspended in 12ml full culture
medium, with lOpg/ml Concanavalin A. Cells were plated out in 60mm dishes.
Lymphocytes were cultured amd irradiated with UVR to investigate the effects of UVR
on DNA content and apoptosis. Lymphocytes were chosen due to their relatively easy
availability and short length of time required in culture.
Lymphocyte medium
44ml RPMI
0.5ml non-essential amino acids
0.5ml Sodium Pyruvate
5ml fetal calf serum




The lymphocytes were grown for 3 days in a Sanyo CO2 incubator at a temperature of
37°C with 5% CO2. Dishes were irradiated with OJ/m2 (control dishes), 100J/m2 or
400J/m2 with UVC. A germicidal lamp, with an output at 254nm, was used. The UV
source was suspended above the dishes at a height of 29cm. Lengthening the period of
time the cells were exposed to the UVR increased UV doses. Following irradiation, 2mls
fresh lymphocyte medium was added to each dish.
Cells were collected 2, 4, 8 or 24 hours after irradiation with UVR. Each dish was split
into 2 to allow detection of apoptosis, and evaluation of the DNA content of cells.
Apoptosis Detection
The Annexin V-FITC Apoptosis Detection Kit was used to determine what percentage of
cells underwent apoptosis after UV irradiation. Cells were collected either 2, 4, 8 or 24
hours after exposure to UVR by centrifugation at 500g for 5 minutes, then washed by
resuspending in 500pl cold (4°C) lx PBS and pelleted as above. Cells were then
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resuspended in Annexin V Incubation Reagent, which was made up as below, at a
concentration of lxl05 to lxl06 cells per lOOpl, and incubated in the dark for 15 minutes
at room temperature. 400pl lx Binding buffer was then added to each sample. Samples
were then analysed by flow cytometry within one hour.
Annexin V incubation Reagent - for 1 OOpl





Flow cytometry was used to analysis the DNA content of the cultured cells.
Cells were collected by centrifugation at 1300g for 5 minutes. The pellet was
resuspended in lOOpl of citrate buffer and 450pl Solution A added. The samples were
mixed gently by inversion, and incubated for 10 minutes at room temperature. 325pl
Solution B was then added and the sample mixed and incubated as before. Finally, 250pl
of the propidium iodide-containing Solution C were added, the sample mixed by






make up to 1000ml with dH20.






dissolve in dH20 to 2000ml.
Adjust pH to 7.6
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Solution A
15mg trypsin in 500ml stock solution. pH 7.6




in 500ml stock solution




in 500ml stock solution.
Store frozen; bring to 0°C before use.
Chapter 3. Effect of polymorphisms in repair genes on sensitivity to UVR.
XPD Exon 6.
Samples were genotyped for the XPD exon 6 polymorphism using PCR and an RFLP
assay. A PCR product of 288 base pairs (bp) was obtained using the primers detailed in
table 1 of the Methods chapter. The exon 6 polymorphism consists of an A to C change at
position 22541 on the GenBank entry L47234, and does not lead to an amino acid
substitution. A Hinfl restriction site exists when an A is present. The CC homozygote
does not contain this restriction site, and after digestion gives one fragment of 288bp. The
AA homozygote yields two fragments of 206 and 82 bp, while the AC heterozygote gives










Figure 4.XPD exon 6 PCR products
Lanes 1-5, PCR products
Lane 6 - negative control
M - Bioline HyperLadder I, a size marker
Figure 5.XPD exon 6 digestion products




XPD exon 6 Genotype frequencies
Genotype Group 1 (%) Group 2 (%)
AA 13/74(17.57%) 11/31 (35.48%)
AC 37/74 (50.00%) 15/31 (48.39%)
CC 24/74 (32.43%) 5/31 (16.13%)
Total 74(100%) 31 (100%)
Genotype frequencies varied between the two study groups, but not statistically
significantly (DF = 2, P-Value = 0.075). The heterozygous AC genotype had a similar
frequency in both groups (50% in Group 1, 48.39% in Group 2), whereas the
homozygous AA was the least common genotype in Group 1, but the second most
frequent (after the heterozygotes) in Group 2. This may be due to chance, to the number
of individuals in each group, or some factor that determined selection in each group.
However, the exon 6 polymorphism has not previously been found to be associated with
psoriasis or other atopic skin disease, nor is there evidence to suggest that such an
association might be likely. As the presence of psoriasis in group 2 is the only common
difference between the two study groups, it is likely that the genotype frequencies
observed in the two study groups differ only by chance.
The erythemal response to each UVR dose was plotted against individual genotypes.
Note that, as mentioned before, some values are superimposed upon others, which is a
limitation of the Minitab software used. Analysis of variance tests were carried out, and
data obtained given below.
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Erythema induced by incremental doses of UVR by XPD exon 6 genotype in Group
1.
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Figure 6. Erythema induced by 119mJ per cm UV by XPD exon 6 genotype
































Figure 7. Erythema induced by 150mJ per cm2 UV by XPD exon 6
genotype.

































Figure 6. Erythema induced by 189mJ per cm UV by XPD exon 6 genotype.















Figure 7. Erythema induced by 238mJ per cm2 UV by XPD exon 6 genotype.
































Figure 8. Erythema induced by 300mJ per cm2 UV by XPD exon 6 genotype.
UVR on lower back, measured at 48 hours, n=74.
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Genotype N Mean StDev SE Mean
AA 13 22.53 25.71 7.13
AC 37 22.07 23.44 3.85
CC 24 25.48 29.47 6.02
Analysis of variance of level of erythema from 119mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 178 89 0.13 0.876
Error 71 47683 672
Total 73 47861
150mJ per cm2
Genotype N Mean StDev SE Mean
AA 13 48.20 33.78 9.37
AC 37 55.73 34.21 5.62
CC 24 61.41 48.93 9.99
# ^
Analysis of variance of level of erythema from 150mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 1490 745 0.48 0.623
Error 71 110892 1562
Total 73 112382
189mJ per cm2
Genotype N Mean StDev SE Mean
AA 13 92.6 48.4 13.4
AC 37 94.83 44.72 7.35
CC 24 97.7 53.6 10.9
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Genotype N Mean StDev SE Mean
AA 13 125.6 47.2 13.1
AC 37 123.64 45.84 7.54
CC 24 129.0 52.1 10.6
Analysis of variance of erythema induced by 238mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 421 210 0.09 0.913
Error 71 164674 2319
Total 73 165095
300mJ per cm2
Genotype N Mean StDev SE Mean
AA 13 155.40 43.30 12.00
AC 37 148.00 46.01 7.56
CC 24 158.90 35.47 7.24
Analysis of variance of erythema induced by 300mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1836 918 0.51 0.602
Error 71 127647 1798
Total 73 129483
Discussion
At none of the UV doses examined was there any significant difference in erythemal
response to UV between the three genotypes, with P values ranging from 0.950 to 0.602.
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The mean level of erythema was highest, at each dose, in the CC homozygotes, with a
smaller spread of data points than the AC heterozygotes, but not than the AA group. This
difference was not significant.
The XPD exon 6 genotype of the individuals had little effect on the variation of the levels
of erythema at each UV dose examined in group 1. The sum of squares (SS) values of the
factor and error were compared. The SS(Total) value (the SS(factor) plus SS(error))
accounts for all the variation, both between the genotype groupings, and within the
genotype groupings. SS(factor) accounts for variation between the different genotypes,
while SS(error) accounts for all external error, which is error within the different
genotype groupings. On analysis of the two highest UV doses the volunteers were
irradiated with, if the XPD exon 6 polymorphism was associated with UV-induced
erythema, one might expect to see an enhanced difference between genotypes. It is
apparent here that the error due to the different genotypes is insignificant when compared
to that due to other factors. At 238mJ per cm2, the SS(factor) value is 421, compared with
the SS(error) value of 164674. At 300mJ per cm2, the SS(factor) value is 1836, while the
SS(error) value is 127647, accounting for the vast majority of the total error (SS(total) =
129483).
In order to measure the power of the above statistical analysis, retrospective power
calculations were performed using the R Foundation for Statistical Computing software,
which is downloadable from www.r-project.org. For analysis of the one-way ANOVA
test, the level of variance between the populations (each different genotype) and the level
of variance within the populations were analysed. The variation between populations is
equivalent to the mean square (MS) of the factor in the ANOVA test, where factor is the
genotype. The variation within populations is equivalent to the MS error value in the
ANOVA test. The significance level was set to 0.05.
As the number of individuals with each genotype was unequal in this study, the ANOVA
tests were unbalanced. In order to estimate power here, tests were performed assuming
balanced groups, which would give the upper limit of power for this study, and for the
least balanced the ANOVA could be, where all three groups contained the lowest number
of individuals observed in the genotype groups. This test gave the lower limit of power of
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the ANOVA calculations. Power calculations were performed for the lowest and highest
UV doses in each group, in order to give an idea of power.
In group 1, a balanced ANOVA test would have had three groups with equal numbers of
individuals in each, in this case, n=25. The genotype group with the fewest individuals
was n=13, a power test carried out with 3 groups of 13 would give the lower limit of
power for these samples. At 119mJ, the between variance value of 89 and the within
variance value of 672 gave power values of 0.61 where n=25, and 0.33 where n=13. The
true power therefore lies between these values. At 300mJ, the between variance value of
918 and within variance value of 1798 gave power values of 0.99 for a balanced ANOVA
test, and 0.88 for the least balanced scenario. A power value of 1 is considered to be
perfect power, and 0.8 considered highly desirable, therefore the power values obtained
here are acceptable. The p values obtained in the ANOVA tests can be considered to be
real.
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Figure 11. Erythema induced by 0.47J per cm2 UV by XPD exon 6 genotype. UVR
























Figure 12. Erythema induced by 0.6J per cm2 UV by XPD exon 6 genotype.
































Figure 9. Erythema induced by 0.75J per cm UV by XPD exon 6 genotype.











Figure 10. Erythema induced by 0.95J per cm2 UV by XPD exon 6 genotype.



























Figure 15. Erythema induced by 1.2J per cm UV by XPD exon 6 genotype.























Figure 16. Erythema induced by 1.5J per cm2 UV by XPD exon 6 genotype.
UVR on inner forearm, measured at 24 hours, n=31.
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Analysis of XPD exon 6 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
AA 11 0.455 1.508 0.455
AC 15 9.00 23.36 6.03
CC 5 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.47J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 585 293 1.07 0.357
Error 28 7661 274
Total 30 8246
0.6J per cm
Genotype N Mean StDev SE Mean
AA 11 4.88 16.18 4.88
AC 15 30.2 46.9 12.1
CC 5 7.80 10.83 4.84
Analysis of variance of erythema induced by 0.6J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 4642 2321 1.92 0.166
Error 28 33914 1211
Total 30 38555
0.75J per cm2
Genotype N Mean StDev SE Mean
AA 11 20.06 32.77 9.88
AC 15 49.5 60.6 15.7
CC 5 22.4 31.0 13.8
Analysis of variance of erythema induced by 0.75J per cm2 UV
Source DF SS MS F P
Factor 2 6385 3192 1.35 0.275
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Error 28 66023 2358
Total 30 72408
0.95J per cm2
Genotype N Mean StDev SE Mean
AA 11 74.7 85.4 25.7
AC 15 79.1 68.1 17.6
CC 5 65.4 72.3 32.3
Analysis of variance of erythema induced by 0.95J per cm UV between genotypes:
Source DF SS MS F P
Factor 2 709 355 0.06 0.939
Error 28 158640 5666
Total 30 159349
1.2J per cm2
Genotype N Mean StDev SE Mean
AA 11 110.5 94.3 28.4
AC 15 118.0 77.6 20.0
CC 5 96.2 53.7 24.0
Analysis of variance of erythema induced by 1.2J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1816 908 0.14 0.872
Error 28 184772 6599
Total 30 186588
1.5J per cm2
Genotype N Mean StDev SE Mean
AA 11 169.8 100.3 30.2
AC 15 165.9 84.4 21.8
CC 5 127.7 61.9 27.7
Analysis of variance of erythema induced by 1.5J per cm2 UV between genotypes:
Source DF SS MS F P
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Factor 2 6775 3388 0.44 0.649
Error 28 215667 7702
Total 30 222442
In group 2, again no significant association was observed at any of the UV doses
examined and any genotype (P values ranged from 0.939 to 0.166). The heterozygous AC
genotype tended to have higher mean levels of erythema than either homozygote, except
at 1.5J per cm2 UV.
In group 2, the total amount of variation at each UV dose examined was shown to be due
to factors other than XPD exon 6 genotype. At 0.6J per cm2, the UV dose with lowest p
value (0.166) (which was not significant) the SS of total variation was 38555, of which
the SS of variation due to genotype comprised very little, with a value of 4642. At the
highest UV dose examined, variation due to the genotype was small when compared with
the total variation. At all doses, variation due to other factors, the variation within each
genotype group accounted for the majority of total variation.
Power calculations were carried out at 0.47J and 1.5J. A balanced ANOVA would have
contained 10 individuals, and the least balanced 5. At 0.47J, the between variance value
of 293 and within variance value of 274 gave a power of 0.98 where n=10, and 0.73
where n=5. At 1.5J the between variance value of 3388 and within variance value of 7702
gave powers of 0.71 where n=10, and 0.36 where n=5. This would suggest that not
enough samples were looked at, as the true power level lies between 0.36 and 0.71, which
is not high enough to accurately accept or reject the hypothesis.
XPD exon 6 Discussion
The reported association between the exon 6 polymorphism and melanoma (Tomescu et
al, 2001) saw an over representation of the A allele at exon 6 in 28 patients with
melanoma (aged under 50 years old) compared with 22 matched controls (Or 2.0, 95% CI
0.9-4.5, P=0.08). The CC genotype of the exon 6 polymorphism has been reported to be
protective against basal cell carcinoma (BCC) (Dybdahl et al, 1999; Vogel et al, 2001).
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In the complete study group, of 66 cases and 110 controls, individuals with an AA or AC
genotype were reported to be at greater risk of BCC than those with the CC genotype
(OR 1.9, 95% CI 0.96-3.75, p=0.0062). When only individuals with no family history of
NMSC were analysed, individuals with the AA or AC genotype were found to be at
greater risk of BCC (OR, 3.3, 95% CI 1.15-23.93, p=0.007). The effect of the exon 6
polymorphism is in the same direction as that reported by Tomescu and colleagues, who
found the A allele to be over represented in patients with melanoma, suggesting the C
allele offers more protection against cancers where UVR is the major causative agent
than the A allele. Vogel and colleagues suggested that family history of BCC could
override the effect of the XPD exon 6 polymorphism, explaining why formal significance
was only observed in those with no family history of NMSC. It is, however, possible that
individuals with a family history of NMSC were also carriers of another polymorphism
involved with risk of developing BCC which those without the family history did not
carry, and that the findings of the protective effect of the CC genotype in those without
family history was either affected by another polymorphism, or due to chance. If the data
obtained from this study were to support the findings of Tomescu et al and Vogel et al, it
might be expected that the AA genotype would display higher levels of erythema than the
AC genotype, and one would expect both these genotypes containing the A allele to be
significantly more susceptible to UV (and hence have higher erythemal responses) than
the CC homozygotes. This was not observed at any dose of UV examined in either study
group. This does not necessarily disagree with the findings that the A allele is associated
with melanoma, or that the C allele has a protective effect against basal cell carcinoma, as
it might be involved in some step of carcinogenesis not directly related to UV, or be the
marker for another polymorphism that is the causative change for melanoma. In order to
resolve this, a greater number of individuals could be analysed, with the study group
containing both those with a history of BCC and melanoma, and also healthy individuals
with no prior skin cancers.
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XPD exon 22
The XPD exon 22 polymorphism was genotyped using a PCR and RFLP assay. A PCR
product of 229 bp was produced, which contained the polymorphism. The exon 22
polymorphism is a C to T change at position 35326 on the GenBank sequence L47234. A
Fokl restriction site exists in the presence of the T allele. The C allele is not digested by
Fokl, which gives a single fragment of 229bp. The T allele, which contains the restriction
site, yields two fragments, of 135 and 94 bp. The heterozygous CT genotype therefore
gives 3 fragments, the uncut 229 bp fragment, and the 135 and 94 base pair fragments
observed in the presence of the Fokl site.





Figure 11XPD exon 22 PCR products
Lanes 1-3, PCR products
Lane 4 - negative control




Lane 4, undigested PCR product
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XPD exon 22 Genotype frequencies
Genotype Group 1 (%) Group 2 (%)
CC 34/74 (45.945%) 16/31 (51.61%)
CT 34/74 (45.945%) 10/31 (32.26%)
TT 6/74 (8.11%) 5/31 (16.13%)
Total (100%) 74 (100%) 32 (100%)
The XPD exon 22 polymorphism showed a similar pattern of genotype frequency in both
study groups. There was no significant genotype frequency between group 1 and group 2
(X2, DF = 2, P-Value = 0.291)
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Erythema induced by incremental doses of UVR by XPD exon 22 genotype for group
1.


























Figure 13 Erythema induced by 119mJ per cm UV by XPD exon 22 genotype.



























Figure 14. Erythema induced by 150mJ per cm2 UV by XPD exon 22 genotype.
































Figure 15. Erythema induced by 189mJ per cm UV by XPD exon 22 genotype.































Figure 16. Erythema induced by 238mJ per cm2 UV by XPD exon 22 genotype.













Figure 17. Erythema induced by 300mJ per cm2 UV by XPD exon 22 genotype.
UVR on lower back, measured at 48 hours, n=74.
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Analysis of XPD exon 22 genotype and erythemal response to UVR for each dose in
group 1.
119mJper cm2
Genotype N Mean StDev SE Mean
CC 34 22.27 25.09 4.30
CT 34 24.45 24.28 4.16
TT 6 22.1 38.8 15.8
• • 2 i
Analysis of variance of erythema induced by 119mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 89 45 0.07 0.936
Error 71 47772 673
Total 73 47861
150mJ per cm2
Genotype N Mean StDev SE Mean
CC 34 54.76 38.47 6.60
CT 34 59.81 37.16 6.37
TT 6 44.5 57.7 23.6
Analysis of variance of erythema induced by 150mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1332 666 0.43 0.655
Error 71 111050 1564
Total 73 112382
189mJ per cm2
Genotype N Mean StDev SE Mean
CC 34 94.62 47.71 8.18
CT 34 97.57 46.93 8.05
TT 6 87.1 59.8 24.4
Analysis of variance of erythema induced by 189mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 599 299 0.13 0.880




Genotype N Mean StDev SE Mean
CC 34 125.19 49.48 8.49
CT 34 129.98 43.76 7.51
TT 6 104.6 59.7 24.4
Analysis of variance of erythema induced by 238mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 3308 1654 0.73 0.487
Error 71 161787 2279
Total 73 165095
2300mJ per cm
Genotype N Mean StDev SE Mean
CC 34 153.71 46.54 7.98
CT 34 152.94 39.80 6.83
TT 6 147.3 33.2 13.6
Analysis of variance of erythema induced by 300mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 210 105 0.06 0.944
Error 71 129273 1821
Total 73 129483
No significant difference was observed between any genotype and response to UV at any
dose examined (P values ranged from 0.944 to 0.487). The TT genotype had lower mean
erythemal responses at each UV dose, but this was not significant. The number of TT
homozygotes examined in group 1 was also far fewer than the number of individuals with
CC or CT genotypes. Given the high p values observed in group 1, it is not surprising that
almost all variation in levels of UV-induced erythema was due to factors other than the
XPD exon 22 genotype. The exon 22 genotype accounted for very little of the total
variation, at 238mJ per cm2 (UV dose with lowest P value, 0.487) the SS(factor) equalled
3308, while SS(error) was 161787, accounting for almost all the total variation (SS(total)
value 165095). At 300mJ per cm2, where the p value was 0.944 (the highest observed in
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this group for XPD exon 22 genotype) the XPD exon 22 genotype accounted for almost
none of the total variation (SS(factor)), with a value of only 210, compared with the
SS(error) value of 129273.
A balanced ANOVA test would have had n=25, where n is the number of individuals in
each group, and the least balanced would be where n=6. At 119mJ, the between variance
value of 45 and within variance value of 673 gave power values of 0.34 and 0.10
respectively. At 300mJ, the between variance value of 105 and within variance value of
1821 gave power values of 0.30 and 0.09. The power here is too low to able to accept or
reject the hypothesis with confidence; therefore a larger study group is required.
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Figure 24. Erythema induced by 0.47J per cm2 by XPD exon 22 genotype.



























Figure 25. Erythema induced by 0.6J per cm2 UV by XPD exon 22 genotype.






























Figure 26 Erythema induced by 0.75J per cm UV by XPD exon 22 genotype.



















Figure 27 Erythema induced by 0.95J per cm2 UV by XPD exon 22 genotype.




















Figure 28 Erythema induced by 1.2J per cm UV by XPD exon 22 genotype.

















Figure 29. Erythema induced by 1.5J per cm2 UV by XPD exon 22 genotype.
UVR on inner forearm, measured at 24 hours, n=31.
Analysis of XPD exon 22 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
CC 16 0.438 1.315 0.329
CT 10 6.80 21.50 6.80
TT 5 13.0 29.1 13.0
Analysis of variance of erythema induced by 0.47J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 678 339 1.25 0.301
Error 28 7568 270
Total 30 8246
0.6J per cm2
Genotype N Mean StDev SE Mean
CC 16 7.23 16.41 4.10
CT 10 21.2 43.5 13.8
TT 5 43.6 55.3 24.7
Analysis of variance of erythema induced by 0.6J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 5230 2615 2.20 0.130
Error 28 33325 1190
Total 30 38555
0.75J per cm2
Genotype N Mean StDev SE Mean
CC 16 23.67 35.38 8.85
CT 10 38.4 57.7 18.2
TT 5 62.4 66.6 29.8
Analysis of variance of erythema induced by 0.75J per cm2 between genotypes:
Source DF SS MS F P
Factor 2 5921 2960 1.25 0.303
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Error 28 66487 2375
Total 30 72408
0.95J per cm2
Genotype N Mean StDev SE Mean
CC 16 54.7 58.2 14.5
CT 10 64.5 62.4 19.7
TT 5 163.0 82.4 36.8
Analysis of variance of erythema induced by 0.95J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 46413 23207 5.75 0.008
Error 28 112936 4033
Total 30 159349
1.2J per cm2
Genotype N Mean StDev SE Mean
CC 16 84.5 65.2 16.3
CT 10 109.8 61.5 19.4
TT 5 203.4 93.4 41.7
Analysis of variance of erythema induced by 1,2J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 53901 26950 5.69 0.008
Error 28 132687 4739
Total 30 186588
1.5J per cm2
Genotype N Mean StDev SE Mean
CC 16 137.4 67.7 16.9
CT 10 151.3 77.3 24.5
TT 5 256.8 105.1 47.0
Analysis of variance of erythema induced by 1.5J per cm2 UV between genotypes:
Source DF SS MS F P
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Factor 2 55759 27879 4.68 0.018
Error 28 166683 5953
Total 30 222442
In group 2, the TT homozygotes displayed higher mean erythemal responses at each dose
examined. Significant variation in response to UV was seen at the three highest UV doses
examined, 0.95J per cm2 (p= 0.008), 1.2J per cm2 (p=0.008) and 1.5J per cm2 (p=0.018),
although errors were wide. Although there was significant variation in level of erythemal
response to UVB by genotype at 0.95, 1.2 and 1.5 J per cm2 UV, the variation due to
genotype was still considerably less than the variation within the genotype groupings,
which was variation due to other factors. At 0.95 and 1,2J per cm2, where the p value was
0.008, the majority of variation was still due to factors other than the genotype, with
SS(factor) values of 46413 for 0.95J per cm2 and 53901 for 1.2J per cm2 compared with
the SS(error) values of 112936 and 132687 for 0.95 and 1.2J per cm2 respectively. At
1.5 J per cm2 UV, (p value 0.018) the SS(total) value was 222442, of which only 5579
was accounted for by the XPD exon 22 genotype. The p values for group 2 alone might
suggest an association between an increased susceptibility to UV (with higher erythemal
response) and the TT genotype. However, this is not in agreement with the larger group
1, where no significant association between any genotype and level of UV-induced
erythema was observed, and the trend (although not significant) was for the TT genotype
to have lower levels of erythema.
This may be due to chance, or may be some peculiarity due to the make up of the study
groups. Group 2 consisted ofpatients who were about to undergo phototherapy for
psoriasis, the association seen in group 2 might be some artefact of this, or, more likely,
due to chance.
Tomescu et al (2001) found the exon 22 polymorphism of XPD to be associated with
melanoma in individuals under 50 years old. They found the C allele to be over
represented in melanoma patients, compared with matched controls. From this, one
would expect the CC genotype to have higher erythemal responses, which is not seen in
group 2, and is not significant in group 1. The small number of individuals studied by
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Tomescu et al might have exacerbated any artefacts, which lead to the finding of an
association between the polymorphism and melanoma. The different data seen in the two
independent study groups described here suggests that the association seen at the higher
UV doses in group 2 is due to chance. The low power values obtained suggest a need for
larger sample sizes in order to be confident there is no association between the XPD exon
22 genotype and erythema.
94
XPD exon 23
The exon 23 polymorphism in the only polymorphism in XPD examined in this study that
leads to an amino acid change. An A to C change at position 35931 on the GenBank entry
L47234 results in a non-synonymous amino acid change, from Lys to Gin.
A PCR-RFLP assay was used to genotype samples for the exon 23 polymorphism. PCR
gave a 344 bp product, which contains the polymorphic site. The CC homozygote
contains two PstI restriction sites, including one at position 35931 on GenBank entry
L47234, giving fragments of 172, 110 and 62 bp after digestion. The AA homozygote
only contains one restriction site, as in the presence of an A at the above position, no PstI
restriction sited exists. This yields two fragments, of 234 and 110 bp. The heterozygous
AC genotype gives four fragments, of 234, 172, 110 and 62 base pairs. (62bp fragment
not seen on gel in Figure 30 below).
Figure 30, XPD exon 23 PCR products
Lanes 1-8, PCR products
Lane 9, negative control
Figure 31 XPD exon 23 digests
Lane 1, CC
Lanes 2,5,8, AC
Lanes 3-4, 6-7, AA
Lane 9, undigested PCR product
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XPD exon 23 Genotype frequencies
Genotype Group 1 (%) Group 2 (%)
AA 34/74 (45.95%) 17/31 (54.84%)
AC 33/74 (44.59%) 9/31 (29.03%)
CC 7/74 (9.46%) 5/74(16.13%)
Total (100%) 74 (100%) 31 (100%)
The genotype frequencies observed in group 1 and group 2 followed a similar
distribution. No significant difference was observed between the genotype frequencies in
the two groups (j2, DF = 2, P-Value = 0.282)
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Figure 32 Erythema induced by 119mJ per cm UV by XPD exon 23 genotype.





























Figure 33 Erythema induced by 150mJ per cm2 UV by XPD exon 23 genotype.














Figure 34 Erythema induced by 189mJ per cm2 UV by XPD exon 23 genotype.




























Figure 35. Erythema induced by 238mJ per cm2 UV by XPD exon 23 genotype.














Figure 36. Erythema induced by 300mJ per cm2 UV by XPD exon 23 genotype.
UVR on lower back, measured at 48 hours, n=74.
99
Analysis of XPD exon 23 genotype and erythemal response to UVR for each dose in
group 1.
119mJ per cm2
Genotype N Mean StDev SE Mean
AA 34 21.74 25.45 4.36
AC 33 25.37 24.09 4.19
CC 7 20.7 35.7 13.5
Analysis of variance of erythema induced by 119mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 272 136 0.20 0.817
Error 71 47589 670
Total 73 47861
2150mJ per cm
Genotype N Mean StDev SE Mean
AA 34 53.71 39.17 6.72
AC 33 61.79 36.44 6.34
CC 7 42.5 52.8 19.9
Analysis of variance of erythema induced by 150mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 2556 1278 0.83 0.442
Error 71 109826 1547
Total 73 112382
189mJ per cm2
Genotype N Mean StDev SE Mean
AA 34 91.16 48.67 8.35
AC 33 102.51 44.78 7.79
CC 7 82.1 58.4 22.1
Analysis of variance of erythema induced by 189mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 3525 1762 0.77 0.467




Genotype N Mean StDev SE Mean
AA 34 121.41 49.51 8.49
AC 33 135.33 41.77 7.27
CC 7 101.3 58.5 22.1
Analysis of variance of erythema induced by 238mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 7849 3924 1.77 0.177
Error 71 157246 2215
Total 73 165094
300mJ per cm2
Genotype N Mean StDev SE Mean
AA 34 148.68 45.64 7.83
AC 33 158.94 40.07 6.97
CC 7 144.3 34.3 13.0
Analysis of variance of erythema induced by genotype:
Source DF SS MS F P
Factor 2 2324 1162 0.65 0.526
Error 71 127158 1791
Total 73 129483
In group 1, no significant association between any genotype and erythemal response was
observed at any UV dose examined (p values from 0.817 to 0.177). The CC homozygote
had lower mean levels of erythema at all doses, although errors were large, and this was
not significant. The XPD exon 23 genotype explained very little of the overall amount of
variation seen between levels of UV-induced erythema, as seen by low SS(factor) levels
compared with the SS(error) and SS(total) values.
The number of individuals in each group if the ANOVA was balanced, and as least
balanced as possible, would be n=25 and n=7 respectively. At 119mJ, the between
variance value of 136 and within variance value of 670 gave power values of 0.80 where
n=25 and 0.26 where n=7. At 300mJ, the between variance value of 1162 and within
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variance value of 1791 gave power values of 0.99 and 0.70 respectively. The difference
in power at the different UV doses suggests the sample size would need to be increased in
order to ensure the p values obtained in the analysis of variance tests were accurate.
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Figure 37. Erythema induced by 0.47J per cm2 UV by XPD exon 23 genotype.






































































Figure 39 Erythema induced by 0.75J per cm2 UV by XPD exon 23 genotype.







































Figure 40 Erythema induced by 0.95J per cm UV by XPD exon 23 genotype.


































Figure 41 Erythema induced by 1.2J per cm UV by XPD exon 23 genotype.




























Figure 42 Erythema induced by 1.5J per cm2 UV by XPD exon 23 genotype.
UVR on lower back, measured at 24 hours, n=31.
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Analysis of XPD exon 23 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
AA 17 4.24 15.71 3.81
AC 9 7.56 22.67 7.56
CC 5 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.47J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 186 93 0.32 0.726
Error 28 8059 288
Total 30 8246
0.6J per cm2
Genotype N Mean StDev SE Mean
AA 17 14.45 33.75 8.19
AC 9 21.7 46.1 15.4
CC 5 21.0 27.0 12,1
Analysis of variance of erythema induced by 0.6J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 375 188 0.14 0.872
Error 28 38180 1364
Total 30 38555
0.75J per cm2
Genotype N Mean StDev SE Mean
AA 17 31.1 49.9 12.1
AC 9 40.0 58.3 19.4
CC 5 37.2 35.0 15.7
Analysis of variance of erythema induced by 0.75J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 505 252 0.10 0.907




Genotype N Mean StDev SE Mean
AA 17 73.8 83.6 20.3
AC 9 73.6 54.1 18.0
CC 5 83.8 77.0 34.5
Source DF SS MS F P
Factor 2 428 214 0.04 0.963
Error 28 158922 5676
Total 30 159349
1.2J per cm2
Genotype N Mean StDev SE Mean
AA 17 107.6 96.4 23.4
AC 9 122.5 53.9 18.0
CC 5 107.0 57.7 25.8
Analysis of variance of erythema induced by 1.2J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1448 724 0.11 0.897
Error 28 185140 6612
Total 30 186588
1.5 J per cm2
Genotype N Mean StDev SE Mean
AA 17 160.2 101.2 24.5
AC 9 176.4 66.5 22.2
CC 5 136.9 67.3 30.1
Analysis of variance of erythema induced by 1.5J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 5049 2525 0.33 0.725
Error 28 217393 7764
Total 30 222442
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In group 2, again no significant association was observed between any genotype and
erythemal response at any UV dose studied (p values ranging from 0.963 at 0.95J per cm
to 0.725 at 1.5J per cm2). Variation in levels of erythema was in the main due to factors
other than XPD exon 23 genotype, for example, at 1.5J per cm2 UV, the genotype
explained little of the total variation, with a SS(factor) value of only 5049, compared with
the SS(total) of 217393, which made up the majority of the SS(total) value of 222442.
Power calculations for group 2 were carried out using n=10, which was equal to a
balanced test, and n=5, the least balanced. 0.47J UV gave between variance values of 93
and within variance values of 288, giving power values of 0.57 when n=10 and 0.27
when n=5. At 1.5J the between variance value was 2525 and the within variance value
7764, which gave power values of 0.57 and 0.28, similar to those observed at the lower
UV dose. Therefore, the ANOVA tests on this data are not very powerful, and require
increased power, which could be achieved by a greater sample size, in order to be more
confident in the p-values obtained.
Exon 23 Discussion
Previously, an association has been reported between the A allele of the exon 23
polymorphism and melanoma (Tomescu et al) OR 2-8, 95% CI 1.2-7.0, P=0.02. From
this, it might be expected to see increased erythema in AA homozygotes than
heterozygotes and CC homozygotes. The CC genotype did have lower erythema values in
group 1, but this was not at all significant, and only seen at 1.2 and 1.5J per cm in group
2, where again it was not at all significant.
The lower level of chromosomal aberrations in cells from individuals with the CC
genotype compared with those from AA and AC genotypes found by Vodicka and
colleagues (2004) also suggests that the CC genotype may have some protective role in
the development of cancer, as chromosomal aberrations are associated with onset of
cancer. Vodicka and colleagues also report a higher level of irradiation specific DNA
repair after gamma irradiation in lymphocytes with the CC genotype, compared to AA
and AC genotypes (p=0.033), as measured by number of single stranded breaks in the
DNA. The CC genotype did not display a protective role against UV-induced erythema,
which would have been indicated by lower levels of erythema in both study groups,
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suggesting that if it does provide some protective effect that lowers risk of cancers, this
protection does not extend to protection from UV damage which could be linked to the
ability of cells to carry out NER pathways. That the findings here are not in agreement
with those of Tomescu et al, who found the A allele to be associated with melanoma,
might be due to the lower sample sizes compared with the study in this thesis. Winsey et
al (2000) also examined the exon 23 polymorphism for association with melanoma, and
found no association between the two. This was a larger study, with 125 cases and 211
controls, compared with the 28 cases and 33 controls in the Tomescu study, which would
suggest that the association seen by Tomescu and colleagues was due to chance.
However, the use of cadavers as controls in the study by Winsey et al could be
questioned. No mention is made of whether these individuals had had a history of
melanoma, or any other skin cancer, or indeed whether this was investigated. If it were
the case that any of the controls had previously had melanoma, their presence in the
control group would affect the validity of the observed non-association between exon 23
and melanoma.
In their study investigating an association between the exon 23 polymorphism and lung
cancer, Zhou et al (2002) saw no association between lung cancer and the XPG exon 23
polymorphism in their overall data set. When non-smokers were analysed alone, they
observed an increased risk of lung cancer in individuals with the CC genotype when
compared to those with an AA genotype (OR 2.0; 95% CI, 1.1-3.4. Zhou and colleagues
suggested that as smoking reduces DNA repair capacity, any protective effect of the AA
genotype wiped out by the carcinogens in tobacco in smokers. Although this study used a
large number of cases and controls (1092 lung cancer patients, 1240 controls), the
numbers of non-smokers were few in both sub-groups. Not surprisingly, amongst cases,
the number of non-smokers (that is those who had never smoked) was only 73 out of
1092 (6.7%). The non-smokers composed more of the control group, but still only
accounted for 434/1240 (35.0%). This is in effect a study of 73 cases and 434 controls,
which could have skewed results due to the small number of cases compared with
controls. Although most lung cancers are at least in part due to smoking, thus making it
difficult to study large numbers of non-smoking, lung cancer patients, such a study would
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be valuable in resolving this association. In a similar study, Hou et al (2002) analysed
185 Swedish lung cancer patients (97 smokers, 88 non-smokers) and 162 matched
controls (83 smokers, 70 non-smokers), and found the presence of the C allele to be
associated with increased risk of lung cancer in non-smokers only (OR 3.2; 95% CI 1.3-
8.0). Other studies have, however, found no association between the exon 23
polymorphism and lung cancer risk. Park et al (2002) found no significant difference in
the exon 23 genotype frequencies between Korean lung cancer patients and matched
controls. David-Beabes and colleagues (2001) also found no association between exon
23, smoking status, and lung cancer risk. The evidence to both support, and disagree,
with the association of exon 23 with lung cancer is inconclusive, but if such an
association did exist, in affecting risk of lung cancer, it is reasonable to assume it would
also affect risk of skin cancer, as DNA lesions induced by tobacco and UVR are both
repaired by NER. The finding of an association with melanoma by Tomescu and
colleagues is refuted in the larger study by Winsey et al. Data observed in this study
implies no association between exon 23 and sensitivity to UVR, which is in agreement
with no association being seen by Winsey et al in their melanoma study.
Of the three XPD polymorphisms studied here, only the exon 23 change affects the
coding sequence (amino acid change of Lys to Gin). Tomescu et al found this association
to be the strongest for this region of the gene, proposing that it could be causative. In this
study, the exon 23 polymorphism was found to be no more associated with increased
susceptibility to UV than exon 6 or exon 22. Lunn et al (2000) studied DNA repair
capabilities of the two alleles of exon 23 and found the Lys allele to have reduced repair
in an X-ray induced chromosome aberration assay. This is, however, ionising radiation,
and the involvement of NER and XPD in repair of such damage is questionable. Dybdah
et al (1999) found no difference in repair between the Lys and Gin alleles when using
host cell reactivation and comet assays. This supports the findings here of no association
between exon 23 and UV-induced erythemal response.
None of the polymorphisms of XPD studied here can be conclusively associated with an
increased sensitivity to UVR. This is not in agreement with the study by Tomescu and
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colleagues. Either susceptibility to UVR and development of melanoma are not related,
or else the association seen between the polymorphisms of exon 6, 22 and 23 and
melanoma are due to chance. It is well established that sensitivity to UVR is a risk facto r
for the development of cutaneous malignancies, including melanoma. This, and the small
number of individuals examined in the Tomescu study suggests that their reported
association might be due to chance, as it is not backed up by the erythemal response data.
In the absence of further study, where larger study groups could be analysed, there is
evidence to support an association of any of the polymorphisms examined in XPD (at
exon 6, 22 and 23) and sensitivity to UVR. This suggests the findings of an association
between these polymorphisms and melanoma (Tomescu et al) is due to chance.
Ill
CKM 8
A PCR-RFLP assay was used to genotype the CKM exon 8 polymorphism. PCR
generated a 1099 bp product, which contained the polymorphic region. The
polymorphism consists of a T to C chance at position 23977 on GenBank entry
AC005781. In the presence of the C allele, a TaqI restriction site exists. The T allele is
uncut, producing a single fragment of 1099 bp. The C allele yields two fragments, of 999
and 100 bp (not seen on gel below), and the heterozygous CT genotype this having 3
fragments after digestion; 1099, 999 and 100 bp (not seen on gel below).
Figure 43, CKM exon 8 PCR
Lanes 1-8, PCR products
Lane 9, negative control
Figure 44 CKM exon 8 digest
Lanes 1-3, 5, 7, CT
Lanes 4, 8, TT
Lane 6, CC
It would not be expected to see any association between CKM exon 8 and susceptibility
to UVR, as CKM has no role in the repair of UV-induced damage (or in any DNA repair
pathway), and was included here to see if the reported association between XPD and
melanoma (and hence susceptibility to UVR) by Tomescu et al extended to CKM, which
is the nearest flanking marker to XPD. Tomescu and colleagues did not observe the
reported association extending to CK M, but it this larger study group it is possible that if
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an association was observed between any of the XPD polymorphisms it might extend to
CKM. As no association was observed between any of the polymorphisms studied in
XPD, no association was expected to be seen here in CKM.
CKM exon 8 Genotype frequencies
Genotype Group 1 (%) Group 2 (%)
TT 5/74 (6.76%) 2/31 (6.45%)
TC 28/74 (37.84%) 16/31 (51.%)
CC 41/74 (55.40%) 13/31 (41.94%)
Total (100%) 74 (100%) 31 (100%)
Genotype frequencies were similar between both study groups. Chi-square analysis
confirmed that no significant genotype frequencies existed between the two groups (DF =
2, P-Value = 0.414). As the frequency of TT homozygotes was low, which very few
being observed in either group, as well as analysing variance between all three genotypes,
the TT homozygotes were grouped with the heterozygotes (TC) to determine variation
between these and the CC homozygotes.
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Erythema induced by incremental doses of UVR by CKM exon 8 genotype in group 1.




































Figure 45. Erythema induced by 119mJ per cm UV by CKM exon 8 genotype.































Figure 46. Erythema induced by 150mJ per cm2 UV by CKM exon 8 genotype.


































Figure 47 Erythema induced by 189mJ per cm UV by CKM exon 8 genotype.






























Figure 48. Erythema induced by 238mJ per cm2 UV by CKM exon 8 genotype.














Figure 49. Erythema induced by 300mJ per cm2 UV by CKM exon 8 genotype.
UVR on lower back, measured at 48 hours, n=74.
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Analysis of CKM exon 8 genotype and erythemal response to UVR for each dose in
group 1.
119mJ per cm2
Genotype N Mean StDev SE Mean
TT 5 26.0 43.4 19.4
TC 28 20.32 23.24 4.39
CC 41 24.93 25.17 3.93
Analysis of variance of erythema induced by 119mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 395 197 0.30 0.745
Error 71 47466 669
Total 73 47861
Comparison of TT and TC genotypes together with CC homozygotes:
Genotype N Mean StDev SE Mean
TT/TC 33 21.18 26.38 4.59











Error 72 47605 661
Total 73 47861
150mJ per cm2
Genotype N Mean StDev SE Mean
TT 5 43.8 54.9 24.5
TC 28 53.71 39.90 7.54
CC 41 59.51 37.40 5.84
Analysis of variance of erythema induced by 150mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1391 695 0.44 0.643
Error 71 110991 1563
Total 73 112382
Comparison of TT and TC genotypes together with CC homozygotes:
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Genotype N Mean StDev SE Mean
TT/TC 33 52.21 41.63 7.25
CC 41 59.51 37.40 5.84
Source DF SS MS F P
Factor 1 974 974 0.63 0.430
Error 72 111407 1547
Total 73 112382
189mJ per cm2
Genotype N Mean StDev SE Mean
TT 5 77.5 76.6 34.2
TC 28 93.21 47.52 8.98
CC 41 99.01 44.61 6.97
• • 9
Analysis of variance of erythema induced by 189mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 2278 1139 0.49 0.613
Error 71 164040 2310
Total 73 166318
Comparison of TT and TC genotypes together with CC homozygotes:
Genotype N Mean StDev SE Mean
TT/TC 33 90.82 51.68 9.00









Error 72 165091 2293
Total 73 166318
238mJ per cm2
Genotype N Mean StDev SE Mean
TT 5 104.3 76.1 34.0
TC 28 123.78 49.29 9.32
CC 41 129.66 42.80 6.68
2
Analysis of variance of erythema induced by 238mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 3044 1522 0.67 0.517
Error 71 162051 2282
Total
Comparison of TT and TC genotypes together with CC homozygotes:
Genotype N Mean StDev SE Mean
TT/TC 33 120.82 53.15 9.25









Error 72 163666 2273
Total 73 165094
300mJ per cm2
Genotype N Mean StDev SE Mean
TT 5 133.0 73.3 32.8
TC 28 154.02 42.67 8.06
CC 41 154.46 37.66 5.88
Analysis of variance of erythema induced by 300mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 2114 1057 0.59 0.557
Error 71 127369 1794
Total 73 129483
Comparison of TT and TC genotypes together with CC homozygotes:
Genotype N Mean StDev SE Mean
TT/TC 33 150.83 47.61 8.29
CC 41 154.46 37.66 5.88
Source DF SS MS F P
Factor 1 240 240 0.13 0.716
Error 72 129243 1795
Total 73 129483
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No association was seen between any genotype and susceptibility to UV at any dose.
When analysing variation between each genotype, errors were wide for the TT genotype,
due to small numbers. SS(factor) values were low at all UV doses examined when
compared with the SS(error) values. This indicates the majority of variation is not
attributable to the genotype of the individuals, and that the CKM exon 8 polymorphism is
not associated with levels of UV-induced erythema in this study group.
If the analysis of variance was balanced, each group would contain the same number of
individuals, which would be n=25. The least balance the test would be would be where
n=5 in all groups. These values were used to give a range for the power of the tests. At
119mJ, the between variance value was 197, and the within variance 669. Power was
0.93 when n=25 and 0.25 when n=5. At 300mJ the between variance value was 1057 and
within variance 1794, which gave powers of 0.99 and 0.47 when n=25 and 5 respectively.
The true power will lie within this range, at the upper limit this would be acceptable, but
greater power would enable it to be determined more confidently that the CKM genotype
is not related to erythemal response.
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Figure 50. Erythema induced by 0.47J per cm UV by CKM exon 8 genotype.





























Figure 51 Erythema induced by 0.6J per cm UV by CKM exon 8 genotype.

























Figure 52. Erythema induced by 0.75J per cm2 UV by CKM exon 8 genotype.
























Figure 53. Erythema induced by 0.95J per cm2 UV by CKM exon 8 genotype.































Figure 54. Erythema induced by 1.2J per cm UV by CKM exon 8 genotype.






















Figure 55. Erythema induced by 1.5J per cm UV by CKM exon 8 genotype.
UVR on inner forearm, measured at 24 hours, n=31.
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Analysis of CKM exon 8 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
TT 2 2.50 3.54 2.50
TC 16 0.125 0.50 0.125
CC 13 10.23 24.98 6.93
2
Analysis of variance of erythema induced by 0.47J per cm UV between genotypes:
Source DF SS MS F P
Factor 2 741 371 1.38 0.268
Error 28 7505 268
Total 30 8246
Comparison of TT and TC genotypes together with CC homozygotes:
Genotype N Mean StDev SE Mean
TT/TC 18 0.389 1.243 0.293
CC 13 10.23 24.98 6.93
Source DF SS MS F P
Factor 1 731 731 2.82 0.104
Error 29 7515 259
Total 30 8246
0.6J per cm2
Genotype N Mean StDev SE Mean
TT 2 26.8 38.0 26.8
TC 16 3.88 10.81 2.70
CC 13 33.1 49.2 13.6
Analysis of variance of erythema induced by 0.6J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 6299 3149 2.73 0.082
Error 28 32257 1152
Total 30 38555
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Comparison of TT and TC genotypes together with CC homozygotes:
Genotype N Mean StDev SE Mean
TT/TC 18 6.43 15.59 3.67
CC 13 33.1 49.2 13.6
Source DF SS MS F P
Factor 1 5361 5361 4.68 0.039
Error 29 33194 1145
Total 30 38555
0.75J per cm2
Genotype N Mean StDev SE Mean
TT 2 67.8 30.6 21.7
TC 16 15.06 30.00 7.50
CC 13 53.7 60.9 16.9
Analysis of variance of erythema induced by 0.75J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 23578 11789 5.60 0.009
Error 28 58956 2106
Total 30 82535
Comparison of TT and TC genotypes together with CC homozygotes:
Genotype N Mean StDev SE Mean
TT/TC 18 26.2 43.6 10.3
CC 13 53.7 60.9 16.7
Source DF SS MS F P
Factor 1 5704 5704 2.15 0.153
Error 29 76831 2649
Total 30 82535
0.95J per cm2
Genotype N Mean StDev SE Mean
TT 2 143.67 8.96 6.33
TC 16 54.3 71.1 17.8
CC 13 90.7 73.0 20.3
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Analysis of variance of erythema induced by 0.95J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 19451 9725 1.95 0.162
Error 28 139898 4996
Total 30 159349
Comparison of TT and TC genotypes together with CC homozygotes:
Genotype N Mean StDev SE Mean
TT/TC 18 64.3 72.8 17.2
CC 13 90.7 73.0 20.3
Source DF SS MS F P
Factor 1 5264 5264 0.99 0.328
Error 29 154085 5313
Total 30 159349
1.2J per cm2
Genotype b Mean StDev SE Mean
TT 2 150.17 9.67 6.83
TC 16 96.8 88.4 22.1
CC 13 124.5 71.1 19.7
Analysis of variance of erythema induced by 1.2 J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 8669 4334 0.68 0.514
Error 28 177919 6354
Total 30 186588
Comparison of TT and TC genotypes together with CC homozygotes:
Genotype N Mean StDev SE Mean
TT/TC 18 102.7 84.8 20.0
CC 13 124.5 71.1 19.7
Source DF SS MS F P
Factor 1 3597 3597 0.57 0.456
Error 29 182991 6310
Total 30 186588
1.5 J per cm2
Genotype N Mean StDev SE Mean
TT 2 163.0 14.1 10.0
TC 16 159.6 103.2 25.8
CC 13 162.7 72.2 20.0
Analysis of variance of erythema induced by 1.5J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 73 36 0.00 0.995
Error 28 222369 7942
Total 30 222442
Comparison of TT and TC genotypes together with CC homozygotes:
Genotype N Mean StDev SE Mean
TT/TC 18 160.0 97.0 22.9









Error 29 222389 7669
Total 30 222442
In group 2, no significant association was observed between any genotype and
susceptibility to UVR at any dose examined when comparing the three genotypes. At
0.75J per cm2 the mean level of erythema of the TC genotype did seem to be lower than
that observed in TT and CC genotypes, however, this was not formally significant
(P=0.06).
From the SS values, it can be seen that the CKM exon 8 genotype contributed little to the
total amount of variation of the different levels of erythema observed. The SS(factor)
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levels were extremely small, with the variation due to factors other than genotype
(SS(error)) comprising almost all of the SS(total) values, for example at 1.5 J per cm2 the
SS(total) value was 222442, with the genotype (SS(factor)) value being only 53.
In group 2, power calculations were performed using n=10 (balanced) and n=2 (lowest
group size seen). At 0.47J, the between variance of 371 and within variance of 268 gave a
power of 0.99 when n=10, and 0.24 when n=2. At 1.5J, the between variance was 36, and
within variance 7942, giving powers of 0.06 when n=10 and 0.05 when n=2. These are
extremely low, and are probably due to the small sample size, highlighting the need for
greater numbers.
No association was observed between the CKM exon 8 genotype and erythemal response
to UVR at any UV dose examined in either study group. CKM is located 3' to XPD on
chromosome 19. If an association had been observed between XPD and erythemal
response, this association may have extended to CKM. No such association was observed
with respect to XPD, therefore the finding of no association between CKM and erythemal




Along with XPF, ERCCl acts as a 5' endonuclease, incising damaged DNA during NER.
As NER repairs UV-induced damage, it is possible that if any polymorphisms of ERCCl
affect NER capability, this will reflect upon UVR sensitivity.
The ERCCl exon 4 polymorphism is located at position 19007 on the GenBank entry
M63796. The polymorphism was genotyped by a PCR-RFLP assay. PCR was used to
generate a 252 base pair product. The polymorphism is a G to A change, which does not
result in an amino acid substitution. The A allele contains a BsrDI restriction site, which
gives two fragments to 179 and 73 (not seen on gel below) bp after digestion. The G
allele does not contain this restriction site, and is therefore not cut, giving one fragment
of 252 bp.
1 2 34 5 67M8 12345 67M8 bp
252
179
Figure 56. ERCC1 PCR products
Lanes 1-7, PCR product
Lane 8, negative control
Figure 57 ERCC1 restriction digests
Lane 1, GG
Lanes 2,4,6, AG
Lanes 3, 5, 7, AA
Lane 8, uncut PCR product
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ERCC1 exon 4 Genotype frequencies
Genotype Group 1 (%) Group 2 (%)
GG 13/74(17.57%) 7/31 (22.58%)
GA 12/74(16.21%) 7/31 (22.58%)
AA 49/74 (66.22%) 17/31 (54.84%)
Total (100%) 74 (100%) 31 (100%)
The AA homozygous genotype was most common in both study groups, accounting for
the majority of individuals genotyped. The GG and GA genotype frequencies were
similar to each other in both groups. No significant difference existed between the
genotype frequencies of the two groups (x2 DF = 2, P-Value = 0.541).
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Erythema induced by incremental doses of UVR by ERCC1 exon 4 genotype in group
1.
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Figure 58. Erythema induced by 119mJ per cm UV by ERCC1 exon 4 genotype.



























Figure 59 Erythema induced by 150mJ per cm UV by ERCC1 exon 4 genotype.




































Figure 60 Erythema induced by 189mJ per cm2 UV by ERCC1 exon 4 genotype.







































Figure 61. Erythema induced by 238mJ per cm2 UV by ERCC1 exon 4 genotype.



















Figure 62. Erythema induced by 300mJ per cm UV by ERCC1 exon 4 genotype.
UVR induced on lower back, measured at 48 hours, n=74.
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Analysis of ERCC1 exon 4 genotype and erythemal response to UVR for each dose
in group 1.
119mJ per cm2
Genotype N Mean StDev SE Mean
GG 13 12.26 12.42 3.45
GA 12 24.33 30.17 8.71
AA 49 25.91 26.64 3.81
Analysis of variance of erythema induced by 119mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1931 966 1.49 0.232




Genotype N Mean StDev SE Mean
GG 13 36.91 30.96 8.59
GA 12 52.9 42.2 12.2
AA 49 62.20 39.41 5.63
Analysis of variance of erythema induced by 150mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 6729 3365 2.26 0.112
Error 71 105652 1488
Total 73 112382
189mJ per cm
Genotype N Mean StDev SE Mean
GG 13 69.1 42.4 11.7
GA 12 98.4 59.8 17.3
AA 49 101.58 44.34 6.33
Analysis of variance of erythema induced by 189mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 10996 5498 2.51 0.088




Genotype N Mean StDev SE Mean
GG 13 100.5 44.1 12.2
GA 12 128.3 57.7 16.7
AA 49 131.77 44.48 6.35
Analysis of variance of erythema induced by 23 8mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 10139 5069 2.32 0.105
Error 71 154956 2182
Total 73 165094
3 00mJ per cm2
Genotype N Mean StDev SE Mean
GG 13 140.01 28.24 7.83
GA 12 153.1 52.8 15.2
AA 49 156.18 42.48 6.07
Analysis of variance of erythema induced by 300mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 2688 1344 0.75 0.475
Error 71 126795 1786
Total 73 129483
In group 1, the AA genotype displayed higher mean levels of erythema at each UV dose
examined. The GG genotype similarly displayed the lowest levels of erythema, with the
heterozygotes falling between the two. This was not significant at any dose examined,
although at 189mJ per cm2, the level of significance was approached (p=0.08). Although
the level of significance was approached at 189mJ per cm2, a comparison of factor and
error reveal that the genotype explains very little of the total variation between erythema
levels, SS(factor) being 10996, while SS(error) equals 155322, and a SS(total) value of
166318. As p values are not significant at any other UV dose examined, and, from factor
and error values, it can be determined that most of the variation in erythemal response is
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due to factors other than genotype, the ERCC1 exon 4 polymorphism is not implicated in
the erythemal response to UV in group 1.
Power calculations were carried out in group 1 using n=25 (balanced ANOVA) and n=12
(most unbalanced) to give a range of true values the power would lie within. At 119mJ
UV, the between variance value of 966 and within variance value of 647 gave a power of
1 when n=25 and a power of 0.99 when n=12. At 300mJ, between variance was 1344,
and within variance 1786, which, when n=25 gave a power of 0.99 and when n=12, a
power of 0.96. For this polymorphism the sample size in group 1 appears to be adequate
due to the acceptable level of power. It can be confidently said that the ANOVA results
which indicated that the ERCC1 polymorphism is not associated with erythemal response
is likely to be true.
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Figure 63 Erythema induced by 0.47J per cm UV by ERCC1 exon 4 genotype.
































Figure 64. Erythema induced by 0.6J per cm2 UV by ERCC1 exon 4 genotype.































Figure 65 Erythema induced by 0.75J per cm UV by ERCC1 exon 4 genotype.
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Figure 66. Erythema induced by 0.95J per cm UV by ERCC1 exon 4 genotype.






























Figure 67 Erythema induced by 1.2J per cm2 UV by ERCC1 exon 4 genotype.






























Figure 68 Erythema induced by 1.5J per cm2 UV by ERCC1 exon 4 genotype.
UVR induced on inner forearm, measured at 24 hours, n=31.
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Analysis of ERCC1 exon 4 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
GG 7 9.71 25.70 9.71
GA 7 9.29 24.57 9.29
AA 17 0.412 1.278 0.310
Analysis of variance of erythema induced by 0.47J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 635 317 1.17 0.326
Error 28 7611 272
Total 30 8246
0.6J per cm2
Genotype N Mean StDev SE Mean
GG 7 27.9 51.4 19.4
GA 7 23.9 48.8 18.4
AA 17 10.80 20.39 4.94
Analysis of variance of erythema induced by 0.6J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1796 898 0.68 0.513
Error 28 36760 1313
Total 30 38555
0.75J per cm2
Genotype N Mean StDev SE Mean
GG 7 38.3 67.9 25.7
GA 7 42.3 63.9 24.1
AA 17 30.04 34.79 8.44
Analysis of variance of erythema induced by 0.75J per cm2 UV between genotypes:
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Source DF SS MS F P
Factor 2 862 431 0.17 0.846
Error 28 71546 2555
Total 30 72408
0.95J per cm2
Genotype N Mean StDev SE Mean
GG 7 44.9 74.3 28.1
GA 7 69.1 75.2 28.4
AA 17 90.5 71.4 17.3
• • 2
Analysis of variance of erythema induced by 0.95J per cm UV between genotypes:
Source DF SS MS F P
Factor 2 10659 5330 1.00 0.379
Error 28 148690 5310
Total 30 159349
1,2J per cm2
Genotype N Mean StDev SE Mean
GG 7 82.4 70.9 26.8
GA 7 122.3 95.8 36.2
AA 17 119.6 76.5 18.5
Analysis of variance of erythema induced by 1.2J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 7857 3928 0.62 0.548
Error 28 178731 6383
Total 30 186588
1.5 J per cm2
Genotype N Mean StDev SE Mean
GG 7 129.3 69.3 26.2
GA 7 165.3 115.2 43.5
AA 17 172.5 80.9 19.6
141
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At the highest three doses examined in group 2, a similar pattern to that seen in group 1
was observed, with the AA genotype having higher mean levels of erythema than the
heterozygotes, which in turn had higher mean erythema levels than the GG genotype.
This was not significant, and P values ranged from 0.846 to 0.326, indicating that in
group 2, similar to group 1, the ERCC1 exon 4 polymorphism is not associated with UV-
induced erythema.
Power calculations were performed for group 2 using n=10 (balanced) and n=7
(unbalanced). At 0.47J, the between variance was 317 and within variance 272. When
n=10 this gave a power of 0.99 and 0.92 when n=7. At 1.5J, the between variance was
4698 and the within variance 7609, giving a power of 0.85 when n=10, and 0.67 when
n=7. For this polymorphism the levels of power are acceptable, and the hypothesis that
ERCC1 exon 4 genotype is associated with erythemal response can be rejected due to
non-significant p values in the analysis of variance with confidence.
In their study of melanoma risk, Winsey and colleagues (2000) analysed the ERCC1 exon
4 polymorphism. No association was observed between melanoma risk and exon 4
genotype in 125 patients and 211 controls. Elowever, as mentioned above, the controls in
this study were cadavers. In their report, Winsey and colleagues do not discuss whether
the controls had any past history of skin cancer, which could have had an effect on the
statistical analysis. However, if one were to assume no history of melanoma in the
cadaver group, this relatively large study is in agreement with that observed by this
research project. No association was observed between the ERCC1 exon 4 polymorphism
and erythemal response, a measure of cutaneous sensitivity to UVR. This implies this
polymorphism is not associated with a decreased NER capacity, in the repair of UV-
induced DNA photoproducts, which is reinforced by the study by Winsey and colleagues,
which found no association between this polymorphism and melanoma.
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XPFexon 11
As a component, along with ERCC1, of the endonuclease that incises DNA 5' to damage
during NER, it is feasible that polymorphisms in the XPF gene might affect ability of
NER to repair UV-induced DNA damage, and susceptibility to UVR.
To genotype for XPF exon 11, a PCR product of 709 bp was produced, which contains
the polymorphism at exon 11. This polymorphism consists of a T to C change, at position
30028 on GenBank entry L76568. The T allele contains an AlwNI restriction site, which
results in two fragments, of 442 and 267 bp. The C allele has no AlwNI restriction site,
and yields a single fragment of 709 bp.
Figure 69, XPF exon 11 PCR products
Lanes 1-5, PCR products
Lane 6, negative control





XPF exon 11 Genotype frequencies
Genotype Group 1(%) Group 2 (%)
TT 34/74 (45.95%) 18/31 (58.06%)
TC 33/74 (44.59%) 10/31 (32.26%)
CC 7/74 (9.46%) 3/31 (9.68%)
Total (100%) 74(100%) 31 (100%)
The CC genotype frequency was extremely similar in the two study groups, although
there were slight differences in the frequencies of the TT and TC genotypes within the
two study groups. The genotype frequencies observed were not statistically different from
each other (x2 DF = 2, P-Value = 0.482)
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Figure 71 Erythema induced by 119mJ per cm UV by XPF exon 11 genotype.
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Figure 72 Erythema induced by 150mJ per cm2 UV by XPF exon 11 genotype.






























Figure 73 Erythema induced by 189mJ per cm UV by XPF exon 11 genotype.





























Figure 74 Erythema induced by 238mJ per cm UV by XPF exon 11 genotype.





































Figure 75. Erythema induced by 300mJ per cm UV by XPF exon 11 genotype.
UVR induced on lower back, measured at 48 hours, n=74.
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Analysis of XPF exon 11 genotype and erythemal response to UVR for each dose in
group 1.
119mJ per cm2
Genotype N Mean StDev SE Mean
TT 34 25.96 29.59 5.07
TC 33 23.76 22.90 3.99
CC 7 7.74 6.39 2.42
Analysis of variance of erythema induced by 119mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1943 972 1.50 0.230
Error 71 45918 647
Total 73 47861
150mJ per cm2
Genotype N Mean StDev SE Mean
TT 34 53.97 42.61 7.31
TC 33 61.33 37.94 6.60
CC 7 43.4 26.5 10.0
Analysis of variance of erythema induced by 150mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 2183 1091 0.70 0.498
Error 71 110199 1552
Total 73 112382
189mJ per cm2
Genotype N Mean StDev SE Mean
TT 34 92.20 50.94 8.74
TC 33 98.10 49.02 8.53
CC 7 97.81 22.94 8.67
Analysis of variance of erythema induced by 189mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 630 315 0.13 0.874




Genotype N Mean StDev SE Mean
TT 34 122.47 52.94 9.08
TC 33 128.13 46.16 8.04
CC 7 130.14 24.99 9.44
• • 2
Analysis of variance of erythema induced by 238mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 688 344 0.15 0.862
Error 71 164406 2316
Total 73 165094
300mJ per cm2
Genotype N Mean StDev SE Mean
TT 34 149.88 47.24 8.10
TC 33 155.33 40.84 7.11
CC 7 155.50 17.92 6.77
Analysis of variance of erythema induced by 300mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 552 276 0.15 0.859
Error 71 128930 1816
Total 73 129483
In group 1, no pattern was seen in response to UV, and this was confirmed by statistical
analysis. No statistically significant association was observed at any of the UV doses
examined. P values increased as the UV doses examined increased, p=0.230 for 119mJ
2 2
per cm , p=0.859 for 300mJ per cm . A comparison of factor and error reveals that most
of the variation observed in erythemal response is due to external factors other than the
XPF exon 11 polymorphism.
In group 1, the balanced ANOVA would have had all three groups contained 25
individuals. The least frequent genotype had 7 individuals in it, therefore n=7 was used as
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the least balanced option for the power calculations. At 119mJ, the between variance
value was 972, and the within variance value was 647. This gave a power of 1 where
n=25, and 0.97 when n=7. The between variance was 276 at 300mJ, and the within
variance 1816, giving power of 0.67 when n=25 and 0.21 when n=7. The difference in
power at the two UV doses is probably due to more variation at the higher dose.
Increased power, which could be achieved by increasing the sample size, could allow
greater accuracy of the statistical analysis.
150
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Figure 76. Erythema induced by 0.47J per cm2 UV by XPF exon 11 genotype.
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Figure 77. Erythema induced by 0.6J per cm UV by XPF exon 11 genotype.



































Figure 78 Erythema induced by 0.75J per cm UV by XPF exon 11 genotype.















Figure 79 Erythema induced by 0.95J per cm UV by XPF exon 11 genotype.




























Figure 80 Erythema induced by 1.2J per cm2 UV by XPF exon 11 genotype.



























Figure 81 Erythema induced by 1.5J per cm2 UV by XPF exon 11 genotype.
UVR induced on inner forearm, measured at 24 hours, n=31.
Analysis of XPF exon 11 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
TT 18 4.17 15.98 3.77
TC 10 6.50 20.55 6.50
cc 3 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.47J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 103 51 0.18 0.839
Error 28 8143 291
Total 30 8246
0.6J per cm
Genotype N Mean StDev SE Mean
TT 18 18.48 34.70 8.18
TC 10 21.3 43.5 13.7
CC 3 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.6J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1080 540 0.40 0.672
Error 28 37475 1338
Total 30 38555
0.75J per cm2
Genotype N Mean StDev SE Mean
TT 18 35.6 49.8 11.7
TC 10 37.1 56.5 17.9
CC 3 20.7 21.0 12.1
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Analysis of variance of erythema induced by 0.75J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 665 332 0.13 0.879
Error 28 71743 2562
Total 30 72408
0.95J per cm2
Genotype N Mean StDev SE Mean
TT 18 62.7 60.4 14.2
TC 10 93.3 95.7 30.3
CC 3 91.3 63.4 36.6
Analysis of variance of erythema induced by 0.95J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 6855 3428 0.63 0.540
Error 28 152494 5446
Total 30 159349
1.2J per cm2
Genotype N Mean StDev SE Mean
TT 18 98.7 60.0 14.1
TC 10 135.9 110.7 35.0
CC 3 110.7 55.6 32.1
Analysis of variance of erythema induced by 1.2J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 8917 4458 0.70 0.504
Error 28 177671 6345
Total 30 186588
1.5 J per cm2
Genotype N Mean StDev SE Mean
TT 18 143.9 56.2 13.2
TC 10 191.8 129.1 40.8
CC 3 162.6 44.3 25.6








In group 2, the TC genotype had the highest mean values of level of erythema at each UV
dose, and TT the lowest, except at 0.75J per cm2. This was not significant, with wide
errors. P values ranged from 0.879 to 0.383, and erythemal response varied between
individuals due to other factors than genotype, as can be seen by low SS(factor) values
compared with SS(error) and SS(total) values. No association can be claimed on the basis
of these results between XPF exon 11 and UV sensitivity.
N=10 and n=3 were used in the power calculations for group 2 to give a range for power
to fall within. 0.47J gave a between variance value of 51, and a within variance value of
1291, which gave a power of 0.11 when n=10, and 0.06 when n=3. 1.5J gave a between
variance value of 7377 and a within variance value of 7417, resulting in a power of 0.97
when n=10 and 0.38 when n=3. The power of the lower dose is too low to draw any
conclusive result from, and suggests the higher UV doses are likely to have a higher
power, but greater power at all doses would be ideal.
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XPG exon 15
The polymorphism at exon 15 of XPG results in a non-synonymous amino acid change,
from His to Asp. The polymorphism is a G to C change, which is present at position 3507
on the cDNA of GenBank entry NM_000123. A 271 bp PCR product was generated,
which was digested with Nlalll in order to genotype samples. The C allele contains a
Nlalll restriction site, and yields two fragments of 227 and 44 bp (44bp fragment not seen
on gel below). The G allele does not have a restriction site for Nlalll, and is uncut by the
enzyme, giving a single fragment of 271 bp. The heterozygous CG genotype yields
fragments of 271, 227 and 44 bp.
bp M 1 2 3 4 M M 1 2 3 4 M bp
271 271
227
Figure 82 XPG exon 15 PCR
Lanes 1-3 PCR products
Lane 4 negative control




Lane 4 undigested PCR product
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XPG exon 15 Genotype frequencies
The XPG exon 15 shows global variation in the frequency of the different genotypes. The
CC genotype is rare in Caucasians, but more frequent in Asians and Africans, where the
majority of the population are heterozygous for the polymorphism.







CC 3.6% 26.67% 31.3%
CG 35% 61.4% 46.7%
GG 61.4% 16.67% 22%
Total 100% 100% 100%
(Scottish healthy sample data, personal communication with Prof David Melton, Korean
healthy control data, Jeon et al, 2003. Ivory Coast samples were a kind donation from Dr
Rosalind Harding, Oxford University, and were genotyped as above alongside samples
from Group 1 and 2).
The allele frequencies of the exon 15 polymorphism showed considerable variation
between the different populations, in particular between the Scottish and African groups.
In the Scottish population, the homozygous CC genotype accounted for only 3.6% of the
total, and the heterozygous CG 38%, whilst the Ivory Coast samples had genotype
frequencies of 26.67% for the CC genotype, and 61.4% for the CG genotype. This
difference in genotype frequencies could be due to genetic drift caused by a Founder
effect, where changes in the gene pool of a particular population are attributable to
colonisation by a limited number of individuals from a parent population and could have
no survival advantage. Alternatively, the CC genotype frequency in the Ivory Coast
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samples could be a result of natural selection, where having the C allele conferred a
degree of evolutionary advantage in that population, for example, if the XPG exon 15
genotype is associated with cutaneous sensitivity to UVR, it could be that the CC
genotype confers greater protection against UVR, which would be an advantage in Africa
due to the increased exposure to UVR of the local population. This would be much less
of an advantage in Scotland, however, where exposure to UVR is greatly reduced. It is
also possible that the XPG exon 15 polymorphism frequency variation between
populations is due to a confounding association with another gene, which itself is present
in the population as a result of a Founder effect or a selection advantage.
159
Genotype frequencies in this study:
Genotype Group 1(%) Group 2 (%)
CC 4/74 (5.40%) 2/31 (6.45%)
CG 20/74 (27.03%) 6/31 (19.35%)
GG 50/74 (67.57%) 23/31 (74.20%)
Total 74 (100%) 31 (100%)
Genotype frequencies were similar in the two groups studies here (x2 DF = 2, P-Value =
0.705)
(As the frequency of CC homozygotes was extremely low (less than 7% in each group),
as well as analysing variance between each genotype, the CC homozygotes were grouped
with the CG heterozygotes for further analysis.
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Figure 84 Erythema induced by 119mJ per cm UV by XPG exon 15 genotype.

































Figure 85 Erythema induced by 150mJ per cm2 UV by XPG exon 15 genotype.





























Figure 86 Erythema induced by 189mJ per cm2 UV by XPG exon 15 genotype.






































Figure 87 Erythema induced by 238mJ per cm2 UV by XPG exon 15 genotype.
















Figure 88 Erythema induced by 300mJ per cm2 UV by XPG exon 15 genotype.
UVR on lower back, measured at 48 hours, n=74.
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Analysis of XPG exon 15 genotype and erythemal response to UVR for each dose in
group 1.
119mJ per cm2
Genotype N Mean StDev SE Mean
CC 4 23.17 14.72 7.36
CG 20 20.63 24.42 5.46
GG 50 24.32 26.99 3.82
Analysis of variance of erythema induced by 119mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 195 97 0.14 0.865
Error 71 47666 671
Total 73 47861
Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 24 21.05 22.85 4.66
GG 50 24.32 26.99 3.82
Source DF SS MS F P
Factor 1 173 173 0.26 0.611




Genotype N Mean StDev SE Mean
CC 4 70.00 17.64 8.82
CG 20 44.90 39.50 8.83
GG 50 59.69 39.87 5.64
Analysis of variance of erythema induced by 150mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 3925 1963 1.28 0.283
Error 71 108457 1528
Total 73 112382
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Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 24 49.08 37.69 7.69
GG 50 59.69 39.87 5.64
Source DF SS MS F P
Factor 1 1825 1825 1.19 0.279
Error 72 110557 1536
Total 73 112382
189mJ per cm2
Genotype N Mean StDev SE Mean
CC 4 115.5 25.2 12.6
CG 20 74.1 51.9 11.6
GG 50 102.23 45.21 6.39
Analysis of variance of erythema induced by 189mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 12987 6494 3.01 0.056
Error 71 153330 2160
Total 73 166318
Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 24 81.0 50.6 10.3
GG 50 102.23 45.21 6.39
Source DF SS MS F P
Factor 1 7277 7277 3.29 0.074





Genotype N Mean StDev SE Mean
CC 4 139.5 34.2 17.1
CG 20 102.4 54.9 12.3
GG 50 133.96 42.66 6.03
Analysis of variance of erythema induced by 238mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 15072 7536 3.57 0.033
Error 71 150023 2113
Total 73 165094
Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 24 108.5 53.3 10.9
GG 50 133.96 42.66 6.03
Source DF SS MS F P
Factor 1 10474 10474 4.88 0.030
Error 72 154621 2148
Total 73 165094
300mJ per cm
Genotype N Mean StDev SE Mean
CC 4 151.5 32.0 16.0
CG 20 133.2 49.8 11.1
GG 50 160.81 37.34 5.28
Analysis of variance of erythema induced by 300mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 10914 5457 3.27 0.044
Error 71 118569 1670
Total 73 129483
Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 24 136.23 47.25 9.65
GG 50 160.81 37.34 5.28
Source DF SS MS F P
Factor 1 9801 9801 5.90 0.018
Error 72 119682 1662
Total 73 129483
In group 1, the two lowest doses of UV showed no significant association between any
genotype and level of erythema produced, either when comparing the three genotypes
separately, or when combining the CC and CG genotypes, and comparing these to the GG
genotype. At the higher UV doses examined, the CC and CG genotypes had significantly
lower levels of erythema than the GG genotype (p =0.033 at 238mJ per cm , p= 0.044 at
300mJ per cm2).
In group 1, n=25 and n=4 were used to determine the power of the ANOVA tests. At
119mJ, the between variance of 97 and within variance of 671 gave a power of 0.65 when
n=25, and 0.12 when n=4, the true power lying between these values. At 300mJ, the
between variance was 5457 and within variance 1670, which gave a power of 1 when
n=25 and a power of 0.97 when n=4. At the higher UV dose, the power is high enough to
assume the p value of 0.044 is correct, and that there was a significant difference between
genotypes. A larger study would increase the power, and perhaps increase the level of
significance.
When the CC and CG genotypes were combined and compared together against the GG
genotype, the level of significance increased to p=0.03 at 238mJ per cm2 and p=0.018 at
300mJ per cm2. Comparing factor with error revealed that, although at the highest doses
there as significant association between genotype and erythemal response, factors other
than genotype were responsible for much of the variation in erythemal values, for
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example, at 300mJ per cm2, where p=0.018 for combined CC/CG genotypes against the
GG genotype, the SS(factor) value was 9801, whilst the SS(error) was 119682,
contributing towards most of the SS(total) of 129483.
As this polymorphism results in an amino acid change at the protein level, it is possible
that this association, with the GG genotype being more susceptible to UVR, might be
causative.
168





















Figure 89.Erythema induced by 0.47J per cm UV by XPG exon 15 genotype.


































Figure 90 Erythema induced by 0.6J per cm UV by XPG exon 15 genotype.



























Figure 91. Erythema induced by 0.75J per cm UV by XPG exon 15 genotype.




























Figure 92 Erythema induced by 0.95J per cm2 UV by XPG exon 15 genotype.




































Figure 93. Erythema induced by 1.2J per cm UV by XPG exon 15 genotype.




























Figure 94 Erythema induced by 1.5J per cm UV by XPG exon 15 genotype.
UV on inner forearm, measured at 24 hours
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Analysis of XPG exon 15 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
CC 2 2.50 3.54 2.50
CG 6 0.333 0.816 0.333
GG 23 5.78 19.16 4.00
Analysis of variance of erythema induced by 0.47J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 150 75 0.26 0.773
Error 28 8096 289
Total 30 8246
Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 8 0.875 1.808 0.639
GG 23 5.78 19.16 4.00
Source DF SS MS F P
Factor 1 143 143 0.51 0 .480
Error 29 8103 279
Total 30 8246
0.6J per cm2
Genotype N Mean StDev SE Mean
CC 2 26.8 38.0 26.8
CG 6 15.2 26.8 11.0
GG 23 17.43 38.91 8.11
Analysis of variance of erythema induced by 0.6J per cm2 UV between genotypes:
Source DF SS MS F P
172
Factor 2 207 103 0.08 0.927
Error 28 38349 1370
Total 30 38555
Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 8 18.08 27.37 9.68
GG 23 17.43 38.91 8.11
Source DF SS MS F P
Factor 1 143 143 0.51 0.480
Error 29 8103 279
Total 30 8246
0.75J per cm2
Genotype N Mean StDev SE Mean
CC 2 46.8 66.2 46.8
CG 6 29.7 39.8 16.2
GG 23 34.9 52.1 10.9
Analysis of variance of erythema induced by 0.75J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 448 224 0.09 0.917
Error 28 71960 2570
Total 30 72408
Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 8 34.0 42.7 15.1
GG 23 34.9 52.1 10.9
Source DF SS MS F P
Factor 1 5 5 0.00 0.963
Error 29 72402 2497
Total 30 72408
0.95J per cm2
Genotype N Mean StDev SE Mean
CC 2 68.7 97.1 68.7
CG 6 53.0 66.7 27.2
GG 23 81.7 75.0 15.6
Analysis of variance of erythema induced by 0.95J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 4026 2013 0.36 0.699
Error 28 155324 5547
Total 30 159349
Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 8 56.9 67.7 23.9
GG0 23 81.7 75.0 15.6
Source DF SS MS F P
Factor 1 3657 3657 0.68 0.416
Error 29 155692 5369
Total 30 159349
1.2J per cm
Genotype N Mean StDev SE Mean
CC 2 71.7 101.3 71.7
CG 6 80.0 69.7 28.4
GG 23 123.6 79.6 16.6








Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 8 77.9 70.4 24.9









Genotype N Mean StDev SE Mean
CC 2 76.5 108.2 76.5
CG 6 116.2 76.8 31.4
GG 23 180.2 81.6 17.0
Analysis of variance of erythema induced by 1.5J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 34834 17417 2.60 0.092
Error 28 187608 6700
Total 30 222442
Comparison of CC and CG genotypes together with GG homozygotes:
Genotype N Mean StDev SE Mean
CC/CG 8 106.3 78.9 27.9
GG 23 180.2 81.6 17.0
Source DF SS MS F P
Factor 1 32474 32474 4.96 0.034
175
Error 29 189968 6551
Total 30 222442
2
In group 2, the same pattern was observed (except at 0.6J per cm ) of the GG genotype
having higher levels of erythema, which is thus more susceptible to UVR, than the CC
and CG genotypes. An increased susceptibility to UVR could be due to the GG genotype
being less able to repair DNA damage induced by UV, which would in turn lead to an
increases risk of cancer. This was only significant at the highest UV dose examined
though, 1.5J per cm2 (p=0.034). Although no significant association was observed at the
other UV doses, it is encouraging that it was the highest dose examined that was
significant, as this would cause the greatest amount of DNA damage. As was the case in
group 1, although the association between XPG exon 15 and erythemal response was
significant at 1.5J per cm2, the genotype does not explain all of the variation in erythema
values, with most due to other factors.
In group 2, n=10 was used to determine the power of a balanced test, and n=2 used for
the power of the least balanced test. At 0.47J, the between variance was 75, and within
variance 289, which gave a power of 0.47 when n=10, and 0.08 when n=2. At 1,5J, the
between variance of 17417 and within variance of 6700 gave power of 0.99 when n=10,
and 0.39 when n=2. As in group lm higher power values are observed at higher UV
doses, this is also where significant difference between genotypes was observed. The
power of these tests would need to be increased in order to fully examine the effect of the
polymorphism.
The lower frequency of chromosomal aberrations seen in cells which were CC genotype
compared with cells which were CG and GG (although not significant) in the study by
Vodicka and colleagues (2004) strengthens the reasoning that the GG genotype could be
more susceptible to DNA damage and hence at an increased risk of cancer, as
chromosomal aberrations are correlated with onset of cancer. The same group also
measured DNA repair capacity of lymphocytes after gamma ray irradiation, as
determined by the number of single strand breaks in the DNA measured by a Comet
assay. XPG exon 15 CC homozygotes were found to have a moderately higher DNA
repair rate than GG homozygotes, which again, although not significant (p=0.089) is of
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interest, as if the CC homozygotes are more efficient at repairing DNA damage, they are
likely to be less susceptible to DNA-damaging agents, such as UVR, which would
provide some support for the hypothesis investigated here, that the GG genotype is more
susceptible to UVR.
Jeon et al (2003) found the GG genotype at a lower frequency in lung cancer patients
than in healthy controls, and suggested that the GG genotype might confer a decreased
risk of lung cancer than the CC or CG genotypes. As NER removes both UV-induced
photoadducts and DNA adducts induced by tobacco carcinogens, it would be expected
that if the XPG exon 15 association was associated with susceptibility to cancer, the same
genotype would confer protection in different cancer types, which is not seen here. The
different genotype frequencies of the exon 15 polymorphism by geographical location
might impinge on results seen in fairly small studies on a homogenous population.
As significant associations were seen in both study groups, with the GG genotype being
more susceptible to UV, it was decided to analyse further polymorphisms along the XPG
gene, to determine if an extension of this association was observed.
Additional XPG SNPs analysed
In order to see if the above association extended along the XPG gene, three additional
SNPs were investigated. These were chosen from the NCBI SNP database. Factors taken
into consideration when choosing snps were the position of the snp in relation to the exon
15 polymorphism and the reported allele frequency. Many of the snps had an extremely
low variant allele frequency. The variant alleles with low reported frequencies would not
necessarily have been picked up in a study of this size, therefore these polymorphisms
were ignored. exon 15




The SNP rs4150265 (also identified as rs 1047768) consists of a C to T polymorphism,
and is located in exon 2 of XPG. The polymorphism leads to a nonsynonymous amino
acid change. An RFLP assay was used to genotype samples for the rs4150265
polymorphism. A Ncol recognition site exists in the 377bp PCR product in the presence
of the T allele, and is lost when there is C. The CC homozygote is undigested, and results
in a 377bp fragment. The TT homozygote yields two fragments, of 254 and 123 bp
(123bp fragment not seen in gel below). The heterozygous CT therefore results in
fragments of 377, 254 and 123 bp.
bp M 1 M 1 4 M bp
377
Figure 96 , rs4150265 PCR
Lanes 1-4, PCR product
Lane 5, negative control
Figure 97 , rs4150265 digest





Genotype Group 1 Group 2
CC 30/73 (41.10%) 9/31 (29.03%)
CT 31/73 (42.46%) 12/31 (38.71%)
XT 12/73 (16.44%) 10/31 (32.26%)
Total (100%) 73 (100%) 31 (100%)
No statistically significant difference was observed in genotype frequencies between the
two study groups (x2 DF = 2, P-Value = 0.174)
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Figure 98. Erythema induced by 119mJ per cm UV by rs4150265 genotype.











































Figure 99 Erythema induced by 150mJ per cm UV by rs4150265
genotype.


































Figure 100 Erythema induced by 189mJ per cm UV by rs4150265 genotype.





























Figure 101. Erythema induced by 238mJ per cm UV by rs4150265 genotype.


































Figure 102. Erythema induced by 300mJ per cm2 UV by rs4150265 genotype.
UV on lower back, measured at 48 hours.
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Analysis of rs4150265 genotype and erythemal response to UVR for each dose in
group 1.
119mJ per cm
Genotype N Mean StDev SE Mean
CC 30 26.59 29.62 5.41
CT 31 22.51 25.35 4.55
TT 12 17.62 14.52 4.19
Analysis of variance of erythema induced by 119mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 731 365 0.54 0.583
Error 70 47037 672
Total 72 47768
150mJ per cm2
Genotype N Mean StDev SE Mean
CC 30 60.74 46.23 8.44
CT 31 55.93 35.39 6.36
TT 12 48.51 30.86 8.91
Analysis of variance of erythema induced by 150mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1313 657 0.42 0.660
Error 70 110025 1572
Total 72 111338
189mJ per cm
Genotype N Mean StDev SE Mean
CC 30 96.16 50.15 9.16
CT 31 98.14 48.56 8.72
TT 12 86.3 44.1 12.7
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Analysis of variance of erythema induced by 189mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1240 620 0.26 0.770
Error 70 165075 2358
Total 72 166315
238mJ per cm2
Genotype N Mean StDev SE Mean
CC 30 127.91 48.12 8.78
CT 31 127.24 48.70 8.75
TT 12 115.5 47.9 13.8
Analysis of variance of erythema induced by 238mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1474 737 0.32 0.730
Error 70 163514 2336
Total 72 164988
3 00mJ per cm2
Genotype N Mean StDev SE Mean
CC 30 150.21 41.96 7.66
CT 31 155.41 46.90 8.42
TT 12 152.12 32.96 9.51
• • • 9
Analysis of variance of erythema induced by 300mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 419 209 0.11 0.893
Error 70 129002 1843
Total 72 129421
No statistically significant association was observed between any of the genotypes and
the level of UV-induced erythema at any UV dose examined. The TT homozygote
displayed slightly lower mean values of erythema at each dose, but this was not
significant. P-values ranged from 0.583 to 0.893. Almost none of the variation in
erythemal response could be attributed to genotype, for example at 119mJ per cm2 (the
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lowest dose examined, also dose where p-value was lowest) the SS(factor) value was
731, which makes up only a small amount of the SS(total) value of 47768, the SS(error)
value of 47037 accounting for almost all the observed variation.
The balanced analysis of variance would contain three groups each with 25 individuals,
and the least, three groups each with 12 individuals. N=25 and n=12 were therefore used
for power calculations. At 119mJ, the between variance was 365 and the within variance
672, which gave a power of 0.99 when n=25 and 0.88 when n=12. At 300mJ, the between
variance was 209 and within variance was 1843. The power values were 0.54 when n=25,
and 0.27 when n=12. The power levels are not high enough at 300mJ, and if the
experiment were to be repeated, it would be desirable to use larger number of samples in
order to increase the power and be able to confidently accept the p values.
185




























Figure 103 Erythema induced by 0.47J per cm2 UV by rs4150265 genotype.



















Figure 104 Erythema induced by 0.6J per cm UV by rs4150265 genotype.



































Figure 105 Erythema induced by 0.75J per cm UV by rs4150265 genotype.



























Figure 106 Erythema induced by 0.95J per cm2 UV by rs4150265 genotype.









































Figure 107 Erythema induced by 1.2J per cm UV by rs4150265 genotype.































Figure 108. Erythema induced by 1.5J per cm UV by rs4150265 genotype.
UV on inner forearm, measured at 24 hours.
188
Analysis of rs4150265 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
CC 9 7.22 21.67 7.22
CT 12 0.167 0.577 0.167
TT 10 7.30 21.39 6.76
Analysis of variance of erythema induced by 0.47J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 370 185 0.66 0.525
Error 28 7875 281
Total 30 8246
0.6J per cm2
Genotype N Mean StDev SE Mean
CC 9 25.7 45.3 15.1
CT 12 3.50 8.35 2.41
TT 10 27.3 44.0 13.9
Analysis of variance of erythema induced by 0.6J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 3906 1953 1.58 0.224
Error 28 34650 1237
Total 30 38555
0.75J per cm2
Genotype N Mean StDev SE Mean
CC 9 42.9 60.9 20.3
CT 12 18.50 30.82 8.90
TT 10 46.7 54.9 17.3
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Analysis of variance of erythema induced by 0.75J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 5185 2592 1.08 0.353
Error 28 67223 2401
Total 30 72408
0.95J per cm2
Genotype N Mean StDev SE Mean
CC 9 69.3 80.2 26.7
CT 12 48.9 51.3 14.8
TT 10 112.5 79.2 25.0
Analysis of variance of erythema induced by 0.95J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 22519 11260 2.30 0.118
Error 28 136830 4887
Total 30 159349
1.2J per cm2
Genotype N Mean StDev SE Mean
CC 9 111.0 85.5 28.5
CT 12 88.8 61.2 17.7
TT 10 140.3 89.7 28.4
Analysis of variance of erythema induced by 1.2J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 14523 7262 1.18 0.322
Error 28 172064 6145
Total 30 186588
190
1.5 J per cm2
Genotype N Mean StDev SE Mean
CC 9 166.1 72.6 24.2
CT 12 136.2 79.2 22.9
TT 10 186.6 103.8 32.8
• • 9








In group 2, the rs4150265 genotype was not found to be associated with erythemal
response. P values ranged from 0.118 to 0.525. Factor and error values show that very
little of the variation is due to genotype.
Power calculations were performed using n=10, and n=9. At 0.47J, the between variance
value was 185, and the within variance value 281. These gave a power of 0.88 when
n=10, and 0.83 when n=9. At 1.5J, the between variance was 7084 and the within
variance 7438, which gave power values of 0.97 when n=10, and 0.94 when n=9. These
powers are sufficient to consider the p values which show no significant variation in
erythemal response between genotypes to be true.
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rs3918332
The SNP rs 3918332 is located within an intron of XPG, between exons 6 and 7. It
therefore does not affect the coding sequence. The polymorphism is an A to G change.
No restriction site exists for this polymorphism, so the SNaPshot technique was used to
genotype samples.
rs3918332 Genotype frequencies
Genotype Group 1 (%) Group 2 (%)
AA 12/69(17.4%) 9/26 (34.6%)
AG 31/69 (44.9%) 10/26 (38.5%)
GG 26/69 (37.7%) 7/26 (26.9%)
Total (100%) 69 (100%) 26 (100%)
The frequency of the different genotypes of the single nucleotide polymorphism
rs3918332 was not statistically significantly different between the two study groups (x2,
DF = 2, P-Value = 0.188).
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Figure 109 Erythema induced by 119mJ per cm UV by rs3918332 genotype.




























Figure 110 Erythema induced by 150mJ per cm2 UV by rs3918332
genotype.




































Figure 111. Erythema induced by 189mJ per cm UV by rs3918332 genotype.


































Figure 112 Erythema induced by 238mJ per cm UV by rs3918332 genotype.































Figure 113 Erythema induced by 300mJ per cm2 UV by rs3918332 genotype.
UV on lower back, measured at 48 hours
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Analysis of rs3918332 genotype and erythemal response to UVR for each dose in
group 1.
119mJ per cm2
Genotype N Mean StDev SE Mean
AA 12 17.62 14.52 4.19
AG 31 25.45 28.79 5.17
GG 26 23.85 27.44 5.38
• • • 2
Analysis of variance of level of erythema induced by 119mJ per cm UV between
genotypes:
Source DF SS MS F P
Factor 2 535 268 0.38 0.683
Error 66 46004 697
Total 68 46539
150mJ per cm2
Genotype N Mean StDev SE Mean
AA 12 48.51 30.86 8.91
AG 31 59.40 39.78 7.15
GG 26 55.14 42.46 8.33
Analysis of variance of level of erythema induced by 150mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 1050 525 0.34 0.716
Error 66 103019 1561
Total 68 104069
189mJ per cm2
Genotype N Mean StDev SE Mean
AA 12 86.3 44.1 12.7
AG 31 101.83 50.90 9.14
GG 26 89.44 47.67 9.35
Analysis of variance of level of erythema induced by 189mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 3134 1567 0.66 0.519
Error 66 155935 2363
Total 68 159069
238mJ per cm2
Genotype N Mean StDev SE Mean
AA 12 115.5 47.9 13.8
AG 31 130.63 50.16 9.01
GG 26 122.07 47.24 9.26
Analysis of variance of level of erythema induced by 238mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 2291 1145 0.48 0.619
Error 66 156509 2371
Total 68 158800
300mJ per cm
Genotype N Mean StDev SE Mean
AA 12 152.12 32.96 9.51
AG 31 158.86 47.01 8.44
GG 26 145.69 42.31 8.30
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Analysis of variance of level of erythema induced by 3 00mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 2457 1229 0.66 0.521
Error 66 123015 1864
Total 68 125472
No association was observed between any of the genotypes and erythemal response to
UV at any dose examined. The AA genotype had lower mean values of erythema at all
doses except at 300mJ per cm2, while the heterozygous AG had the highest mean values
of erythema. There was no statistical significance between genotypes and erythemal
response, with p values ranging from 0.516 to 0.716. In this study group, the SNP rs
3918332 is not associated with erythemal response.
Power calculations were carried out using n=23 (balanced) and n=12 (least balanced). At
119mJ, the between variance value was 268, and the within variance 697. These gave
power values of 0.96 when n=23 and 0.74 when n=12. At 300mJ, the between variance
value was 1229 and the within variance value 1864, which gave a power of 0.99 when
n=23, and 0.93 when n=12. There is sufficient power between these ranges of values to
consider that the results obtained with the ANOVA are accurate.
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Figure 114 Erythema induced by 0.47J per cm UV by rs3918332 genotype.




























Figure 115 Erythema induced by 0.6J per cm2 UV by rs3918332 genotype.


























Figure116. Erythema induced by 0.75J per cm UV by rs3918332 genotype.



























Figure 117 Erythema induced by 0.95J per cm2 UV by rs3918332 genotype.
































Figure 118 Erythema induced by 1.2J per cm UV by rs3918332 genotype.



























Figure 119 Erythema induced by 1.5J per cm UV by rs3918332 genotype.
UV on inner forearm, measured at 24 hours
Analysis of rs3918332 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
AA 9 8.11 22.52 7.51
AG 10 0.20 0.632 0.200
GG 7 0.00 0.00 0.00
2
Analysis of variance of level of erythema induced by 0.47J per cm UV between
genotypes:
Source DF SS MS F P
Factor 2 376 188 1.07 0.361
Error 23 4060 177
Total 2
0.6J per cm2
Genotype N Mean StDev SE Mean
AA 9 30.3 45.6 15.2
AG 10 2.50 7.91 2.50
GG 7 5.29 13.98 5.29
Analysis of variance of level of erythema induced by 0.6J per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 4211 2106 2.64 0.093
Error 23 18356 798
Total 25 22568
0.75J per cm2
Genotype N Mean StDev SE Mean
202
AA 9 49.9 57.2 19.1
AG 10 16.00 30.10 9.52
GG 7 16.3 29.1 11.0
Analysis of variance of level of erythema induced by 0.75J per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 6697 3349 1.95 0.164
Error 23 39407 1713
Total 25 46104
0.95J per cm2
Genotype N Mean StDev SE Mean
AA 9 119.9 80.3 26.8
AG 10 44.4 48.5 15.3
GG 7 41.0 59.7 22.5










Genotype N Mean StDev SE Mean
AA 9 143.8 94.4 31.5
AG 10 87.3 64.7 20.5
GG 7 80.0 60.7 22.9
Analysis of variance of level of erythema induced by 1.2J per cm2 UV between
genotypes:
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Source DF SS MS F P
Factor 2 21078 10539 1.85 0.180
Error 23 131110 5700
Total 25 152188
1.5J per cm2
Genotype N Mean StDev SE Mean
AA 9 188.0 110.0 36.7
AG 10 135.1 87.2 27.6
GG 7 141.8 53.9 20.4
Analysis of variance of level of erythema induced by 1.5 J per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 14977 7489 0.94 0.404
Error 23 182583 7938
Total 25 197561
In group 2, the AA genotype displayed the highest levels of erythema at all doses
examined. This was significant at 0.95J per cm2, but not at any other UV dose. At all
doses, including 0.95J per cm2 where p<0.05, and therefore significant, analysis of the
factor and error values revealed almost none of the variation in erythemal response can be
explained by genotype. If the AA allele were truly associated with an increased
sensitivity to UV, it would be expected to reveal itself at all doses, or at least the higher
doses where more DNA damage is likely to be caused. This was not the case here. It
would that the observed association at 0.95J per cm2 is due to chance, when factor and
error, and p-values at other doses are examined.
Power calculations were carried out, using n=9 (balanced) and n=7. 0.47J gave a between
variance value of 188 and within variance value of 177. Power values were 0.96 when
n=9 and 0.89 when n=7. 1.5J gave a between variance value of 7489 and a within
variance value of 7938. Power values were 0.94 when n=9, and 0.86 when n=7. The
power values in this group for this polymorphism were therefore sufficient.
204
rs4150374
The SNP rs4150374 was the closest snp to the exon 15 polymorphism which was
analysed. It has a position in the intron, between exon 14 and 15, and is therefore not a
coding change. The polymorphism is an A to G change. No restriction site exists for this
polymorphism, therefore the SNaPshot technique was used to genotype samples.
rs4150374 Genotype frequencies
Genotype Group 1 (%) Group 2 (%)
AA 45/63 (71.4%) 13/26 (50%)
AG 15/63 (23.8%) 11/26 (42.3%)
GG 3/63 (4.8%) 2/26 (7.7%)
Total (100%) 63 (100%) 26 (100%)
No significant difference in genotype frequencies was observed between the two study
groups (x DF = 2, P-Value = 0.155)
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Figure 120. Erythema induced by 119mJ per cm2 UV by rs4150374 genotype.































Figure 121 Erythema induced by 150mJ per cm UV by rs4150374 genotype.
















Figure 122 Erythema induced by 189mJ per cm2 UV by rs4150374 genotype.




































Figure 123 Erythema induced by 238mJ per cm2 UV by rs4150374 genotype.





























Figure 124 erythema induced by 300mJ per cm2 UV by rs4150374 genotype
UV on lower back, measured at 48 hours.




Genotype N Mean StDev SE Mean
AA 45 24.78 25.89 3.86
AG 15 21.62 24.99 6.45
GG 3 0.33 3.61 2.08
• • • 9
Analysis of variance of level of erythema induced by 119mJ per cm UV between
genotypes:
Source DF SS MS F P
Factor 2 1711 855 1.34 0.269
Error 60 38265 638
Total 62 39976
AA genotype against combined AG/GG genotypes:
Genotype N Mean StDev SE Mean
AA 45 24.78 25.89 3.86
AG/GG 18 18.07 24.13 5.69
source DF SS MS F P
Factor 1 578 578 0.90 0.348
Error 61 39398 646
Total 62 3997
150mJ per cm2
Genotype N Mean StDev SE Mean
AA 45 58.42 38.24 5.70
AG 15 57.1 39.6 10.2
GG 3 6.33 0.667 0.385
Analysis of variance of level of erythema induced by 150mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 7675 3838 2.67 0.077
Error 60 86242 1437
Total 62 93917
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AA genotype compared with combined AG/GG genotypes:
Genotype N Mean StDev SE Mean
AA 45 58.42 38.24 5.70
AG/GG 18 48.66 40.84 9.63
Source DF SS MS F P
Factor 1 1224 1224 0.81 0.373
Error 61 92693 1520
Total 62 93917
189mJ per cm2
Genotype N Mean StDev SE Mean
AA 45 96.49 46.36 6.91
AG 15 95.2 50.5 13.0
GG 3 25.11 2.34 1.35
Analysis of variance of level of erythema induced by 189mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 14443 7221 3.33 0.043
Error 60 130286 2171
Total 62 144729
AA genotype compared with combined AG/GG genotypes:
Genotype N Mean StDev SE Mean
AA 45 96.49 46.36 6.91
AG/GG 18 83.5 53.1 12.5
Source DF SS MS F P
Factor 1 2175 2175 0.93 0.338




Genotype N Mean StDev SE Mean
AA 45 127.44 46.24 6.89
210
AG 15 126.5 52.1 13.4
GG 3 50.56 11.59 6.69
Analysis of variance of level of erythema induced by 238mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 16792 8396 3.81 0.028
Error 60 132269 2204
Total 62 149060
AA genotype compared with combined AG/GG genotypes:
Genotype N Mean StDev SE Mean
AA 45 127.44 46.24 6.89
AG/GG 18 113.8 55.6 13.1
Source DF SS MS F P
Factor 1 2387 2387 0.99 0.323
Error 61 146674 2404
Total 62 149060
300mJ per cm2
Genotype N Mean StDev SE Mean
AA 45 152.03 40.54 6.04
AG 15 155.9 50.1 12.9
GG 3 106.9 29.3 16.9
Analysis of variance of level of erythema induced by 3 00mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 6247 3123 1.72 0.189
Error 60 109234 1821
Total 62 115480
AA genotype compared with combined AG/GG genotypes:
Genotype N Mean StDev SE Mean
AA 45 152.03 40.54 6.04
211
AG/GG 18 147.8 50.3 11.8
Source DF SS MS F P
Factor 1 236 236 0.12 0.725
Error 61 115245 1889
Total 62 115480
When the three genotypes were compared individually, the GG genotype displayed lower
mean erythemal responses at all UV doses examined in group 1. This was significant at
189 and 238mJ per cm2, with p-values of 0.043 and 0.028. The level of significance was
approached at 150mJ per cm2, p = 0.077 although this was not formally significant. No
association was observed at 119 and 300mJ per cm2. Analysis of factor and error revealed
that most variation could not be explained by genotype. The low number of individuals in
the GG genotype group could affect the level of significance; therefore it was decided to
combine the AG and GG genotypes.
For group 1, power calculations were carried out using n=21, and n=3. At 119mJ, the
between variance was 855 and within variance 638. This gave a power of 0.99 when
n=21 and 0.49 when n=3. At 300mJ, the between variance was 3123 and within variance
1821. Power was 1 when n=21, and 0.59 when n=3. The true power will lie between the
two values, and it would be preferable to be able to increase the power to be able to be
more confident on the association or non-association of this polymorphism and erythemal
response.
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Figure 125. Erythema induced by 0.47J per cm UV by rs4150374 genotype.



























Figure 126. Erythema induced by 0.6J per cm UV by rs4150374 genotype.





























Figure 127 Erythema induced by 0.75J per cm2 UV by rs4150374 genotype.





















Figure 128 Erythema induced by 0.95J per cm2 UV by rs4150374 genotype.



































Figure 129 Erythema induced by 1.2J per cm UV by rs4150374 genotype.

























Figure 130. Erythema induced by 1.5J per cm2 UV by rs4150374 genotype.
UV on inner forearm, measured at 24 hours.
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Analysis of rs4150374 genotype and erythemal response to UVR at each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
AA 13 0.00 0.00 0.00
AG 11 6.82 20.35 6.14
GG 2 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.47J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 295 148 0.82 0.453
Error 23 4142 180
Total 25 4437
AA genotype compared with combined AG/GG genotypes:
Genotype N Mean StDev SE Mean
AA 13 0.00 0.00 0.00
AG/GG 13 5.77 18.75 5.20
Source DF SS MS F P
Factor 1 216 216 1.23 0.278
Error 24 4220 176
Total 25 4437
0.6J per cm2
Genotype N Mean StDev SE Mean
AA 13 9.62 20.43 5.67
AG 11 19.1 40.8 12.3
GG 2 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.6J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 891 445 0.47 0.629
Error 23 21677 942
Total 25 22568
AA genotype compared with combined AG/GG genotypes:
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Genotype N Mean StDev SE Mean
AA 13 9.62 0.43 5.6
AG/GG 13 16.1 38.0 10.5
source DF SS MS F P
Factor 1 276 276 0.30 0.591
Error 24 22292 929
Total 25 22568
0.75J per cm2
Genotype N Mean StDev SE Mean
AA 13 24.00 29.93 8.30
AG 11 37.3 57.1 17.2
GG 2 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.75J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 2733 1367 0.72 0.495
Error 23 43371 1886
Total 25 46104
AA genotype compared with combined AG and GG genotypes:
Genotype N Mean StDev SE Mean
AA 13 24.00 29.93 8.30
AG/GG 13 31.6 54.0 15.0
source DF SS MS F P
Factor 1 374 374 0.20 0.662
Error 24 45730 1905
Total 25 46104
0.95J per cm2
Genotype N Mean StDev SE Mean
AA 13 63.4 57.7 16.0
AG 11 88.7 87.0 26.2
GG 2 12.0 17.0 12.0
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Analysis of variance of erythema induced by 0.95J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 11133 5566 1.10 0.348
Error 23 115932 5041
Total 25 127065
AA genotype compared with combined AG and GG genotypes:
Genotype N Mean StDev SE Mean
AA 13 63.4 57.7 16.0
AG/GG 13 76.9 84.6 23.5
source DF SS MS F P
Factor 1 1178 1178 0.22 0.640
Error 24 125887 5245
Total 25 12706
1,2J per cm2
Genotype N Mean StDev SE Mean
AA 13 95.6 60.5 16.8
AG 11 129.4 93.5 28.2
GG 2 58.00 12.73 9.00
• • 2
Analysis of variance of erythema induced by 1,2J per cm UV between genotypes:
Source DF SS MS F P
Factor 2 12003 6002 1.05 0.366
Error 23 131522 5718
Total 25 143525
AA genotype compared with combined AG and GG genotypes:
Genotype N Mean StDev SE Mean
AA 13 95.6 60.5 16.8
AG/GG 13 118.4 89.6 24.8
source DF SS MS F P
Factor 1 3377 3377 0.58 0.454
Error 24 140148 5839
Total 25 143525
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1.5 J per cm2
Genotype N Mean StDev SE Mean
AA 13 141.2 60.9 16.9
AG 11 191.2 104.5 31.5
GG 2 110.50 4.95 3.50
Analysis of variance of erythema induced by 1.5 J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 20221 10110 1.51 0.241
Error 23 153630 6680
Total 25 173851
AA genotype compared with combined AG/GG genotypes:
Genotype N Mean StDev SE Mean
AA 13 141.2 60.9 16.9
AG/GG 13 178.8 100.1 27.8
source DF SS MS F P
Factor 1 9196 9196 1.34 0.258
Error 24 164655 6861
Total 25 173851
In group 2, when all three genotypes were compared individually, there was no
significant difference in erythemal response at any of the UV doses examined. The GG
genotype had the lowest mean levels of erythema at all doses examined, although this
was not statistically significant. P-values ranged from 0.629 to 0.241. Analysis of factor
and error revealed that very little of the variation in erythema response can be explained
by genotype. The low number of GG homozygotes (2/26, 7.7%) could interfere with
statistical analysis, therefore it was decided to combine the GG and AG genotype groups,
as in group 1, to ask if the presence of the G allele had any affect on erythemal response.
Power calculations were performed for group 2 using n=9 (balanced) and n=2 (least
balanced). At 0.47J, the between variance was 148, and within variance 180. Power was
219
0.91 when n=9, and 0.16 when n=2. 1.5J gave a between variance value of 10110 and a
within variance value of 6680, which gave power of 0.99 when n=9 and 0.25 when n=2.
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Discussion of XPG and UV-induced erythema
The association observed between the exon 15 polymorphism and sensitivity to UVR did
not extend to the additional SNPs studied. The rs4150374 SNP did tend to approach the
level of formal significance (p=0.05) at some doses in group 1, with the GG genotype
having lower mean erythemal responses. However, the level of significance was never
reached.
It was unfortunate that none of the SNPs identified in the NCBI SNP database, which
were closer to the exon 15 polymorphism, had allele frequencies which would have made
them feasible for analysis in this size of study. A larger study group would be likely to
allow for these rare alleles to be detected. One would expect that if there were a true
association between the exon 15 polymorphism and sensitivity to UVR that this would be
in linkage disequilibrium with SNPs nearby. Analysis of these SNPs would show the
association too in this case.
It would be of interest to conduct an investigation into any functional effect the XPG
exon 15 polymorphism might have. One way to do so would be to take skin biopsies of
irradiated skin and look for sunburn cells in individuals with different genotypes at this
polymorphism. Sunburn cells have undergone apoptosis as a result of DNA damage, and
the hypothesis would be that if the exon 15 polymorphism does have any functional
significance, cells from individuals with the GG genotype, which had higher mean levels
of erythema in this study, would have a greater number of sunburn cells than cells from
individuals with CC or CG genotypes.
In a recent study the XPG exon 15 polymorphism was analysed for association with
melanoma (Blankenburg et al (2005). 294 Caucasian patients with malignant melanoma
and 375 healthy controls were genotyped. No significant difference was observed in
genotype frequencies between the cases and controls (OR 1.168, 95% CI 0.670-2.
044). Analysis of subgroups of the melanoma population compared with all controls also
revealed no association of this polymorphism with increased risk of developing multiple
primary melanomas (n=28), negative family history of melanoma (n=227), melanoma in
221
individuals with low numbers of nevi (n=273), melanoma in individuals over fifty years
of age (n=144) and melanomas thicker than 1mm (n=126).
222
XRCC1 exon 10
The XRCC1 exon 10 polymorphism is located at position 28152 on the GenBank entry
L34079. This polymorphism consists of a G to A change, resulting in an amino acid
change from Arg to Gin at codon 399. A PCR-RFLP assay was used to genotype samples
for the XRCC1 exon 10 polymorphism. A PCR product of 154bp was amplified, which
contained an Mspl restriction site in the presence of the G allele. The A allele does not
contain this site, and results in one fragment of 154bp. The G allele yields two fragments,
of 93 and 79 bp.
bp 12 3 M 4 Ml 2 3 4 M bp




Lane 4, undigested PCR product
Figure 131, XRCC1 exon 10 PCR products
Lanes 1-3, PCR products
Lane 4, negative control
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XRCC1 exon 10 Genotype frequencies
Genotype Group 1 (%) Group 2 (%)
GG 19/74 (25.68%) 11/31 (35.48%)
GA 37/74 (50.00%) 17/31 (54.84%)
AA 18/74 (24.32%) 3/31 (9.68%)
Total (100%) 74(100%) 31 (100%)
The pattern of frequency distribution was similar between the two study groups, with the
GA heterozygote genotype being the most frequent in each group, and the variant AA
homozygote the least frequent. No significant difference was observed in genotype
frequency between the two groups (j2 DF = 2, P-Value = 0.204).
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Erythema induced by incremental doses of UVR by XRCC1 exon 10 genotype.






























Figure 133 Erythema induced by 119mJ per cm UV by XRCC1 exon 10 genotype.
































Figure 134 Erythema induced by 150mJ per cm2 UV by XRCC1 exon 10 genotype.






























Figure 135. Erythema induced by 189mJ per cm UV by XRCC1 exon 10 genotype.
































Figure 136 Erythema induced by 238mJ per cm UV by XRCC1 exon 10 genotype.















Figure 137. Erythema induced by 300mJ per cm2 UV by XRCC1 exon 10 genotype.
UVR on lower back, measured at 48 hours, n=74.
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Analysis of XRCC1 exon 10 genotype and erythemal response to UVR at each dose
in group 1.
119mJ per cm2
Genotype N Mean StDev SE Mean
GG 19 20.40 32.26 7.40
GA 37 21.92 19.05 3.13
AA 18 29.02 29.94 7.06
• • • 9
Analysis of variance of erythema induced by 119mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 819 409 0.62 0.542
Error 71 47042 663
Total 73 47861
150mJ per cm2
Genotype N Mean StDev SE Mean
GG 19 44.6 45.4 10.4
GA 37 55.21 32.27 5.31
AA 18 70.7 43.1 10.1
Analysis of variance of erythema induced by 150mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 6338 3169 2.12 0.127
Error 71 106043 1494
Total 73 112382
189mJ per cm2
Genotype N Mean StDev SE Mean
GG 19 83.2 54.9 12.6
GA 37 94.12 40.36 6.64
AA 18 110.8 52.2 12.3
Analysis of variance of erythema induced by 189mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 7177 3588 1.60 0.209





Genotype N Mean StDev SE Mean
GG 19 113.1 57.6 13.2
GA 37 126.91 39.27 6.46
AA 18 136.6 151.3 12.1
m 2
Analysis of variance of erythema induced by 238mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 5194 2597 1.15 0.322
Error 71 159901 2252
Total 73 165094
300mJ per cm2
Genotype N Mean StDev SE Mean
GG 19 145.78 42.84 9.83
GA 37 151.98 37.81 6.22
AA 18 162.1 50.0 11.8
Analysis of variance of erythema induced by 300mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 2503 1252 0.70 0.500
Error 71 126979 1788
Total 73 129483
In group 1, no association was observed between the XRCC1 exon 10 polymorphism and
erythemal response at any UV dose examined. P values did not approach significance,
and ranged from 0.542 to 0.127. Analysis of factor and error revealed almost all variation
between levels of erythema was due to factors other than genotype. The AA genotype
displayed higher mean erythemal responses compared with the GG and GA genotypes,
but as revealed above, this was no significant.
To analyse the power of these ANOVA tests, power calculations were performed using
n=25 (balanced) and n=18 (least balanced). At 119mJ, the between variance was 409 and
within variance 663, giving power of 0.99 when n=25 and 0.98 when n=18. 300mJ had a
between variance value of 1252 and a within variance value of 1788. Power was 0.99
229
when n=25 and also when n=18. It can be seen from these values that the power
adequate in this study group.



























Figure 138 Erythema induced by 0.47J per cm UV by XRCC1 exon 10 genotype.




































Figure 139. Erythema induced by 0.6J per cm2 UV by XRCC1 exon 10 genotype.
































Figure 140 Erythema induced by 0.75 J per cm UV by XRCC1 exon 10 genotype.






































Figure141 Erythema induced by 0.95 J UV per cm by XRCC1 exon 10 genotype.



































Figure 142 Erythema induced by 1.2 J per cm UV by XRCC1 exon 10 genotype.



























Figure 143 Erythema induced by 1.5 J per cm2 UV by XRCC1 exon 10 genotype.
UVR on lower back, measured at 24 hours, n=31.
233
Analysis of XRCC1 exon 10 genotype and erythemal response to UVR at each dose
in group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
GG 11 6.36 19.51 5.88
GA 17 4.12 16.47 3.99
AA 3 0.00 0.00 0. 00
Analysis of variance of erythema induced by 0.47J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 101 51 0.17 0.841
Error 28 8144 291
Total 30 8246
0.6J per cm2
Genotype N Mean StDev SE Mean
GG 11 18.7 40.5 12.2
GA 17 20.00 36.31 8.81
AA 3 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.6J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 1040 520 0.39 0.682
Error 28 37515 1340
Total 30 38555
0.75J per cm2
Genotype N Mean StDev SE Mean
GG 11 38.2 54.8 16.5
GA 17 38.5 49.0 11.9
AA 3 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.75J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 3992 1996 0.82 0.452
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Error 28 68416 2443
Total 30 72408
0.95J per cm2
Genotype N Mean StDev SE Mean
GG 11 74.8 80.9 24.4
GA 17 80.2 75.2 18.2
AA 3 49.4 23.0 13.3
Analysis of variance of erythema induced by 0.95J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 2422 1211 0.22 0.807
Error 28 156927 5605
Total 30 159349
1.2J per cm2
Genotype N Mean StDev SE Mean
GG 11 101.5 90.7 27.4
GA 17 116.2 78.4 19.0
AA 3 125.3 43.3 25.0
Analysis of variance of erythema induced by 1.2J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 2052 1026 0.16 0.857
Error 28 184535 6591
Total 30 186588
1.5 J per cm
Genotype N Mean StDev SE Mean
GG 11 135.9 86.8 26.2
GA 17 173.2 86.2 20.9
AA 3 184.9 92.3 53.3
Analysis of variance of erythema induced by 1,5J per cm2 UV between genotypes:
Source DF SS MS F P
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Factor 2 11165 5582 0.74 0.486
Error 28 211277 7546
Total 30 222442
In group 2, no association was observed between the polymorphism and levels of
erythema induced at any UV dose examined. The AA genotype displayed higher mean
erythema levels than the GG and GA genotypes at the two highest UV doses, but the
lowest levels of erythema at all other doses. P values ranged from 0.452 to 0.857,
showing no significance.
Power calculations were carried out for group 2 using n=10 (balanced) and n=3 (least
balanced). 0.47J gave a between variance value of 51 and a within variance value of 291.
These gave a power of 0.33 when n=10, and 0.10 when n=3. 1.5J had a between variance
value of 5582 and a within variance value of 7546. These gave a power of 0.91 when
n=10 and 0.29 when n=3. The low power shows a need to increase the sample size, which
should lead to increase power and more accuracy.
XRCC1 is required for the ligation of newly synthesised DNA to the damaged strand to
complete the final stages of the BER pathway. UV induces both direct DNA damage,
photoproducts, and indirectly through the production of oxidative stress. The BER
pathway repairs oxidised bases. Whether or not an association exists between this
polymorphism and cancer risk is the subject of some controversy. The XRCC1
polymorphism has linked to increased risk of various cancers, but also to decreased risk
of others. As it is involved with the repair of damage induced by UV, the exon 10
polymorphism was a promising candidate for an association with UV-induced erythemal
response.
The AA genotype was reported to lead to a decreased risk ofNMSC by Nelson et al
(2002), OR 0.7; 95% CI 0.4-1.0 for BCC, and OR 0.6; 95% CI 0.3-0.9 for SCC.
However, Winsey et al (2000) reported no association between the polymorphism and
melanoma. As both NMSC and melanoma have UVR in common as a causative agent,
these results seem to be in dispute with each other. If the AA genotype did lead to a
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decreased risk of NMSC, it might be expected that individuals with this genotype would
have lower erythemal responses following exposure to UVR, hence be less sensitive to
UV. No significant difference was observed at any UV dose in either study group,
implying the exon 10 polymorphism is not involved with the erythemal response to UV,
and, by association not involved in the repair of oxidative DNA damage induced by UV.
A larger study, investigating the polymorphism in all cutaneous malignancies, and
erythemal response could resolve the apparent discrepancies between studies.
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XRCC3 exon 7
The XRCC3 exon 7 polymorphism consists of a C to T change at position 18067 on the
GenBank entry AF037222, resulting in a Thr to Met amino acid change. When there is a
T at this position, a recognition site for Nlalll is present in the PCR product. The C allele
does not contain this site, and is not cut by the restriction digest, giving a single fragment
of 346bp. The T allele yields two fragments, of 242 and 104bp, with the heterozygous CT




Figure 144 XRCC3 exon 7 PCR
digest
Lanes 1-3, PCR products
Lane 4, negative control




Lane 4, undigested PCR product
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XRCC3 exon 7 Genotype frequencies
Genotype Group 1 (%) Group 2 (%)
CC 27/74 (36.49%) 12/31 (38.71%)
CT 41/74 (55.40%) 17/31 (54.84%)
TT 6/74 (8.11%) 2/31 (6.45%)
Total (100%) 74 (100%) 31 (100%)
No significant difference was observed between genotype frequencies in the two study
groups (xDF = 2, P-Value = 0.947)
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Figure 146 Erythema induced by 119mJ per cm UV by XRCC3 exon 7 genotype.
























Figure 147 Erythema induced by 150mJ per cm2 UV by XRCC3 exon 7 genotype.
































Figure 148 Erythema induced by 189mJ per cm UV by XRCC3 exon 7 genotype.





































Figure 149. Erythema induced by 238mJ per cm2 UV by XRCC3 exon 7 genotype.
































Figure 150. Erythema induced by 300mJ per cm2 UV by XRCC3 exon 7 genotype.
UVR on lower back, measured at 48 hours, n=74.
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Analysis of XRCC3 exon 7 genotype and erythemal response to UVR at each dose in
group 1.
119mJ per cm2
Genotype N Mean StDev SE Mean
CC 27 20.80 24.85 4.78
CT 41 24.47 23.53 3.67
TT 6 26.1 43.4 17.7
Analysis of variance of erythema induced by 119mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 270 135 0.20 0.818
Error 71 47591 670
Total 73 47861
150mJ per cm2
Genotype N Mean StDev SE Mean
CC 27 47.92 36.02 6.93
CT 41 60.80 38.12 5.95
TT 6 62.7 59.2 24.2
Analysis of variance of erythema induced by 150mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 2971 1486 0.96 0.386
Error 71 109411 1541
Total 73 112382
189mJ per cm
Genotype N Mean StDev SE Mean
CC 27 78.79 47.52 9.15
CT 41 106.70 44.42 6.94
TT 6 92.4 56.5 23.0
Analysis of variance of erythema induced by 189mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 12742 6371 2.95 0.059




Genotype N Mean StDev SE Mean
CC 27 109.50 51.32 9.88
CT 41 134.75 43.70 6.82
TT 6 137.0 42.5 17.3
Analysis of variance of erythema induced by 238mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 11215 5607 2.59 0.082
Error 71 153880 2167
Total 73 165094
300mJ per cm2
Genotype N Mean StDev SE Mean
CC 27 138.98 43.69 8.41
CT 41 159.42 41.26 6.44
TT 6 170.28 24.36 9.94
Analysis of variance of erythema induced by 300mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 8784 4392 2.58 0.083
Error 71 120699 1700
Total 73 129483
The TT genotype group showed higher mean levels of erythema at all UV doses
examined, excluding 189mJ per cm2, where the heterozygous CT genotype showed the
highest mean. This increased level of erythema in TT genotype was not formally
significant at any dose (p=0.05), but did approach this level of significance at the higher
UV doses. The factor and error values reveal that although significance is approached,
most of the variation in erythemal response is due to factors other than genotype.
Power calculations were performed using n=25 (balanced) and n=6 (unbalanced). At
119mJ, the between variance was 135 and within variance 670. These values gave a
power of 0.80 when n=25 and 0.22 when n=6. At 300mJ, the between variance was 4392
and within variance 1700, resulting in a power of 1 when n=25 and 0.99 when n=6. At
the higher UV dose, the power is good, but it would have been desirable to have had a
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higher level of power at the lower UV dose. Future studies could achieve this by
increasing the sample size.
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Erythema induced by incremental doses of UVR by XRCC3 exon 7 genotype in group
2.



























Figure 151. Erythema induced by 0.47J per cm UV by XRCC3 exon 7 genotype.





































Figure 152 Erythema induced by 0.6J per cm UV by XRCC3 exon 7 genotype.






































Figure 153 Erythema induced by 0.75J per cm UV by XRCC3 exon 7 genotype.
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Figure 154 Erythema induced by 0.95J per cm2 UV by XRCC3 exon 7 genotype.



























Figure 155 Erythema induced by 1.2J per cm UV by XRCC3 exon 7 genotype.





































Figure 156. Erythema induced by 1.5J per cm2 UV by XRCC3 exon 7 genotype.
UVR on inner forearm, measured at 24 hours, n=31.
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Analysis of XRCC3 exon 7 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
CC 12 0.00 0.00 0.00
CT 17 8.24 21.97 5.33
TT 2 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.47J per cm2 UV
Source DF SS MS F P
Factor 2 521 260 0.94 0.401
Error 28 7725 276
Total 30 8246
0.6J per cm2
Genotype N Mean StDev SE Mean
CC 12 10.42 21.12 6.10
CT 17 24.7 44.4 10.8
TT 2 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.6J per cm2 UV
Source DF SS MS F P
Factor 2 2107 1053 0.81 0.455
Error 28 36449 1302
Total 30 38555
0.75J per cm2
Genotype N Mean StDev SE Mean
CC 12 20.83 31.43 9.07
CT 17 46.0 59.0 14.3
TT 2 21.0 29.7 21.0
Analysis of variance of erythema induced by 0.75J per cm2 UV
Source DF SS MS F P
Factor 2 4869 2434 1.01 0.377




Genotype N Mean StDev SE Mean
CC 12 49.6 55.4 16.0
CT 17 93.5 79.4 19.2
TT 2 75.0 106.1 75.0
Analysis of variance of erythema induced by 0.95J per cm2 UV
Source DF SS MS F P
Factor 2 13539 6770 1.30 0.288
Error 28 145810 5207
Total 30 159349
1.2J per cm2
Genotype N Mean StDev SE Mean
CC 12 87.9 55.6 16.1
CT 17 132.6 88.0 21.3
TT 2 78.5 111.0 78.5
Analysis of variance of erythema induced by 1,2J per cm2 UV
Source DF SS MS F P
Factor 2 16451 8225 1.35 0.275
Error 28 170137 6076
Total 30 186588
1.5J per cm2
Genotype N Mean StDev SE Mean
CC 12 141.0 69.2 20.0
CT 17 181.0 95.7 23.2
TT 2 113.0 84.9 60.0
Analysis of variance of erythema induced by 1.5 J per cm2 UV
Source DF SS MS F P
Factor 2 16181 8090 1.10 0.347
Error 28 206261 7366
Total 30 222442
The higher mean level of erythema seen in the TT genotype in group 1 was not observed
in group 2. The low number of TT homozygotes could have masked any effect of this
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genotype, the CT genotype was highest at all doses. The P values did not approach
significance at any dose, ranging from 0.455 to 0.275. Most of the variation can be seen
to be due to factors other than genotype.
Power calculations were performed using n=10 and n=2. At 0.47J, the between variance
value was 260 and within variance 276. This gave a power of 0.96 when n=10, and 0.18
when n=2. At 1.5J, the between variance value was 8090, and within 7366, power was
0.98 when n=10, and 0.20 when n=2. The true power will therefore lie between a large
range, and in order to let the p values be accepted with more confidence, the power would
need to be increased at the lower UV doses. This could be achieved by using a larger
study group.
No significant association was observed between genotype and erythema levels at any
UV dose in either study group. The TT genotype has been previously associated with
malignant melanoma in a study by Winsey and colleagues (2000). From this, one would
expect the TT genotype to be more sensitive to the effects of UVR, that is having higher
levels of erythema in response to UV. This can be observed in the first study group, but is
not significant. In group 2, no such observation is seen. A larger study to investigate this
polymorphism would be useful, both for determining erythemal response, but also the
risk of melanoma and other skin cancers. A study with a large number of melanoma
patients, and, importantly, healthy controls with no history of skin cancer would resolve
any ambiguity over the possibility that the use of cadavers affected the outcome in the
study by Winsey et al. A larger study should also allow for a greater number of TT
homozygotes, which could resolve the issue of whether erythemal response is associated
with this genotype.
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Chapter 4. Effect of UVR on human lymphocytes
The XPG exon 15 polymorphism looked promising as a candidate involved with
determining sensitivity to UVR. A non-synonymous change occurs in the amino acid
sequence with the presence of this polymorphism, from the basic histamine to the acidic
aspartate, which could have a functional effect on the resulting protein. In order to
investigate whether the polymorphism had any functional role, an experiment
investigating its effect on UV-induced apoptosis in cultured lymphocytes was planned. It
was not possible to obtain sufficient fresh blood samples from individuals with each
genotype in order to investigate any effect the exon 15 polymorphism might have on UV-
induced apoptosis. However, as most is known about UV-induced apoptosis on mouse
cells, it was decided to determine whether human lymphocytes undergo apoptosis in a
dose-dependent manner.
Lymphocytes were obtained from fresh blood samples, donated by volunteers in the
Department of Dermatology. Blood samples were processed as described in Chapter 2,
Methods, within one hour of blood donation. Cells were grown in culture for three days,
and then irradiated with UVR. Annexin V-FITC and DNA content assays were
performed in order to detect levels of apoptosis and cell cycle changes, and analysed by
flow cytometry.
Apoptosis is the programmed cell death of cells, where, after the process has been
initiated, cells are destroyed. It can be characterised morphologically by condensation of
nuclear chromatin, compaction of cytoplasmic organelles, cell shrinkage and changes at
the cell surface. At a late stage in the process, the cell in phagocytosed by neighbouring
cells.
Annexin V-FITC assay
The Annexin V-FITC conjugates to facilitate rapid fluorimetric detection of apoptotic
cells. Early in the apoptotic process, the phospholipid asymmetry of the cytoplasmic
membrane of cells is disrupted. This leads to the exposure of the phosphotidyiserine on
the outer surface of the cytoplasmic membrane. Annexin V is an anticoagulant protein,
which preferentially binds negatively charged phospholipids, therefore, when the
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cytoplasmic membrane is disrupted it can bind to the cell surface. The inclusion of
propidium iodide in this assay allows the detection of different stages of apoptosis. The
flow cytometer was set so that the FL1 channel (X-axis of flow charts) would reflect the
log Annexin V-FITC fluorescence, and the FL2 channel reflected the propidium iodine
reflectance (Y-axis on flow charts). Cells which bound Annexin V alone were early
apoptotic and appear in the lower right quadrant of the flow charts (A4). Cells which take
up both Annexin V and PI are late apoptotic, and appear in the upper right quadrant (A2).
Cells which are negative for both Annexin V and PI (lower left quadrant, A3) are normal,
viable cells.
Initial UV doses were 20 and 40J at a wavelength of 254nm. These were chosen on the
basis of past experience in the Melton laboratory, where mouse lymphocytes were shown
to display easily detectable levels of UV-induced apoptosis at these UV doses (personal
communication with Prof. Melton). UVR was delivered to the cells through the
lymphocyte growth medium, as the cultured lymphocytes were not adherent to the dishes
and were growing in suspension. This resulted in some of the radiation being filtered out,
and the cells therefore did not receive the full dose of UV to which they were exposed.
The problem of the media filtering out some UVR could have been circumvented by
replacing the growth medium with phosphate buffered saline (PBS). This would involve
collecting the cells by centrifugation before resuspending them in PBS, a clear solution
that allows UV to pass through it. However, this process of centrifugation and
resuspension of cells in PBS to irradiate them, and then again to resuspend them in
growing medium afterwards would cause additional, unnecessary, stress to the cells.
Exposing the cells to additional stress could induce apoptosis, and it was preferred to
keep other sources of apoptosis to a minimum so as not to interfere with any apoptosis
induced by UVR.
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Figure 158 Cells grown in culture for 3 days, irradiated with 20J UV
FITC FL1
Figure 159 Cells grown in culture for 3 days, irradiated with 40J UV
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Percentage of cells in each quadrant.
Quadrant Control 20J 40J
Al- necrotic cells 0.14% 0.85% 1.93%
A2 - late apoptosis 7.74% 9.81% 14.02%
A3 - healthy cells 75.2% 72.2% 68.34%
A4 -early apoptosis 16.91% 17.35% 15.71%
The initial pilot experiments revealed that little apoptosis was induced following
exposure to the nominal UV doses of 20 and 40J. 40J did cause an increased percentage
of cells to undergo apoptosis, although this only led to a 7% decrease in the number of
healthy cells compared to the control. This was unexpected, as previous studies in the
Melton group on mouse lymphocytes had shown these UV doses to be sufficient to
induce substantial apoptosis. This protocol was repeated with similar results, and it was
concluded that human lymphocyte cells have a much greater resistance to UV-induced
apoptosis than their mouse counterparts.
It can also be seen that human lymphocytes undergo a substantial amount of spontaneous
apoptosis when grown in culture. Almost 25% of the control population of cells had
either started to undergo apoptosis, or had become necrotic.
To investigate whether higher doses of UV could induce greater levels of apoptosis the
cells were irradiated with the nominal doses of 100 and 400J in lymphocytes cultured
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Figure 161 Cells grown in culture for 3 days, irradiated with 100J UV
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Figure 162 Cells grown in culture for 3 days, irradiated with
400J UV
258
Quadrant Control 100J 400J
Al - necrotic cells 4.12% 1.67% 3.61%
A2 - late apoptosis 21.96% 38.55% 51.46%




As can be seen from the flow charts and above table, the higher doses of UV induced
much greater levels of apoptosis. The percentage of cells which were healthy and viable
decreased in a dose dependent manner, from 60.88% in the control population to 37.53%
after 100J and 27.83% after 400J. The high levels of spontaneous apoptosis is again seen
in the control population, with 4.12% necrotic. The percentage of necrotic cells is less in
the two populations which have been irradiated, but here most cells are in early or late
apoptosis. A shift from early to late apoptosis can be seen as the UV dose increases,
indicating that not only does the higher UV dose induce more cells to undergo apoptosis,
these cells also do so faster.
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Figure 165 Cells grown in culture for 3 days, irradiated with 400J
Quadrant Control 100J 400J
Al- necrotic cells 2.67% 1.88% 8.38%
A2 - late apoptosis 15.95% 17.84% 42.79%





In the cells cultured from donor 2, there was again dose dependent UV-induced
apoptosis. The percentage of healthy cells decreased, from 58.22% in the control
population, to 43.95% after 100J UV, and 29.57% after irradiation with 400J UV. There
was a more dramatic shift from early to late apoptosis as the UV dose increased than seen
in the cells from donor 1.17.84% of the cells irradiated with 100J were late apoptotic,
while after 400J 42.79% were in the late stage of apoptosis. This is illustrated in the shift
of cells from quadrant A4 to A2 in the flow charts above, demonstrating again that higher
doses of UV both induce greater levels of UV, and do so faster. This suggests that the
higher UV dose is inducing a greater amount of DNA damage than 100J. The repair
pathways will be less able to cope with the greater amount of damage, thus the apoptosis




Flow cytometry was also used to measure DNA, to examine the effect of UVR on the cell
cycle. Cells start the cell cycle in Gl, before entering S-phase (where DNA synthesis
occurs). DNA content increases, until it doubles and the cell has entered G2. Cells then
enter mitosis (M-phase), and divide, before beginning the cell cycle again. Cells which
are not currently cycling are in the GO phase. The different stages of cell cycle can be
identified in a DNA histogram, as seen in the diagram below.
Propidium iodide can be used to determine the viability of cells, as it is excluded by
viable cells, and binds to nucleic acids only in dead or dying cells, where it fluoresces
red.
At a late stage in apoptosis, double-strand breaks are introduced into the DNA at the
linker regions between the nucleosomes. Some of the lower molecular weight fragments
are lost during fixation of the cells, which leads to a lowering of the DNA content. On a

































n i *T">— 1 1 1 1 1
FL3 LIN
Figure168 Cells grown in culture for 3 days, 400J UV
DNA content of cells, percentage of population in each peak
Peak Control 100J 400J
E 5.85% 10.99% 16.39%
B 84.13% 80.93% 70.69%
C and D 10.02% 8.08% 12.92%
265
Cells from donor 4. DNA content assay, 100J and 400J UV
FL3 LIN
Figure 169 Cells grown in culture for 3 days, no UV
Figure 170 Cells grown in culture for 3 days, 100J UV
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Figure 171 Cells grown in culture for 3 days, 400J UV
DNA content of cells, percentage of population in each peak
Peak Control 100J 400J
E 13.3% 13.51% 23.52%
B 81.72% 79.35% 72.48%
C and D 4.98% 7.4% 4%
The DNA content assay was used to determine what proportion of cells were undergoing
mitosis and replicating their DNA content. The E peak seen on the flow charts above
corresponds to cells which are sub-Gl phase of the cell cycle. These cells are not
undergoing mitosis, and no DNA replication is occurring in them. It is this proportion
that are of interest, as these cells have damaged DNA and are not undergoing mitosis to
prevent the mutations they have acquired being incorporated into the genome.
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In both cells samples which were analysed for DNA content, there is a dose dependent
increase in the number of cells that are sub-Gl, and a decrease in the number of healthy,
viable cells. This indicates that there is a dose dependent increase in DNA damage
occurring within the cells.
Discussion
From this experiment, it can be seen that UVR induces DNA damage in a dose dependent
manner in cultured human lymphocytes. There is a related dose dependent increase in the
levels of UV-induced apoptosis. Cultured human lymphocytes display fairly high levels
of spontaneous apoptosis, as seen from the control data. There are differences in the
levels of apoptosis induced by UV between individuals.
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Chapter 5 Analysis of repair gene polymorphisms for association with response to
anthralin.
As previously mentioned, anthralin is an irritant to the skin, and induces oxidative stress,
which leads to DNA damage in the same way that UVR induces DNA damage indirectly
through the generation of reactive oxygen species. Such DNA damage is repaired in the
main by the BER pathway, but also by the NER pathway. Therefore, if any of the
polymorphisms investigated here were to be associated with cutaneous sensitivity
following exposure to anthralin, one would expect this to be the XRCC1 exon 10
polymorphism, XRCC1 being crucial for efficient BER.
Sensitivity to anthralin was measured by laser Doppler flow cytometry. This technique
measures blood flow in the superficial dermis. The blood flow measured by the laser
Doppler technique is referred to as "flux", a quantity proportional to the product of the
average speed of the blood cells and the blood volume, and is measured in arbitrary units
(Farr and Diffey; 1986). Upon application of an irritant, such as anthralin, a feature of the
immune response is vasodilation of blood vessels in the superficial dermis and an
increase in blood flow to the surface of the skin. The greater the sensitivity to an irritant,
the greater the blood flow, therefore a higher level of "flux" response to anthralin would
indicate increased sensitivity to the substance.
269
XPD exon 6
























Figure 172. Flux induced by 0.01% Anthralin by XPD exon 6 genotype.




























Figure 173 Flux induced by 0.02% Anthralin by XPD exon 6 genotype.

























Figure 174 Flux induced by 0.04% Anthralin by XPD exon 6 genotype.
























Figure 175 Flux induced by 0.08% Anthralin by XPD exon 6 genotype.
Anthralin on lower back, flux measured at 48 hours
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Analysis of flux induced by anthralin and XPD exon 6 genotype in group 1.
0.01% Anthralin
Genotype N Mean StDev SE Mean
AA 14 193.0 155.5 41.6
AC 39 145.4 104.2 16.7
CC 25 166.7 111.6 22.3
Analysis of variance of flux from 0.01% anthralin between genotypes:
Source DF SS MS F P
Factor 2 24560 12280 0.90 0.412
Error 75 1025767 13677
Total 77 1050326
0.02% Anthralin
Genotype N Mean StDev SE Mean
AA 14 349.1 220.6 59.0
AC 39 270.6 128.8 20.6
CC 25 302.9 133.5 26.7
Analysis of variance of flux from 0.02% anthralin between genotypes:
Source DF SS MS F P
Factor 2 65804 32902 1.46 0.239
Error 75 1690984 22546
Total 77 1756788
0.04% Anthralin
Genotype N Mean StDev SE Mean
AA 14 428.0 188.4 50.4
AC 39 370.8 134.5 21.5
CC 25 360.1 116.1 23.2
Analysis of variance of flux from 0.04% anthralin between genotypes:
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Source DF SS MS F P
Factor 2 44989 22495 1.15 0.323
Error 75 1471768 19624
Total 77 1516757
0.08% Anthralin
Genotype N Mean StDev SE Mean
AA 14 431.9 171.1 45.7
AC 39 415.0 152.4 24.4
CC 25 386.3 115.8 23.2
Analysis of variance of flux from 0.08% anthralin between genotypes:
Source DF SS MS F P
Factor 2 21655 10828 0.51 0.601
Error 75 1585610 21141
Total 77 1607265
At no dose of anthralin examined was there an XPD exon 6 genotype-dependent response
to anthralin. The AA genotype had a higher mean flux in response to anthralin at each
dose of anthralin examined, although the standard errors of mean were largest in this
group at all doses. P values showed no significant associated between the exon 6
polymorphism and flux, ranging from 0.239 to 0.60. The genotype of individuals
explained very little of the variation in response to anthralin, the SS(factor) values being
greatly smaller than the SS(error), the two values making up the SS(total), accounting for
the total amount of variation observed between individual responses to anthralin. This
implies that the exon 6 polymorphism of XPD is not involved with the repair of DNA
damage induced by anthralin, which is primarily due to oxidative stress.
Power calculations were carried out for 0.01% and 0.08% using n=26 (balanced) and
n=14. At 0.01% anthralin, the between variance value was 12280, and the within variance
13677. This gave a power of 0.99 when n=26, and 0.99 when n=14. 0.08% had a between
variance value of 10828 and a within variance value of 21141, giving a power of 0.99
when n=26 and 0.91 when n=4. The true power will lie between these values, but this
range is of adequate power.
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XPD exon 22
































Figure 176 Flux induced by 0.01% Anthralin by XPD exon 22 genotype.


























Figure 177 Flux induced by 0.02% Anthralin by XPD exon 22 genotype.































Figure 178. Flux induced by 0.04% Anthralin by XPD exon 22 genotype.























Figure 179 Flux induced by 0.08% Anthralin by XPD exon 22 genotype.
Anthralin on lower back, flux measured at 48 hours
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Analysis of flux response to anthralin and XPD exon 22 genotype in group 1.
0.01% Anthralin
Genotype N Mean StDev SE Mean
CC 39 164.2 130.4 20.9
CT 34 153.4 101.2 17.4
TT 6 181.4 111.1 45.3
Analysis of variance of flux from 0.01% anthralin between genotypes:
Source DF SS MS F P
Factor 2 4849 2425 0.18 0.839
Error 76 1045511 13757
Total 78 1050360
0.02% Anthralin
Genotype N Mean StDev SE Mean
CC 39 309.7 179.8 28.8
CT 34 271.5 121.1 20.8
TT 6 315.4 71.8 29.3
Analysis of variance of flux from 0.02% anthralin between genotypes:
Source DF SS MS F P
Factor 2 29486 14743 0.64 0.528
Error 76 1738542 22876
Total 78 1768028
0.04% Anthralin
Genotype N Mean StDev SE Mean
CC 39 371.9 153.9 24.6
CT 34 379.7 134.8 23.1
TT 6 385.0 74.7 30.5










Genotype N Mean StDev SE Mean
CC 39 400.3 142.6 22.8
CT 34 417.8 158.3 27.2
TT 6 385.0 75.3 30.7
Analysis of variance of flux from 0.08% anthralin between genotypes:
Source DF SS MS F P
• Factor 2 8615 4307 0.20 0.818
Error 76 1628259 21424
Total 78 1636874
As with the exon 6 polymorphisms, no association was observed between flux response
and the XPD exon 22 genotype. No consistent pattern emerged for levels of erythema
between genotypes at different anthralin doses, for example, the heterozygous CT
displayed the lowest mean response at 0.01% and 0.02%, but the homozygous CC was
the lowest at the highest doses. The TT genotype was the highest at 0.01%, 0.02% and
0.04%, but lowest at 0.08%. The p values reflected this, showing no significance and
ranged from 0.961 to 0.528. Analysis of factor and error values shows that almost all the
variation was due to something other than genotype. From this data, it can be seen that
the XPD exon 22 is not involved with the response to anthralin.
Power calculations were carried out using n=26 and n=6. 0.01% anthralin had a between
variance value of 2425 and a within variance value of 13757. This gave a power of 0.76
when n=26, and 0.20 when n=6. 0.08% had a between variance of 4307, and within
variance of 21424. This resulted in a power of 0.82m when n=26, and a power of 0.22
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when n=6. For this polymorphism, an increase in power would be advantageous, which
could be carried out in a future study by using a larger study group.
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XPD exon 23
























Figure 180 Flux induced by 0.01% Anthralin by XPD exon 23 genotype.


























Figure 181. Flux induced by 0.02% Anthralin by XPD exon 23 genotype.























Figure 182 Flux induced by 0.04% Anthralin by XPD exon 23 genotype.





















Figure 183 Flux induced by 0.08% Anthralin by XPD exon 23 genotype.
Anthralin on lower back, flux measured at 48 hours
Analysis of flux response to anthralin and XPD exon 23 genotype in group 1.
0.01% Anthralin
Genotype N Mean StDev SE Mean
AA 39 159.4 126.9 20.3
AC 34 155.8 106.5 18.3
CC 6 199.0 103.7 42.3
Analysis of variance of flux from 0.01% anthralin between genotypes:
Source DF SS MS F P
Factor 2 9686 4843 0.35 0.703
Error 76 1040674 13693
Total 78 1050360
0.02% Anthralin
Genotype N Mean StDev SE Mean
AA 39 306.3 179.0 28.7
AC 34 275.6 123.8 21.2
CC 6 314.2 71.4 29.1
Analysis of variance of flux from 0.02% anthralin between genotypes:
Source DF SS MS F P
Factor 2 19848 9924 0.43 0.651
Error 76 1748180 23002
Total 78 1768028
0.04% Anthralin
Genotype N Mean StDev SE Mean
AA 39 367.8 155.5 24.9
AC 34 381.5 130.9 22.4
CC 6 401.2 87.4 35.7
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Analysis of variance of flux from 0.04% anthralin between genotypes:
Source DF SS MS F P
Factor 2 7445 3723 0.19 0.831
Error 76 1521916 20025
Total 78 1529361
0.08% Anthralin
Genotype N Mean StDev SE Mean
AA 39 396.5 143.5 23.0
AC 34 417.9 156.5 26.8
CC 6 409.1 87.1 35.6
Analysis of variance of flux from 0.08% anthralin between genotypes:
Source DF SS MS F P
Factor 2 8333 4166 0.19 0.824
Error 76 1628541 21428
Total 78 1636874
Analysis of variance of levels of flux induced by incremental doses of anthralin revealed
no significant variation in flux between XPD exon 23 genotypes at any dose examined. P
values did not approach the level of significance (p=0.05) at any dose, from p=0.703 at
0.01% anthralin to p=0.824 at 0.08% anthralin. Variation in flux could not be attributed
to genotype, with the SS(factor) values being very low compared with the SS(error)
values. From this it can be implied that exon 23 is not involved with the repair of
anthralin induced DNA damage.
Power calculations were carried out using n=26 (balanced) and n=6 (least balanced). At
0.01%, the between variance value was 4843 and the within variance value 13693. Power
was 0.97 when n=26 and 0.37 when n=6. 0.08% anthralin gave a between variance value
of 4166 and a within value of 24128. Power was 0.80 when n=26, and 0.22 when n=6. In
order to accept the p values with more confidence, the power values would need to be
increased.
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At none of the three polymorphisms of XPD examined, exon 6, exon 22 and- exon 23,
was there any association observed between genotype and flux response to anthralin,
suggesting that XPD is not involved with the repair of anthralin induced DNA damage,
which is mainly due to oxidative stress. The finding of no association between any of the
polymorphisms of XPD analysed here and anthralin response is in agreement with the






























Figure 184 Flux induced by 0.01% Anthralin by CKM exon 8 genotype.





























Figure 185 Flux induced by 0.02% Anthralin by CKM exon 8 genotype.


























Figure 186 Flux induced by 0.04% Anthralin by CKM exon 8 genotype.




























Figure 187 Flux induced by 0.08% Anthralin by CKM exon 8 genotype.
Anthralin on lower back, flux measured at 48 hours
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Analysis of flux response to anthralin and CKM exon 8 genotype in group 1.
0.01% anthralin
Genotype N Mean StDev SE Mean
TT 6 108.8 120.8 49.3
TC 27 158.5 130.2 25.1
CC 43 173.9 104.3 15.9
Analysis of variance of flux from 0.01% anthralin between genotypes:
Source DF SS MS F P
Factor 2 23257 11629 0.87 0.421
Error 73 970634 13296
Total 75 993892
0.02% anthralin
Genotype N Mean StDev SE Mean
TT 6 242.9 188.6 77.0
TC 27 291.2 161.3 31.0
CC 43 306.0 140.7 21.5
Analysis of variance of flux from 0.02% anthralin between genotypes:
Source DF SS MS F P
Factor 2 21858 10929 0.47 0.625
Error 73 1685032 23083
Total 75 1706889
0.04% anthralin
Genotype N Mean StDev SE Mean
TT 6 304.8 178.6 72.9
TC 27 381.3 143.7 27.6
CC 43 387.2 132.3 20.2
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Genotype N Mean StDev SE Mean
TT 6 295.8 145.9 59.6
TC 27 400.2 141.9 27.3
CC 43 430.7 141.3 21.5
Analysis of variance of flux from 0.08% anthralin between genotypes:
Source DF SS MS F P
Factor 2 99159 49579 2.46 0.092
Error 73 1468497 20116
Total 75 1567656
No significant association was observed between flux from any anthralin dose and CKM
exon 8 genotype. P values ranged from 0.625 to 0.092. Although at 0.08% the p value
was lowest, tending towards significance, this could have been influenced by the low
number of TT homozygotes, the genotype group with the lowest flux response. Analysis
of the factor and error values confirm that variation in response due to genotype
contributes towards almost none of the total variation, implying that the vast majority of
variation in flux response is due to factors other than genotype, such as chance. This is in
agreement with the data observed from the XPD polymorphisms, as CKM was only
included as a marker for this repair gene, it itself having no role in repair. Indeed, it
would be rather worrying if a significant association had been observed between CKM
and flux response, but not in any of the XPD polymorphisms.
N=25 (balanced) and n=6 (least balanced) were used to perform power calculations.
0.01% anthralin had between variance values of 11629 while within variance was 13296.
These values gave a power of 0.99 when n=25 and 0.75 when n=6. 0.08% had a between
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variance value of 49579, and a within variance values of 20116. The power was 1 both
when n=25 and when n=6. Sufficient power was achieved when analysing this
polymorphism to be confident that there was no associated between the CKM 8 genotype
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Figure 188. Flux induced by 0.01% Anthralin by ERCC1 exon 4 genotype.





















Figure 189. Flux induced by 0.02% Anthraiin by ERCC1 exon 4 genotype.

































Figure 190 Flux induced by 0.04% Anthralin by ERCC1 exon 4 genotype.





























Figure 191 Flux induced by 0.08% Anthralin by ERCC1 exon 4 genotype.
Anthralin on lower back, flux measured at 48 hours
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Analysis of flux response to anthralin and ERCC1 exon 4 genotype in group 1.
0.01% anthralin
Genotype N Mean StDev SE Mean
GG 14 111.4 89.0 23.8
GA 12 102.1 79.4 22.9
AA 50 189.7 121.8 17.2
Analysis of variance of flux from 0.01% anthralin between genotypes:
Source DF SS MS F P
Factor 2 117224 58612 4.76 0.011
Error 73 898856 12313
Total 75 1016080
0.02% anthralin
Genotype N Mean StDev SE Mean
GG 14 237.9 160.8 43.0
GA 12 249.1 93.2 26.9
AA 50 324.9 152.9 21.6
Analysis of variance of flux from 0.02% anthralin between genotypes:
Source DF SS MS F P
Factor 2 115495 57747 2.67 0.076
Error 73 1577335 21607
Total 75 1692829
0.04% anthralin
Genotype N Mean StDev SE Mean
GG 14 370.8 148.8 39.8
GA 12 394.6 112.1 32.4
AA 50 380.7 144.5 20.4
Analysis of variance of flux from 0.04% anthralin between genotypes:
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Source DF SS MS F P
Factor 2 3681 1841 0.09 0.912
Error 73 1448514 19843
Total 75 1452196
0.08% anthralin
Genotype N Mean StDev SE Mean
GG 14 400.2 168.0 44.9
GA 12 419.5 130.8 37.8
AA 50 413.1 142.8 20.2
Analysis of variance of flux from 0.08% anthralin between genotypes:
Source DF SS MS F P
Factor 2 2701 1350 0.06 0.939
Error 73 1553845 21286
Total 75 1556546
At the lowest dose of anthralin examined, 0.01%, there was significant variation between
levels of flux and ERCC1 exon 4 genotypes. The AA genotype had significantly higher
mean levels of flux response than GG and GA genotypes (p=0.01). However, analysis of
factor and error values reveal that the majority of variation in response to anthralin is still
due to factors other than genotype (SS(factor) 117224, compared with SS(error) of
898856, which contributes towards the majority of the SS(total) value of 1016080). As
the strength of anthralin applied increases, so the level of significance in flux response by
genotype decreases. At 0.04% and 0.08% there is almost no difference is observed in flux
response between genotypes, with p values of 0.912 and 0.939 respectively. Here the
variation which can be explained by genotype is even less than that seen at the lower
doses. As the amount of DNA damage would be greater at higher anthralin doses, it
would be expected that if the ERCC1 exon 4 polymorphism was associated with the flux
response to anthralin, and thus the repair of such damage, such an association would
reveal itself at the higher anthralin doses. As this was not the case, it seems that the
apparent association of the polymorphism at the lowest dose (0.01%) was due to chance.
No compelling evidence is seen here for the association of the ERCC1 exon 4
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polymorphism with response to anthralin, and repair of DNA damage induced by
anthralin.
XPF exon 11



























Figure 192. Flux induced by 0.01% Anthralin by XPF exon 11 genotype.





























Figure 193 Flux induced by 0.02% Anthralin by XPF exon 11 genotype.

























Figure 194 Flux induced by 0.04% Anthralin by XPF exon 11 genotype.


























Figure 195. Flux induced by 0.08% Anthralin by XPF exon 11 genotype.
Anthralin on lower back, flux measured at 48 hours
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Analysis of flux response to anthralin and XPF exon 11 genotype in group 1.
0.01% Anthralin
Genotype N Mean StDev SE Mean
TT 31 192.5 112.1 20.1
TC 32 145.4 127.5 22.5
cc 7 141.2 80.1 30.3
Analysis of variance of flux from 0.01% anthralin between genotypes:
Source DF SS MS F P
Factor 2 39741 19871 1.45 0.242
Error 67 919373 13722
Total 69 959115
0.02% Anthralin
Genotype N Mean StDev SE Mean
TT 31 304.2 144.3 25.9
TC 32 310.0 171.1 30.2
CC 7 287.4 99.3 37.5
Analysis of variance of flux from 0.02% anthralin between genotypes:
Source DF SS MS F P
Factor 2 2996 1498 0.06 0.939
Error 67 1590660 23741
Total 69 1593656
0.04% Anthralin
Genotype N Mean StDev SE Mean
TT 31 376.0 125.6 22.6
TC 32 404.6 164.1 29.0
CC 7 377.2 62.7 23.7
Analysis of variance of flux from 0.04% anthralin between genotypes:
Source DF SS MS F P
Factor 2 14052 7026 0.35 0.704




Genotype N Mean StDev SE Mean
TT 31 396.9 124.8 22.4
TC 32 436.9 172.0 30.4
CC 7 437.5 79.4 30.0
Analysis of variance of flux from 0.08% anthralin between genotypes:
Source DF SS MS F P
Factor 2 27716 13858 0.65 0.524
Error 67 1421846 21222
Total 69 1449562
The level of significance was not approached at any anthralin dose examined, p values
ranged from 0.242 to 0.524. There was no pattern in the mean flux of a particular
genotype at different genotypes. At 0.01% anthralin, the TT genotype group had the
highest mean flux, while CC the lowest. The genotype with highest mean changes at each
dose examined; at 0.08% TT has the lowest flux. The factor values for SS were much
lower than the values for error at all doses, indicating that factors other than genotype are
responsible for the variation seen in levels of flux. The XPF exon 11 polymorphism, from
this data, is not associated with levels of flux following anthralin exposure.
Power calculations were performed using n=23 and n=7 for 0.01% and 0.08% anthralin.
0.01% had a between variance value of 19871, and a within variance values of 13722,
which gave a power of 1 when n=23 and 0.97 when n=7. 0.08% had a between variance
of 13858 and a within variance value of 21222. This gave a power of 0.99 when n=23
and 0.70 when n=7. The true power will lie between these values.
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XPG exon 15






















Figure 196. Flux induced by 0.01% Anthralin by XPG exon 15 genotype.























Figure 197. Flux induced by 0.02% Anthralin by XPG exon 15 genotype.




























Figure 198 Flux induced by 0.04% Anthralin by XPG exon 15 genotype.




















Figure 199 Flux induced by 0.08% Anthralin by XPG exon 15 genotype.
Anthralin on lower back, flux measured at 48 hours
Analysis of flux response to anthralin by XPG exon 15 genotype in group 1.
0.01% Anthralin
Genotype N Mean StDev SE Mean
CC 5 225.8 213.9 95.7
CG 21 131.7 98.2 21.4
GG 52 165.5 110.7 15.3
Analysis of variance of flux from 0.01% anthralin between genotypes:
Source DF SS MS F P
Factor 2 39993 19996 1.50 0.230
Error 75 1000809 13344
Total 77 1040802
0.02% Anthralin
Genotype N Mean StDev SE Mean
CC 5 356.0 221.1 98.9
CG 21 266.2 151.4 33.0
GG 52 301.4 144.5 20.0
Analysis of variance of flux from 0.02% anthralin between genotypes:
Source DF SS MS F P
Factor 2 38177 19088 0.83 0.439
Error 75 1718390 22912
Total 77 1756567
0.04% Anthralin
Genotype N Mean StDev SE Mean
CC 5 430.5 181.3 81.1
CG 21 326.1 152.2 33.2
GG 52 396.8 129.3 17.9
Analysis of variance of flux from 0.04% anthralin between genotypes:
Source DF SS MS F P
Factor 2 88360 44180 2.29 0.108
Error 75 1447825 19304
Total 77 1536185
0.08% Anthralin
Genotype N Mean StDev SE Mean
CC 5 429.8 196.7 88.0
CG 21 367.9 163.6 35.7
GG 52 426.2 133.6 18.5
Analysis of variance of flux from 0.08% anthralin between genotypes:
Source DF SS MS F P
Factor 2 52732 26366 1.24 0.297
Error 75 1600785 21344
Total 77 1653517
Analysis of variance revealed no association between flux in response to anthralin and
the XPG exon 15 genotype at any dose examined. P values ranged from 0.108 at 0.04%
anthralin to 0.439 at 0.02%. Similarly, the factor values show little of the variation
between flux responses can be attributed to the XPG genotype. This indicates that the
XPG exon 15 polymorphism is not associated with flux response to, or repair of DNA
damaged by, anthralin. XPG is a key component of the NER pathway, and has also been
implicated in the repair of oxidative damage, which suggested it to be a good candidate
for association with anthralin response, as anthralin induces oxidative stress. However,
the exon 15 polymorphism does not appear to be associated with repair of oxidative
damage, as indicated by the lack of association with flux following anthralin exposure.
Power calculations were carried out for 0.01% and 0.08% anthralin, using n=26
(balanced) and n=5 (most unbalanced). 0.01% had a between variance of 19996 and a
within variance of 13344, which gave a power of 1 when n=26 and 0.87 when n=5.
0.08% had a between variance of 26366 and a within variance of 21344. Power was 1
when n=26, and 0.79 when n=5. The true power will lie between these values, but is
sufficient to draw conclusions from the ANOVA tests.
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XRCC1 exon 10
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Figure 200 Flux induced by 0.01% Anthralin by XRCC1 exon 10 genotype.






















Figure 201. Flux induced by 0.02% Anthralin by XRCC1 exon 10 genotype.





























Figure 202 Flux induced by 0.4% Anthralin by XRCC1 exon 10 genotype.


























Figure 203. Flux induced by 0.08% Anthralin by XRCC1 exon 10 genotype.
Anthralin on lower back, flux measured at 48 hours
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Analysis of flux response to anthralin and XRCC1 exon 10 genotype in group 1.
0.01 % Anthralin
Genotype N Mean StDev SE Mean
GG 26 157.0 142.8 28.0
GA 36 166.0 100.3 16.7
AA 17 155.9 107.9 26.2
Analysis of variance of flux from 0.01% anthralin between genotypes:
Source DF SS MS F P
Factor 2 1733 866 0.06 0.939
Error 76 1048628 13798
Total 78 1050360
0.02% Anthralin
Genotype N Mean StDev SE Mean
GG 26 312.7 152.5 29.9
GA 36 305.5 164.6 27.4
AA 17 239.5 104.3 25.3
Analysis of variance of flux from 0.02% anthralin between genotypes:
Source DF SS MS F P
Factor 2 64326 32163 1.43 0.245
Error 76 1703703 22417
Total 78 1768028
0.04% Anthralin
Genotype N Mean StDev SE Mean
GG 26 374.4 141.2 27.7
GA 36 406.0 143.1 23.9
AA 17 316.1 117.3 28.5
Analysis of variance of flux from 0.04% anthralin between genotypes:
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Source DF SS MS F P
Factor 2 93409 46705 2.47 0.091
Error 76 1435952 18894
Total 78 1529361
0.08% Anthralin
Genotype N Mean StDev SE Mean
GG 26 397.3 120.6 23.6
GA 36 442.4 159.7 26.6
AA 17 345.2 129.4 31.4
Analysis of variance of flux from 0.08% anthralin between genotypes:
Source DF SS MS F P
Factor 2 112585 56292 2.81 0.067
Error 76 1524289 20056
Total 78 1636874
The XRCC1 exon 10 polymorphism showed no formal association with flux response at
any dose of anthralin examined. The AA homozygous genotype had lower mean values
of flux at all doses, whilst the heterozygous GA genotype had the highest mean at all
doses except at 0.02%. At the higher doses of 0.04% and 0.08% anthralin, the genotype
variation of response approached the formal level of significance, p=0.05. At 0.04%
anthralin, the p value was 0.091, and at 0.08%, p=0.067. Comparison of factor and error
reveals most variation of flux response is still due to factors other than genotype.
Power calculations were carried out for 0.01% and 0.08% anthralin, using n=26
(balanced) and n=17 (most unbalanced). Between variance was 866 for 0.01% and within
variance was 13798. Power was 0.33 when n=26 and 0.23 when n=17. 0.08% gave a
between variance value of 56292 and a within variance value of 20056. Power was 1 both
when n=26 and when n=17. The power at the lower anthralin dose was extremely low,
although it was good at 0.08%. An increase in numbers of individuals studied would
benefit the power of the ANOVA tests for lower anthralin doses.
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XRCC1 is required to ligate the newly synthesised DNA to the damaged strand on
completion of the BER pathway. As BER repair oxidative damage, this polymorphism
more than any other was thought to be most likely to show an association with flux
response. The lack of formal significance means no conclusive association can be drawn
between the XRCC1 genotype and the repair of anthralin-induced damage, as indicated
by flux response. It would be of interest to repeat this study in a larger group, perhaps
including higher doses of anthralin to see if significance increased. However, higher
































Figure 204. Flux induced by 0.01% Anthralin by XRCC3 exon 7 genotype.
























Figure 205. Flux induced by 0.02% Anthralin by XRCC3 exon 7 genotype.






















Figure 206 Flux induced by 0.04% Anthralin by XRCC3 exon 7 genotype.























Figure 207 Flux induced by 0.08% Anthralin by XRCC3 exon 7 genotype.
Anthralin on lower back, flux measured at 48 hours
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Analysis of flux response to anthralin and XRCC3 exon 7 genotype in group 1.
0.01% Anthralin
Genotype N Mean StDev SE Mean
CC 22 164.5 95.9 20.4
CT 40 165.9 132.1 20.9
TT 9 170.0 103.1 34.4
Analysis of variance of flux from 0.01% anthralin between genotypes:
Source DF SS MS F P
Factor 2 193 96 0.01 0.993
Error 68 959008 14103
Total 70 959201
0.02% Anthralin
Genotype N Mean StDev SE Mean
CC 22 327.7 133.8 28.5
CT 40 292.7 154.7 24.5
TT 9 301.6 183.2 61.1
Analysis of variance of flux from 0.02% anthralin between genotypes:
Source DF SS MS
Factor 2 17490 8745
Error 68 1577493 23198
Total 70 1594983
0.04% Anthralin
Genotype N Mean StDev SE Mean
CC 22 411.1 142.4 30.4
CT 40 380.8 140.6 22.2
TT 9 360.2 132.6 44.2









Genotype N Mean StDev SE Mean
CC 22 437.5 153.6 32.7
CT 40 413.9 148.5 23.5
TT 9 391.1 101.5 33.8








At none of the doses of anthralin examined was there an association of the XRCC3 exon
7 genotype and flux response (p values 0.993 to 0.592). On comparison of factor and
error, the genotype explained very little of the total variation of flux, for example, at
0.01% anthralin the SS(factor) value was 193, SS(error) 1438267, and SS(total) 959201.
At 0.08% anthralin, the SS(factor) 1555, SS(error) 1438267, making a SS(total) value of
1453824. From this data, there is no evidence that the XRCC3 exon 7 polymorphism is
associated with flux response to anthralin, indicating that this polymorphism is not
involved with the response to oxidative stress.
Power calculations were carried out for 0.01% and 0.08% anthralin, using n=24
(balanced) and n=9 (least balanced). 0.01% had a between variance value of 96 and a
within variance value of 14103. This gave a power of .017 when n=24 and 0.06 when
n=9. 0.08% had a between variance value of 7779 and a within variance of 21151. Power
was 0.97 when n=24 and .057 when n=9. The lower dose has poor power, which could be
increased by a larger study group.
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Chapter 6. The GSTT1 gene and response to UVR and anthralin
The GSTT1 deletion leads to a null allele, which produces no functional protein. In order
to genotype samples for this polymorphism, the PCR assay described by Kerb et al
(2002) was initially attempted. However, it was not possible to achieve PCR products
with these primers, either under the published conditions, or when these conditions were
modified. From the NCBI sequence, new primer pairs were designed. The null primers
were situated either side of the deletion region. In the wild-type allele, these primers are
too far apart (approximately 50kb) for a PCR product to be produced under these
conditions. However, in the null allele much of the intervening sequence is deleted, and a
product of 1498 bp was produced. The wild-type primers were situated within the deleted
region. The null allele did not produce a PCR product with these primers, while in the
wild-type allele, a product of 466bp was amplified.
bp 1 M M 1 3 4 5 M bp
Figure 208. GSTT1 null PCR Figure 209 GSTT1 wild type PCR
Lanel, 2 PCR product formed, null allele present Lane 1 no PCR product, no w/t allele
Lane 3 no product, no null allele Lanes 2-4 PCR product, w/t allele
present
Lane 4, negative control Lane 5, negative control
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GSTT1 and erythemal response












Figure 210. Erythema induced by 119mJ per cm UV by GSTT1 genotype.













Figure 211 Erythema induced by 150mJ per cm2 UV by GSTT1 genotype.
































Figure 212. Erythema induced by 189mJ per cm UV by GSTT1 genotype.































Figure 213 Erythema induced by 238mJ per cm UV by GSTT1 genotype.













Figure 214. Erythema induced by 300mJ per cm2 UV by GSTT1 genotype.
UV on lower back, measured at 48 hours
Analysis ofGSTH genotype and erythemal response to UVR for each dose in group
1.
119mJ per cm2
Genotype N Mean StDev SE Mean
null/null 12 25.14 28.60 8.26
null/wt 21 17.95 15.33 3.35
wt/wt 27 22.79 25.39 4.89







Genotype N Mean StDev SE Mean
null/null 12 56.4 35.8 10.3
null/wt 21 44.04 31.51 6.88
wt/wt 27 57.45 40.79 7.85
Analysis of variance of levels of erythema induced by 150mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 2345 1172 0.87 0.426
Error 57 77216 1355
Total 59 79560
189mJ per cm2
Genotype N Mean StDev SE Mean
null/null 12 101.6 49.9 14.4
null/wt 21 85.90 42.16 9.20















Genotype N Mean StDev SE Mean
null/null 12 133.5 51.9 15.0
null/wt 21 121.08 41.83 9.13
wt/wt 27 117.9 54.3 10.5
Analysis of variance of levels of erythema induced by 238mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 2061 1030 0.42 0.662




Genotype N Mean StDev SE Mean
null/null 12 164.1 44.3 12.8
null/wt 21 151.37 24.65 5.38
wt/wt 27 145.3 54.7 10.5
Analysis of variance of levels of erythema induced by 300mJ per cm2 UV between
genotypes:
Source DF SS MS F P
Factor 2 2918 1459 0.75 0.479
Error 57 111471 1956
Total 59 114388
At none of the UV doses examined was there a significant difference in erythemal
response between genotypes. At the higher UV doses, of 189, 238 and 300mJ per cm2,
individuals in the group homozygous for the null allele did display higher mean levels of
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UV-induced erythema, while those homozygous for the wild-type allele had the lowest
mean erythemal response at 238 and 300mJ per cm2. This was, however, not significant
at any dose, with p values ranging form 0.682 to 0.426. Analysis of the factor and error
values reveal how little of the total amount of variation can be attributed to the presence
or absence of the GSTT1 null allele, for example, at 238mJ per cm2, the SS(factor) value
is 2061, while the SS(error) value, which comprises all the variation due to factors other
than genotype, was 141399, contributing most of the SS(total) value of 143460. At
300mJ per cm2 there is a similar picture, with the SS(factor), the variation which can be
explained by genotype , the value being 2918, while the SS(error) is 111471, and the
SS(total) being 114388.
Power calculations were performed for group 1 using n=20 (balanced) and n=12 least
balanced). 119mJ UV had a between variance value of 234 and a within variance value of
534. When n=20, the power was 0.96, and 0.80 when n=12. The between variance value
at 300mJ was 1459 while the within variance value of 1956, giving power of 0.99 when
n=290 and 0.96 when n=T2. The true power of the ANOVA calculations will lie between
these values, but is high enough to accept the p values.
The study by Kerb et al (2002) would suggest that individuals with the null/null genotype
would be expected to display significantly higher erythemal responses to UVR than those
with only one deleted GSTT1 allele and those homozygous for the functional wild-type
allele. Their finding, of those homozygous for the null allele having lower MEDs, and
this being more sensitive to UV, than the heterozygotes and wild-type homozygotes was
not reinforced by this study which used a more analytical measure of sensitivity to UV.
Kerb and colleagues studied 110 German Caucasians, being a larger study than this. Chi-
square analysis of the genotype frequencies reported by Kerb et al compared with those
obtained in this study revealed a significant difference between the two groups (DF=2,
p=0.033). Because of this difference in the genotype frequency, it is difficult to confirm
or deny the findings of Kerb et al. The MED is not an accurate method of determining
UV sensitivity when compared with the use of a reflectance meter, human judgment
errors can be introduced into the equation when determining MED, compared with the
numerical outcome of the reflectance meter. Due to the limitations of the MED, it would
be expected that the findings of this study, which see no association between the GSTT1
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polymorphism and UV sensitivity is likely to give a more accurate picture as to the role
of the GSTT1 polymorphism in determining UV sensitivity. What can be concluded,
however, is that there is no association between the GSTT1 polymorphism and UV
sensitivity in this study.
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GSTT1 and response to anthralin





























Figure 215. Flux induced by 0.01% Anthralin by GSTT1 genotype.





























Figure 216 Flux induced by 0.02% Anthralin by GSTT1 genotype.


























Figure 217. Flux induced by 0.04% Anthralin by GSTT1 genotype.





















Figure 218 Flux induced by 0.08% Anthralin by GSTT1 genotype.
Anthralin on lower back, flux measured at 48 hours
Analysis of flux response to anthralin and GSTT1 genotype in group 1.
0.01% anthralin
Genotype N Mean StDev SE Mean
null/null 11 147.1 120.2 36.3
null/wt 23 170.4 141.5 29.5
wt/wt 23 149.4 108.3 22.6
Analysis of variance of flux induced by 0.01% anthralin between GSTT1 genotypes:
Source DF SS MS F P
Factor 2 6497 3248 0.21 0.813
Error 54 842942 15610
Total 56 849439
0.02% anthralin
Genotype N Mean StDev SE Mean
null/null 11 264.6 137.6 41.5
null/wt 23 330.6 193.9 40.4
wt/wt 23 271.9 133.8 27.9
Analysis of variance of flux induced by 0.02% anthralin between GSTT1 genotypes:
Source DF SS MS F P
Factor 2 51450 25725 0.98 0.380
Error 54 1410513 26121
Total 56 1461962
0.04% anthralin
Genotype N Mean StDev SE Mean
null/null 11 429.2 108.4 32.7
null/wt 23 408.0 171.1 35.7
wt/wt 23 341.9 129.5 27.0
Analysis of variance of flux induced by 0.04% anthralin between GSTT1 genotypes:
Source DF SS MS F P
Factor 2 76426 38213 1.83 0.171




Genotype N Mean StDev SE Mean
null/null 11 486.7 124.8 37.6
null/wt 23 405.7 158.5 33.0
wt/wt 23 379.6 143.5 29.9
Analysis of variance of flux induced by 0.08% anthralin between GSTT1 genotypes:
Source DF SS MS F P
Factor 2 86430 43215 2.01 0.144
Error 54 1161038 21501
Total 56 1247468
No association was observed between the GSTT1 polymorphism and flux response
following exposure to anthralin at any dose examined. P values ranged from 0.813 at the
lowest dose of 0.01% to 0.144 at the highest dose of 0.08%. Analysis of factor and error
values reveal that the majority of error is due to other factors than genotype, implying
that the GSTT1 protein is not associated with anthralin response, or in the detoxification
of cells following exposure to anthralin.
Power calculations were performed at 0.01% anthralin and 0.08% anthralin, using n=19
(balanced) and n=l 1 (most unbalanced). The between variance value at 0.01% was 3248
and within variance was 15610. Power was 0.68 when n=19 and 0.43 when n=l l.The
between variance value at 0.08% anthralin was 43215, and within variance 21501. Power
when n=19 was 1, and 0.99 when n=l 1. The power at the higher anthralin dose is good,
but rather low at 0.01%, In future studies, one would want to increase the power in order
to have more confidence in ANOVA tests, which could be achieved by increasing sample
size.
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Chapter 7. The p53 codon 72 polymorphism and sensitivity to UVR.
Genotypes were determined using a RFLP assay, which utilised the BstUI restriction site,
which spans the codon 72 polymorphism. This was based on the assay first described by
Ara et al (1990) using Accll, an isochizomer of Rs/UI. Using the primers and conditions
detailed in Chapter 2 (methods) a PCR reaction was carried out, giving a PCR product of
296 base pairs. The Arg allele contains the RstUI restriction site, CG/CG, and under
appropriate digestion conditions yields two fragments of 169 and 127 bp. After digestion,
fragments were separated by electrophoresis through a 2% low melting point agarose gel
stained with ethidium bromide, and visualised with a UV source. The Pro allele does not
contain the restriction site, and gives a single band of 296 bp, while the heterozygous
genotype (Arg/Pro) gave three bands of 296, 169 and 127 bp.
Figure 219, p53 codon 72 PCR products Figure 220, p53 codon 72 digest
Lanes 1-3, PCR products Lane 1 Arg/Arg
Lane 4, negative control Lane 2 Arg/Pro
Lane 3 Pro/Pro
Lane 4 undigested PCR product
323
p53 codon 72 Genotype frequencies
Genotype Group 1(%) Group 2(%)
Arg/Arg 37/74 (50.00) 13/31 (41.94)
Arg/Pro 31/74(41.89) 16/31 (51.61)
Pro/Pro 6/74 (8.11) 2/31 (6.45)
Total 74 (100) 31 (100)
No statistically significant difference was observed in genotype frequencies between the
two study groups (x2 DF = 2, P-Value = 0.658).
Allele frequency at codon 72 has previously been shown to correlate with latitude
(Beckman et al, 1994). It was proposed that the codon 72 polymorphism is balanced and
maintained by natural selection, and that alleles encoding a proline at codon 72 might be
selected for in environments subject to high levels ofUV. Their rationale was that they
saw a marked ethnic differentiation, a strong correlation with latitude, and the similarity
of allele frequencies between Indians (from Sri Lanka, Tamil Nada and Keralda) and
African Blacks (Nigerians), who, they claim, show little genetic similarity apart from
dark skin pigmentation. If the p53 codon 72 polymorphism is indeed maintained by
natural selection, and the proline allele selected for in environments where the population
are exposed to high levels of UVR, the proline allele would have to confer some level of
evolutionary advantage to this population, such as giving an increased tolerance to UVR
and a level ofprotection from its deleterious effects. The two study groups investigated
here are fairly homogenous in ethnic mix and are typical of an Edinburgh population. The
latitude of Edinburgh provides little exposure to high levels of UVR, and if the Pro allele
did confer some advantage in populations exposed to high levels of UVR, there would be
no reason for this allele to be selected for in this environment, as it would confer little of
no evolutionary advantage where there is little or no exposure to UVR. The frequency of
the proline allele would therefore be expected to the lower in a Scottish study group
compared to in an African study group, as there would be no reason for it to be selected
for, with a corresponding increase in the frequency of the arginine allele in the Scottish
group.
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As described in the table above, the Arginine allele is the predominant allele found in
both study groups, with individuals homozygous for the Proline allele being observed on
only 6 occasions out of 74 individuals studied in group 1 (8.11%) and 2 occasions out of
31 in group 2 (6.45%). That these allele frequencies agree with the observed correlation
between higher latitude and increased frequency of the Arg allele does not however
automatically imply that the Pro allele might offer protection against high levels of UVR.
It is likely that there is an independent, and confounding, association with skin colour,
which may or may not be involved in protection against UVR. This view is supported by
work from Bastiaens and colleagues (2001). UVR is a known risk factor for development
of non-melanoma skin cancers, therefore, if the pro allele did offer a level of protection
against UVR, it would be expected that there would be a statistically significant
difference in genotype frequency in individuals with a variety of cutaneous malignancies,
and those without. Bastiaens et al studied individuals from the Netherlands with a variety
of cutaneous malignancies. 86 subjects with squamous cell carcinoma, 168 healthy
controls, 121 subjects with basal cell carcinoma and 108 with non-familial malignant
melanoma were genotyped for the p53 codon 72 polymorphism. Genotype frequencies
were similar in each group, with the breakdown of the SCC group being 47.1%
homozygous for the arginine allele, 46.0% heterozygous for the two alleles, and 6.9%
homozygous for the proline allele, versus 47.8%, 45.8% and 6.4% respectively in the
control group. No statistically significant difference in genotype frequencies was seen
between the SCC group and the controls, or between the BCC and non-familiar malignant
melanoma groups and controls, suggesting that harbouring homozygosity for the arginine
allele does not appear to represent a significant risk factor for SCC. That this does not
agree with the view of both McGregor et al, and Shen et al, highlights the necessary for
further investigation of this polymorphism and sensitivity to UVR.
In each of two independent study groups, individuals were exposed to a range of UV
doses, on either the lower back in group 1, or the inner forearm in group 2. UVB-induced
erythema was plotted against genotype (Arg/Arg, Arg/Pro, or Pro/Pro) and analysed for
variance in levels of erythema between genotypes for each dose.
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Figure 221 Erythema induced by 119mJ per cm2 UV by p53 codon 72 genotype.































Figure 222 Erythema induced by 150mJ per cm2 UV by p53 codon 72 genotype.
































Figure 223 Erythema induced by 189mJ per cm2 UV by p53 codon 72 genotype.

































Figure 224 Erythema induced by 238mJ per cm UV by p53 codon 72 genotype.



































Figure 225 Erythema induced by 300mJ per cm2 UV by p53 codon 72 genotype.
UV on lower back, measured at 48 hours
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Analysis of p53 codon 72 genotype and erythemal response UVR for each dose in
group 1.
119mJ per cm2
Genotype N Mean StDev SE Mean
Arg/Arg 37 18.81 22.91 3.77
Arg/Pro 31 28.62 29.58 5.31
Pro/Pro 6 22.97 14.88 6.07
9
Analysis of variance of erythema induced by 119mJ per cm UV between genotypes:
Source DF SS MS F P
Factor 2 1627 813 1.25 0.293
Error 71 46234 651
Total 73 47861
150mJ per cm2
Genotype N Mean StDev SE Mean
Arg/Arg 37 45.61 35.12 5.77
Arg/Pro 31 68.44 42.60 7.65
Pro/Pro 6 58.9 30.7 12.5
Analysis of Variance of erythema induced by 150mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 8841 4420 3.03 0.055
Error 71 103541 1458
Total 73 112382
189mJ per cm2
Genotype N Mean StDev SE Mean
Arg/Arg 37 85.42 49.62 8.16
Arg/Pro 31 106.01 42.73 7.67
Pro/Pro 6 101.6 55.7 22.7
*
Analysis of variance of erythema induced by 189mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 7408 3704 1.65 0.198




Genotype N Mean StDev SE Mean
Arg/Arg 37 115.17 51.98 8.55
Arg/Pro 31 136.43 38.91 6.99
Pro/Pro 6 135.4 53.2 21.7
Analysis of variance of erythema induced by 238mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 8235 4117 1.86 0.163
Error 71 156860 2209
Total 73 16509
300mJ per cm2
Genotype N Mean StDev SE Mean
Arg/Arg 37 145.40 44.44 7.31
Arg/Pro 31 162.42 37.81 6.79
Pro/Pro 6 149.2 45.9 18.7
Analysis of variance of erythema induced by 300mJ per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 4976 2488 1.42 0.249
Error 71 124506 1754
Total 73 129483
Group 1 results - discussion
At none of the doses of UVR examined was there any significant difference between any
of the genotypes and level ofUV-induced erythema. This study group is similar in size to
that studied by McGregor et al to investigate the risk of sunburn (74 compared to 78).
The measurement of erythema by reflectance spectrophotometry as used here gives a
numeric value for sensitivity to UVR, which is not dependent on the human eye for
judgement, therefore is likely to be more accurate and reproducible than use of the
minimal erythemal dose to determine UVR sensitivity.
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Power calculations were carried out in group 1 using n=25 (balanced) and n=6 (least
balanced). Between variance values at 119mJ were 813, while the within variance value
was 651. Power was 1 when n=25, and 0.89 when n=6, the true power therefore lying
between 0.89 and 1, which is good. At 300mJ, the between variance was 2488 and the
within variance 1754. When n=25, power was 1, and 0.92 when n=6. Again these are
good levels of power, and the p values obtained from the ANOVA tests can be accepted
with confidence.
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Figure 226 Erythema induced by 0.47J per cm UV by p53 codon 72 genotype.






































Figure 227. Erythema induced by 0.6J per cm2 UV by p53 codon 72 genotype.





































Figure 228 Erythema induced by 0.75J per cm UV by p53 codon 72 genotype.



































Figure 229 Erythema induced by 0.95J per cm2 UV by p53 codon 72 genotype.










































Figure 230. Erythema induced by 1.2J per cm UV by p53 codon 72 genotype.






























Figure 231 Erythema induced by 1.5J per cm2 UV by p53 codon 72 genotype.
UV on inner forearm, measured at 24 hours
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Analysis of p53 codon 72 genotype and erythemal response to UVR for each dose in
group 2.
0.47J per cm2
Genotype N Mean StDev SE Mean
Arg/Arg 13 5.00 18.03 5.00
Arg/Pro 16 4.69 16.93 4.23
Pro/Pro 2 0.00 0.00 0.00
Analysis of variance of erythema induced by 0.47J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 44 22 0.08 0.927
Error 28 8201 293
Total 30 8246
0.6J per cm2
Genotype N Mean StDev SE Mean
Arg/Arg 13 16.2 38.6 10.7
Arg/Pro 16 19.54 36.77 9.19
Pro/Pro 2 11.0 15.6 11.0
• • • 9
Analysis of variance of erythema induced by 0.6J per cm UV between genotypes:
Source DF SS MS F P
Factor 2 172 86 0.06 0.939
Error 28 38384 1371
Total 30 38555
0.75J per cm2
Genotype N Mean StDev SE Mean
Arg/Arg 13 31.2 53.0 14.7
Arg/Pro 16 38.7 49.6 12.4
Pro/Pro 2 25.0 35.4 25.0
Analysis of variance of erythema induced by 0.75J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 596 298 0.12 0.891




Genotype N Mean StDev SE Mean
Arg/Arg 13 58.5 66.0 18.3
Arg/Pro 16 86.1 79.3 19.8
Pro/Pro 2 99.0 77.8 55.0
Analysis of variance of erythema induced by 0.95J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 6669 3335 0.61 0.550
Error 28 152680 5453
Total 30 159349
1.2J per cm2
Genotype N Mean StDev SE Mean
Arg/Arg 13 101.3 76.5 21.2
Arg/Pro 16 118.7 86.2 21.6
Pro/Pro 2 125.5 48.8 34.5
Analysis of variance of erythema induced by 1.2J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 2565 1283 0.20 0.824
Error 28 184022 6572
Total 30 186588
1.5 J per cm2
Genotype N Mean StDev SE Mean
Arg/Arg 13 162.5 87.8 24.4
Arg/Pro 16 159.0 92.4 23.1
Pro/Pro 2 169.0 41.0 29.0
Analysis of variance of erythema induced by 1.5J per cm2 UV between genotypes:
Source DF SS MS F P
Factor 2 220 110 0.01 0.986
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Error 28 222222 7937
Total 30 222442
Power calculations were carried out for data at 119mJ and 300mJ, using n=10 (balanced)
and n=2 (least balanced). The between variance value was 22 at 119mJ and the within
variance was 293. This gave a power of 0.16 when n=10 and 0.06 when n=2. At 300mJ,
the between variance was 110 and within variance 7937, which gave a power of 0.07
when n=10 and 0.05 when n=2. The power in group 2 is extremely low, and would need
to be increased in order to confirm that no association exists between p53 codon 72
genotype and erythemal response, which could perhaps be achieved by increasing group
size. However, the same trend is seen as in group 1, where power was good.
The results of this study investigating an association between p53 codon 72
polymorphism and sensitivity to UVR in two independent study groups with a range of
UV doses do not support the earlier findings of McGregor et al (2002). Although in both
groups the numbers of Pro/Pro homozygotes is small, and the errors wide, there is no
evidence to support an increased sensitivity to UVR at either body site at any of the UV
doses examined in individuals carrying the Arg allele. If anything, there tended to be a
higher level of erythema in the Pro/Pro groups. The small number of Pro/Pro
homozygotes is in line with the expected frequency in such a population, however, this
contributes to the large errors seen in the statistical analysis. One way to solve this could
be to genotype larger numbers of individuals, then irradiate an equal number of each
genotype with UV and measure their response. This would no longer be a random mix of
the population however, and population-sampling errors would come into force. That the
codon 72 alleles are found at different frequencies throughout the world, correlating as
they do with latitude, suggests that if the codon 72 polymorphism is not itself associated
with UVR sensitivity, as this data implies, it is possible that an independent association
exists with skin colour, which is not related to how the skin responds to UV. A biased
study group with equal numbers of each genotype could also cause any background




Effect ofpolymorphisms of repair genes on sensitivity to UVR.
Polymorphisms in exons 6, 22 and 23 of the XPD gene have previously been reported to
be associated with an increased risk of the development of malignant melanoma
(Tomescu et al, 2002). The study presented here genotyped two, independent, study
groups, one n=74, the other n=31, which were both larger than the population analysed
by Tomescu and colleagues, of 28 patients and 33 controls. The data presented here
shows no association between any of the polymorphisms of XPD and increased
sensitivity to UVR, as measured by erythemal response. UVR is the major causative
agent for the development of melanoma; therefore it is possible that a polymorphism
which leads to increased risk of melanoma would also show increased sensitivity to
UVR. In none of the data analysed, for both study groups, at any UVR dose examined,
was there an association between any polymorphism of XPD and sensitivity to UVR. The
low number of individuals studied by Tomescu et al indicated the association they report
between polymorphisms of XPD and melanoma may be due to chance. That no
association was seen between the XPD polymorphisms of exons 6, 22 or 23 and
sensitivity to UVR is in agreement with another, larger study of the association of these
polymorphisms and risk of melanoma (Winsey et al, 2000), where there was no evidence
of any association of these polymorphisms and risk of melanoma. It is still possible,
however, that the XPD gene is associated with sensitivity to UVR, and that this was not
revealed as the causative polymorphism was not analysed here, nor in linkage
disequilibrium with those polymorphisms that were studied. However, there is little
evidence to justify the analysis of further XPD polymorphisms.
The ERCC1 gene exon 4 polymorphism was not seen to be associated with sensitivity to
UVR at any UV dose examined in either of the two study groups. The analysis of the
two, independent, study groups, both of which gave the same conclusion, indicates there
is no evidence of the exon 4 polymorphisms being involved with determining sensitivity
to UVR. This is in agreement with the study by Winsey et al (2002) which found no
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association between the exon 4 polymorphism and risk of malignant melanoma. The
phenotypic effect of no functional ERCC1 protein is thought to lead to an embryonic
lethal phenotype in humans, therefore it was speculated that a polymorphism which leads
to minor changes in the wild-type protein would show an association with UV sensitivity,
as ERCC1 is crucial in the NER pathway that repairs UV-induced damage. This was not
observed here.
Mouse studies have shown that the lack of functional ERCC 1 protein in mice leads to a
runted phenotype with severe liver abnormalities and death before three weeks of age
(McWhir et al, 1993). It is therefore possible that ERCC1 has another, as yet
unidentified, function, and that the exon 4 polymorphism might lead to an association
with the phenotype of this.
The XPF gene produces a protein which acts in complex with the ERCC1 protein in the
initial incision stage of NER. The polymorphism of exon 11 of the XPF gene was
analysed for an association with sensitivity to UVR. No association was observed
between this polymorphism and erythemal response in either study group at any UV
dose, suggesting it is not involved with determining sensitivity to UVR.
The XPG gene is involved with the initial incision process of damaged DNA in NER, and
is also thought to have an additional role in the repair of oxidative damage. UVR induces
DNA damage, both directly, which is repaired by NER, and indirectly though the
generation of oxidative stress. The exon 15 polymorphism of XPG was therefore of
particular interest in analysing erythemal response. An association was observed between
the polymorphism and erythemal response, with the GG genotype displaying greater
sensitivity to UV than the CG or CC genotypes. Analysis of three additional snps in the
XPG gene revealed the suggestion of an association between the rs4150265
polymorphism and erythemal response. This is located within the intron immediately
preceding exon 15, and therefore cannot be a causative mutation, but could be in linkage
disequilibrium with the exon 15 polymorphism. No association was observed between the
other two snps and erythemal response, which were a greater distance from exon 15.
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Further analysis of this polymorphism is warranted. A larger study could confirm the
association observed here with fewer errors, while a functional study could investigate
whether exon 15 is directly involved, or is a marker for the causative mutation. One way
to do this would be to take skin biopsies of irradiated skin, as mentioned previously. The
number of sunburn cells could then be histologically determined, the hypothesis being
that if the polymorphism does cause increased sensitivity to UVR, then cells from
individuals with the GG genotype should have a greater percentage of sunburn cells,
which have undergone apoptosis as a result of DNA damage.
The XRCC1 exon 10 polymorphism was found to show no association with sensitivity to
UVR as measured by erythemal response. The XRCC1 gene is involved with the BER
pathway, which repairs DNA damaged by oxidative stress. The formation of UV-induced
photoproducts, which are repaired by NER, might be likely to cause a greater immediate
threat to the integrity of the genome than that induced by oxidative stress. It might
therefore be possible that the XRCC1 gene is not crucial for the repair of UV-induced
DNA damage.
XRCC3 has a role in recombination repair, and cells which are deficient in XRCC3 have
an increased sensitivity to a variety of DNA mutagens, including UVR. No association
was observed between the polymorphism in exon 7 of this gene and sensitivity to UVR.
This polymorphism has also been analysed by Winsey and colleagues, who found there to
an association between this polymorphism and risk of developing malignant melanoma.
As previously mentioned, the used of cadavers as the control population in the study by
Winsey et al could introduce some doubt as to the validity to this report. A large study,
with a cohort of melanoma patients, and a healthy, living control population investigated
for any association with melanoma and also for sensitivity to UVR as measured by
erythemal response would go some way to resolving the finding here of no association
between XRCC3 exon 7 and sensitivity to UVR, and the findings of Winsey et al that this
polymorphism is associated with increased risk of melanoma.
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Effect of polymorphisms in repair genes to anthralin sensitivity.
The repair gene polymorphism detailed above were also analysed for any association
with flux response following topical application of anthralin, an inducer of oxidative
stress. As previously mentioned, oxidative stress is repaired in the main by the BER
pathway, of which XRCC1 is a key component. XPG is also thought to have an
additional role in the repair of oxidative stress distinct from its role in NER. None of the
other repair genes analysed have any known role in the BER pathway, therefore if there
were to be an association between anthralin induced flux and one of these
polymorphisms, it would be expected to be XRCC1 or XPG.
At none of the polymorphisms of the repair genes analysed in this study was there an
association with flux response to anthralin. The polymorphisms examined might not be
reflective of the genes as a whole for response to anthralin, but in the absence of further
study there is no evidence to suggest that any of the repair genes, ERCC1, XPD, XPF,
XPG, XRCC 1 or XRCC3 are involved with the repair of oxidative damage induced by
anthralin. To further investigate the effect of these polymorphisms on anthralin response,
a greater number of individuals would need to be studied. The effect of these
polymorphisms at the cellular level could also be investigated, by measuring the repair
capacity of oxidative stress in cells from individuals with different genotypes of these
polymorphisms.
The GSTT1 gene and sensitivity to UVR.
No association was observed between the GSTTl null allele, which produces no
functional protein, and UV sensitivity. This was in contradiction to a study published by
Kerb et al (2002), who report that this polymorphism does lead to increased sensitivity to
UVR. However, the measure of UV sensitivity by in the study by Kerb and colleagues
was by determining the MED. The MED is limited in its accuracy for several reasons as
mentioned earlier, including that it is a threshold measurement, and is open to error by its
need for the human eye to determine UV-induced erythemal. Reflectance
spectrophotometry, as used here, should be likely to give a more accurate measurement
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of sensitivity to UVR. A larger study would determine whether the association reported
by Kerb et al is due to the errors occurring when measuring sensitivity to UVR by MED.
The GSTT1 gene and sensitivity to anthralin.
The GSTT1 null polymorphism was also investigated for any influence on sensitivity to
anthralin, a generator of oxidative stress. As an antioxidant, GSTT1 might limit damage
caused by the topical application of anthralin to cellular DNA. In this study, however, no
association was observed between GSTT1 genotype and the flux response to anthralin at
a variety of doses. From this data, GSTT1 does not seem to be associated with the
prevention of DNA damage induced by anthralin, although a larger study group is needed
to confirm this.
The p53 codon 72 polymorphism and UVR sensitivity.
Much controversy exists over this polymorphism and its resulting effects on increased
risk of a variety of various cancers. Many studies have shown no association between p53
codon 72 polymorphism and risk of developing a particular cancer, while others report it
to confer a greater susceptibility to the development to other cancers.
In this study, no association was observed between codon 72 genotype and sensitivity to
UVR, as measured by reflectance spectrophotometry for erythemal response. It has
previously been reported that this polymorphism leads to an increased sensitivity to UVR
(McGregor et al, 2002). However, in their study, McGregor and colleagues determined
sensitivity to UVR by the MED. As discussed before, the MED is an inadequate measure
of an individual's sensitivity to UVR, being open to error. The data reported here
suggests no such association between the polymorphism at codon 72, and UVR
sensitivity in a study of approximately equal size. The measurement of UV sensitivity is
likely to have been measured more accurately here, suggesting that this result is
indicative of the phenotypic response to the polymorphism, i.e. that it does not appear to
confer sensitivity to UV.
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No Association Between p53 Codon 72 Polymorphisms and
Erythemal Response
To the Editor:
McGregor and colleagues report an association between
allelic variants at codon 72 of the p53 gene and sunburn
and non-melanoma skin cancer, with Pro/Pro homozygotes
having a higher minimal erythema dose (MED), i.e., less
sensitive to ultraviolet radiation (UVR). A subsequent study
in the Journal has also reported an association between
allelic variants at this p53 codon and melanoma (with the
Pro/Pro alleles being less at risk) (Shen et al, 2003). In the
McGregor study, both phototype and the MED were used
as measures of UVR sensitivity. The finding of an associa¬
tion between allelic variants of the p53 gene and acute UVR
sensitivity is important, as it may provide insight into the
mechanism underpinning the reported association with skin
cancer.
We have recently had the opportunity to examine the
same p53 variants and UVR sensitivity, measured not as in
the McGregor study by a threshold measurement, the MED,
but by objective reflectance spectrophotometry, at a range
of UVR doses on a different body site on each of two patient
groups. Our results do not support the findings of McGregor
et al (2002).
In group 1, 74 healthy residents of Edinburgh, UK, were
irradiated on the lower back using a range of UVB doses
(119-300 mJ per cm2) from a lamp unit designed by Prof
Brian Diffey (Regional Medical Physics, Newcastle, UK),
containing a PL-S 9W/12 miniature flourescent lamp
(Philips, Eindhoven, The Netherlands). In group 2, 31
psoriasis patients, prior to phototherapy, were irradiated
on the inner forearm with a similar luminaire with six doses
of UVB from a TL01 Philips tube (0.47-1.5 J per cm2).
Erythema was measured at 48 h in group 1 and at 24 h
in group 2 with readings taken in triplicate. (Erythema
measured at 24 h in group 2 to minimize disruption to
patients' routine care.)
Baseline measurements were also taken on adjacent
unirradiated skin and UVR-induced erythema defined as the
increase in reflectance from the baseline values. Volunteers
were phototyped according to the classification used by
McGregor. Skin type breakdown was as follows: volunteers:
61 (l/ll), 12 (lll/IV), 1 (V/VI); psoriasis patients: 8 (l/ll), 11 (III/
IV), 0 (V/VI). Note this population group appears more
homogeneous in terms of ethnic mix than those studied by
-McGregor.
Genotyping of the p53-72 polymorphism was carried out
■by PCR and restriction fragment length polymorphism
Abbreviations: MED, minimal erythema dose; SEM, standard
errors of the mean; UVB, ultraviolet B; UVR, ultraviolet radiation
analysis, using the primers 5'-ATC TAC AGT CCC CCT
TGC CG-3' and 5'-GCA ACT GAC CGT GCA AGT CA-3' in a
PCR reaction consisting of an initial melting step of 941C for
4 min, followed by 35 cycles of 941C for 40 s, 561C for 30 s
and 721C for 30 s. The resulting 296 base pair (bp) fragment
was digested overnight at 601C by BstUI. Digestion
products were analyzed by electrophoresis through a 2%
agarose gel stained with ethidium bromide. The Arg allele
contains a BstUI restriction site, yielding two fragments of
169 and 127 bp. The Pro allele was not cut, and had a single
band of 296 bp. The heterozygous genotype (Arg/Pro) gave
three bands (296, 169, and 127 bp).
The results expressed as means and SEM for the various
doses for the two study groups are shown (Tables I and II).
Although like the McGregor study the number of Pro/Pro
homozygotes is small, and errors wide, we found no
Table i. Mean erythema values per p53 codon 72 genotype
group 1, n=74 UVB on lower back with lamp unit containing
a Phillips 9w/12 tube. Erythema measured at 48 h.









300 145.4 ± 7.31 162.42 ± 6.79 149.2 ± 18.7
238 115.17 ± 8.55 136.43 ± 6.99 135.4 ± 21.7
189 85.42 ± 8.16 106.01 ±7.67 101.6 ± 22.7
150 45.61 ± 5.77 68.44 ± 7.65 58.9 ± 12.5
119 18.81 ± 3.77 28.62 ± 5.31 22.97 ± 6.07
SEM, standard errors of the mean.
Table II. Mean erythema values per p53 codon 72 genotype
group 2, n =31 UVB inner forearm with TLOl Phillips
tube. Erythema measured at 24 h









1.5 162.5 ± 24.4 159.0 ± 23.1 169.0 ± 29.0
1.2 101.3 ± 21.2 118.7 ± 21.6 125.5 ±34.5
0.95 58.5 ± 18.3 86.1 ± 19.8 99.0 ± 55.0
0.75 31.2 ± 14.7 38.7 ± 12.4 25.0 ± 25.0
0.60 16.2 ± 10.7 19.57 ± 9.19 11.0 ± 11.0
0.47 5.00 ± 5.00 4.69 ± 4.23 0.00 ± 0.00
Copyright r 2004 by The Society for Investigative Dermatology, Inc.
1334
122:5 MAY 2004 LETTER TO THE EDITOR 1335
evidence to support any increase in sun sensitivity at either
body site at any dose examined. If anything, the erythema
tended to be higher in the Pro/Pro group.
There may be a number of reasons—apart from
chance—for these differences. The MED is both a threshold
measure and is influenced by basal pigmentation. Its
reading may therefore be biased by genetic ancestry,
methodological problems that reflectance spectrophoto¬
metry with examination of a range of doses of irradiation
circumvents. It is also well known that the various codon
72 alleles are not distributed uniformly throughout human
populations around the world, implying an independent
(and confounding) association with skin color. Not all
studies have shown an association between p53 codon
72 polymorphism and cutaneous malignancies (Baastiens
et al, 2001). In the absence of further study we believe there
is little compelling evidence to implicate p53 codon 72
alleles with sensitivity to UVR.
Claire Manson,* Lisa Naysmith,* Karen Waterston,* David W. Melton,t
and Jonathan L. Rees*
*Systems Group, Dermatology, University of Edinburgh, Edinburgh,
UK; fSir Alastair Currie Cancer Research UK Laboratories, Molecular
Medicine Centre, University of Edinburgh, Edinburgh, UK
Supported by the Wellcome Trust.
DOI: 10.1111 /J.0022-202X.2004.22526.x
Manuscript received December 5, 2003; revised January 9, 2004;
accepted for publication January 14, 2004
Address correspondence to: Professor Jonathan Rees, Room 4.018,
Dermatology, First Floor, Lauriston Building, Lauriston Place, Edinburgh
EH3 9HA, UK. Email: jrees@staffmail.ed.ac.uk
References
Baastiens MT, Struyk L, Tjong-A-Hung SR et al: Cutaneous squamous cell
carcinoma and p53 codon 72 polymorphs: A need for screening? Mol
Carcinog 30:56-61, 2001
McGregor JM, Harwood CA, Brooks L, et al: Relationship between p53 codon 72
polymorphism and susceptibility to sunburn and skin cancer. J Invest
Dermatol 119:84-90, 2002
Shen H, Liu Z, Strom SS, et al: p53 codon 72 Arg homozygotes are associated
with an increased risk of cutaneous melanoma. J Invest Dermatol 121:
1510-1514, 2003
